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Abstract 
HIV-1 vaccine development has proven an extremely challenging task, largely 
related to the highly variable nature of the virus which generates constantly new 
variants able to escape the immune system surveillance and lack of correlates of 
protection. DNA vaccines have the potential to encode multiple viral antigens, 
thereby eliciting immune responses that could lead to improved containment of the 
HIV-1 virus in a relatively safe way. Furthermore, the endogenous synthesis of the 
plasmid encoded antigen mimics the viral replication and enables the antigen 
presentation in a natural way for immune system cells.   
 
The first aim of this study was to evaluate the immunogenicity of the HIV-1 
multigene DNA plasmid vaccine, encoding for Rev, Nef, Tat, p17, p24 and selected 
T cell epitopes of HIV-1 pol and env in mice. GTU vector encoding the multigene 
is an advanced expression vector resulting in higher expression level and longer 
maintenance of the plasmid in dividing cells compared to conventional DNA 
plasmids. In the first part of the work, we demonstrated that GTU-MultiHIV DNA 
induces cellular and humoral immune responses in mice directed to all components 
of the HIV-1 multigene. Delivery route and DNA dose used were shown to be major 
determinants for the efficiency of the immunization. Biolistic gene gun delivery 
induced strong immune responses with very low DNA doses, whereas intradermal 
and intramuscular administrations were dependent on high DNA doses. The induced 
cellular immune responses as measured by IFN-J secretion were shown to correlate 
with cytotoxic T cell activity in vitro and in vivo. 
 
To evaluate the protective efficacy of the HIV-1 DNA vaccine induced immune 
responses, we developed a novel tumor challenge model. We showed that HIV-1 
specific  cellular  immune  responses  were  able  to  significantly  delay  the  growth  of  
the HIV-1 antigen expressing tumor, thereby demonstrating the cytotoxic activity of 
the induced T lymphocytes, which is an important characteristic of HIV-1 vaccine. 
Furthermore, the HIV-1 specific T cells activated by immunization were shown to 
efficiently clear the HIV-1/MuLV infected cells used for the challenge in another 
experimental  challenge  model.  Indication  of  cross-clade  protection  was  
demonstrated by evaluating the protection induced by immunization with a 
multiclade specific plasmid cocktail, containing antigens derived from HIV-1 strains 
A–C and F-H and subsequently using different HIV-1 subtypes for the challenge. 
Finally, we briefly addressed the significant role of dendritic cells in eliciting 
immune responses by GTU-MultiHIV DNA immunization. 
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Tiivistelmä 
Intensiivinen HIV-1 tutkimus aloitettiin jo lähes kolmekymmentä vuotta sitten, 
mutta HIV-1 rokotteen kehittäminen on yhä kaukainen tavoite. Erityisen haastavaksi 
HIV-1 rokotteen kehittämisen tekee viruksen huomattava muutautumiskyky, minkä 
tuloksena syntyy jatkuvasti uusia virusmuunnoksia, joita immuunijärjestelmän solut 
eivät tunnista. DNA rokote voi koodata viruksen useita yksittäisiä eri antigeenejä, 
joita kohtaan syntynyt elimistön oma immuunivaste voi tällöin tehokkaammin ja 
suhteellisen turvallisesti rajoittaa virusinfektiota. Lisäksi DNA rokotteiden etuna on 
solunsisäinen antigeenin tuotanto, joka mahdollistaa antigeenien esittelyn 
immuunijärjestelmälle virusinfektiota jäljittelevällä, luonnollisella tavalla. 
 
Tässä tutkimuksessa arvioitiin HIV-1 plasmidi-DNA rokotteen immunogeenisyyttä 
hiirimallien avulla. Plasmidi-DNA:n antigeeni koodaa HIV-1 viruksen Rev, Nef, 
Tat, p17 ja p24 proteiineja, sekä T-solu epitooppeja viruksen env ja pol 
geenialueilta. GTU on kehittynyt ekspressiovektori, jonka ominaisuudet auttavat 
ilmentämään antigeeniä tehokkaammin ja pidempikestoisemmin kuin tavallista 
CMV-pohjaista vektoria käytettäessä, plasmidin pysyessä paremmin jakautuvissa 
soluissa. Työn ensimmäisessä osatyössä osoitettiin immunisoinnin GTU-MultiHIV 
plasmidilla aiheuttavan soluvälitteisen ja vasta-ainevälitteisen immuunivasteen 
jokaista plasmidin koodaamaa antigeenia kohtaan. Käytetyn immunisointireitin ja 
DNA:n annostuksen osoitettiin vaikuttavan suuresti immunisaation tehokkuuteen. 
Immunisoinnin biolistisella aseella eli geenipyssyllä osoitettiin aiheuttavan vahvan 
antigeenispesifisen immuunivasteen jo hyvin pienillä annosmäärillä, kun taas 
ihonsisäisen tai lihaksensisäisen injektion herättämä immuunivaste oli riippuvainen 
suuremmasta DNA annoksesta. Soluvälitteistä immuunivastetta arvioitiin 
lymfosyyttien antigeenispesifisellä IFN-J-sytokiinin erityksellä ja sen osoitettiin 
korreloivan solujen sytotoksisuuden kanssa in vivo ja in vitro. 
 
Toisessa osatyössä kehitettiin uusi kasvainmalli HIV-1 DNA rokoteella aiheutetun 
immuunivasteen suojaavan tehon arviointiin. Immunisoinnin näytettiin oleellisesti 
hidastavan HIV-1 antigeeniä ilmentävän kasvaimen kehittymistä, mikä osoittaa 
aktivoitujen T-lymfosyyttien toimivan antigeenispesifisesti sytotoksisina soluina. 
Tämä on tärkeä ominaisuus rokotteelle, jonka tarkoituksena on herättää 
immuunipuolustus tuhoamaan HIV-1 infektoituneita soluja. Kolmannen osatyön in 
vivo hiirimallissa rokotteella aktivoitujen T-solujen osoitettiin tuhoavan HIV-
1/MuLV pseudotyyppi-viruksella infektoituja soluja. Immunisointiin käytettiin 
HIV-1 A-C ja F-H alatyyppi-spesifisiä antigeenejä koodaavaa MultiHIV 
plasmidiseosta. Viitteitä rokotteen suojatehosta eri HIV-1 kantoja vastaan saatiin 
käyttämällä solujen pseudovirusinfektioon HIV-1 kantoja, jotka poikkesivat 
rokotteen antigeenien kannoista. Lopuksi dendriittisolujen oleellista merkitystä 
immuunivasteen syntymisessä GTU-MultiHIV DNA immunisoinnin jälkeen 
tutkittiin uutta lähestymistapaa käyttäen.  
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IFA   incomplete Freunds’ adjuvant 
IFN   interferon 
Ig  immunoglobulin 
IL  interleukin 
LAV   lymphadenopathy-associated virus  
LC   Langerhans cells 
LN   lymph node 
LTNP  long-term non-progressor 
LTR  long terminal repeat  
LV    lentivirus 
mDC   myeloid dendritic cell 
MHC   major histocompatibility class 
MIP  macrophage inflammatory protein 
MuLV   murine leukemia virus 
MVA   Modified vaccinia Ankara 
nAb   neutralizing antibody 
Nef   negative regulatory factor 
NF-țB  Nuclear factor-țB 
NK   natural killer cell 
NKT  natural killer T cell 
PBS   phosphate buffered saline  
PBMC  peripheral blood mononuclear cells 
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RSV   Rous sarcoma virus 
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SHIV  Simian human immunodeficiency virus 
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ss   single-strand 
Tat   trans-activator of transcription 
TCM  central memory T cell  
TEM  effector memory T cell  
Th   T helper cell 
TK   thymidine kinase 
TLR   toll-like receptor 
TNF   tumor necrosis factor 
Treg   regulatory T cell 
URF   unique recombinant forms 
Vif   virion infectivity factor 
VLP   virus-like particle 
Vpr   viral protein R 
Vpu  viral protein U 
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1. Introduction 
A preventive vaccine against human immunodeficiency virus type 1 (HIV-1) has 
remained elusive goal despite considerable efforts during the thirty years since the 
discovery of HIV-1 (Barouch 2010). Intensive work carried out on HIV-1 infected 
individuals, non-human primates with HIV-1 or with related simian 
immunodeficiency virus (SIV) infection and a wide array of vaccine studies have 
pointed out the enormous challenge related to overcoming the HIV-1 epidemic. 
HIV-1 is characterized by several mechanisms enabling efficient viral escape from 
all immune system components and deterioration of the immune defence of the host. 
It has an immense capability to constantly vary its most antigenic envelope 
molecules, thereby leading the immune system onto the wrong track and 
simultaneously delicately hiding the most essential conserved antigens (Biesinger 
and Kimata 2008). According to the prevailing understanding, the successful 
vaccine should be able to activate all arms of the immune system, such as generation 
of broadly neutralizing antibodies (nAb) and polyfunctional cell-mediated immune 
responses  targeted  at  a  variety  of  HIV-1  antigens.  So  far  none  of  the  vaccine  
candidates evaluated in clinical trials have shown true promise of conquering the 
virus even though they have provided new hope for vaccine development (Barouch 
and Korber 2010, Haynes et al. 2010). 
 
However, even a less pronounced protective effect by immunization would be 
highly desirable, as the initial immune response, if not protective, could still 
significantly delay the disease progression and reduce the need for anti-retroviral 
therapy. Therapeutic vaccines have a similar goal, to awake the HIV-1 infected 
host’s immune system to fight more efficiently against the viral infection (Hoffmann 
et al. 2008, Virgin and Walker 2010). At the moment the progression of HIV-1 
infection can only be efficiently constrained by antiretroviral therapy, which is still 
far from the optimal solution while causing severe side effects and, most 
importantly, being still unavailable to millions of HIV-1 infected people. A variety 
of highly diverse HIV-1 vaccine approaches have been developed and analyzed in 
both pre-clinical and clinical settings. Many of the traditional vaccine approaches, 
such as virus-based vaccines and some subtype vaccines have proven to be too 
hazardous or too inefficient to be used as HIV-1 vaccine (Berkhout et al. 1999, 
Connor et al. 1998). However, the rapid development of the molecular biology has 
significantly increased the ways to construct a new generation of vaccines. DNA 
vaccines are highly promising vaccine candidates, being safe but still having the 
potential  to  target  multiple  antigens  and  clades  emerging  due  to  fast  evolution  of  
HIV-1 viruses. Current efforts related to genetic vaccines are focused largely on 
increasing their immunogenicity in human beings. However, the missing link in the 
HIV-1 research causing a major impediment to vaccine development is the lack of 
correlates of protection. As long as no prominent advance is made in clinical trials, 
it cannot be known for certain which immunological parameters should be followed 
when seeking a protective vaccine.   
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2. Review of the literature 
2.1 The human immunodeficiency virus 
2.1.1 From past to the present 
Three decades ago, signs of a new acquired immunodeficiency were already being 
reported in homosexual communities suffering from Pneumocystis pneumonia, 
extensive mucosal candidiasis and several viral infections (Gottlieb et al. 1981). The 
relentless research to curb the HIV-1 epidemic was initiated in 1983, when a T 
lymphotropic retrovirus was first isolated from a lymphadenopathy patient and the 
causative virus was first named lymphadenopathy-associated virus (LAV) by French 
scientists Francoise Barre-Sinoussi and Luc Montagnier (Barre-Sinoussi et al. 
1983), the winners of the 2008 Nobel Prize for medicine and physiology. 
Concurrently, the virus shown to be linked to patients with AIDS was isolated by a 
group led by Robert Gallo at the National Institutes of Health (NIH) and named 
human T-cell leukemia virus type III (HTLV-III) (Broder and Gallo 1984) and by 
another group, denoting the virus as AIDS-associated retrovirus (Levy et al. 1984). 
 
This newly identified retrovirus, belonging to the lentivirus genus of the viral family 
Retroviridae, was named later human immunodeficiency virus (HIV). Lentiviruses 
(lenti-, Latin for “slow”) are mammalian retroviruses able to replicate in non-
dividing cells, characterized with long incubation periods and persistent infection. 
Members of the primate lentivirus group are HIV-1, HIV-2 and simian 
immunodeficiency virus (SIV). Current evidence indicates that transmission of 
HIV-1 crossed the species barrier into humans during the first half of the 20th 
century (Korber et al. 2000) from chimpanzees (SIVcpz) (Gao et al. 1999). HIV-2 
was first recovered from individuals in several countries in West Africa in 1986 and 
has been traced back to sooty mangabeys (SIVsmm) viral strains (Hahn et al. 2000). 
HIV-2 is endemic only in certain countries of West Africa, due to its less effective 
transmission and is characterized by remarkably slower disease progression and 
lower mortality rates (Gottlieb et al. 2002). 
 
Currently there are approximately 35-40 million people infected with HIV-1, and 
more than 25 million people have died of AIDS. While the rate of new HIV-1 
infections in sub-Saharan Africa has slowly declined, it still remains the most 
heavily HIV-1 affected region. HIV-1 incidence has increased most rapidly in 
Eastern Europe and Central Asia. Due to its highly variable nature, HIV-1 has 
proven to be a very challenging virus for the immune system. Efforts to restrain the 
virus by antiretroviral drugs have so far been inadequate to control the spread of the 
virus. Additionally, at the end of 2009, of 15 million people in need of antiretroviral 
treatment in low- and middle-income countries, only ~36% were receiving it 
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(UNAIDS  2010).  The  development  of  a  safe,  effective  and  economically  feasible  
vaccine  against  HIV-1  is  the  priority  for  controlling  the  worldwide  HIV/AIDS  
pandemic. Great advances in the understanding of the HIV-1 immunopathogenesis 
and the immune system itself have brought the goal closer but continuous 
commitment to basic research, preclinical and clinical studies are crucial.  
2.1.2 HIV-1 structure and life cycle  
HIV-1 is a spherical virus with a diameter of approximately 120 nm. All 
lentiviruses, including HIV-1, are transmitted enclosed in a lipid bilayer envelope, 
derived from the host cell membrane. Two copies of single-stranded, positive-sense 
RNA molecules encode altogether nine genes, three of them being polyproteins 
common to all retroviruses, the group-specific antigen (gag), polymerase (pol) and 
envelope (env). HIV-1 and other lentiviruses have developed accessory proteins 
with more sophisticated functions, such as counterattacking the antiviral defenses 
against HIV-1. HIV-1 has acquired genes for two regulatory proteins, regulator of 
virion gene expression (rev) and transcriptional transactivator (tat) and for four 
accessory proteins, the “negative effector” (nef), viral infectivity factor (vif) and the 
viral protein r (vpr) and viral protein u (vpu). Protein expression is highly regulated 
and the viral life cycle can be separated into early regulatory phase and late 
assembly  phase  when  different  proteins  are  allowed  to  be  synthesized  (Frankel  
1998). The genome of ~9 kb is stabilized by nucleocapsid protein (p7) and packed 
inside the viral particle, composed of inner conical capsid (p24) and outer matrix 
(p17) shell, further surrounded by the envelope. The envelope (Env) glycoprotein 
spikes project from the surface of the HIV-1 particles, composed of a trimeric, non-
covalently associated complex of the surface glycoprotein gp120 and the 
transmembrane glycoprotein gp41 (Frankel and Young 1998). 
 
 
 
 
Figure 1. Organization of HIV-1 virion and genome. Adapted from Frankel and Young 1998. 
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HIV-1 fusion is initiated and mediated by gp120 spikes (Wyatt and Sodroski 1998), 
which bind to the target cell CD4 (cluster of differentiation) receptors (Dalgleish et 
al. 1984, Klatzmann et  al. 1984). The binding leads to a major conformational 
change of gp120, that allows subsequent interaction with the specific coreceptors on 
the target cell, mainly CCR5 or CXCR4 (Alkhatib 2009, Deng et al. 1996, Feng et 
al. 1996). Co-receptor binding and further structural changes enable gp41 to insert 
its N-terminal fusion peptide into the target cell membrane, promoting the fusion of 
the viral and target cell membranes and subsequent entry of the viral core into the 
host cell cytoplasm (Wyatt and Sodroski 1998).  
 
 
 
 
 
Figure 2. HIV-1 life cycle. Viral life cycle is initiated by binding of the free virus (1) to CD4 
receptor ands co-receptor on the target cell surface (2), followed by fusion and (3) uncoating of viral 
RNA  genome.  (4)  Reverse  transcription  of  ssRNA  to  dsDNA  by  viral  RT  and  formation  of  pre-
integration complex precedes the (5) proviral DNA integration into the host genome. (6) 
Transcription is inititated by the cellular machinery and multiply spliced mRNA are transported to 
cytoplasm and (7) translated to early proteins Rev, Tat and Nef, followed by (8) nuclear import of 
Rev and Tat. Tat efficiently enhances the transcription of viral genome. Rev facilitates the shuttling 
of the unspliced and single-spliced mRNA from the nucleus to the cytoplasm and (9) late proteins are 
translated. The mRNAs are translated as polyproteins and cleaved later into functional late proteins. 
(10) Structural polyproteins and viral RNA genome are carried to the cell membrane for the assembly 
of new virions. New virions get the surrounding lipid envelope from the host cell when budding out 
of the cells, also containing the trimeric transmembrane Env spikes. 
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Once in the cell cytosol, the RNA genome is reverse transcribed into double-
stranded  DNA  by  HIV-1  reverse  transcriptase  (RT),  enzyme  common  to  all  
retroviruses. RNAse H domain of RT has a ribonuclease H activity that is used for 
the degradation of viral RNA and DNA-dependent DNA polymerase activity of RT 
creates  another  strand  of  DNA.  The  extremely  low  fidelity  of  RT  lacking  the  
proofreading function leads to error-prone viral DNA synthesis, with error 
frequency  of  more  than  3  substitutions  per  10-5 incorporated nucleotides (Mansky 
and Temin 1995, Onafuwa-Nuga and Telesnitsky 2009). The extensive genetic 
heterogeneity of HIV-1 is largely based on the mismatches made during replication. 
Additionally, action of a host cell cytidine deaminase ABOBEC3G found in some 
cell types such as macrophages results in very high rate of G-to-A substitutions in 
retroviral genomes (Zhang et al. 2003). 
 
Pre-integration complex containing viral genome, integrase, matrix and Vpr along 
with host cell co-factors is formed and after being transported to the nucleus the 
dsDNA integrates into the host cell genome. The integrated HIV DNA persists as a 
provirus flanked by 5-bp long terminal repeats (LTR) needed both for integration 
and transcription (Vincent et al. 1990). The 5' LTR functions as a promoter while 
the 3' LTR site is where viral transcripts become polyadenylated. The integration 
has been shown to be preferentially targeted at genes activated in cells after 
infection by HIV-1 (Schroder et al. 2002).  
 
Integrated viral DNA may then lie dormant in the latent stage for a long time while 
the infected cell functions and replicates normally, passing on the HIV-1 genome to 
its progeny (Ranki et al. 1987). Post-integration latency is established at the 
beginning of HIV-1 infection, mostly in resting CD4+ memory T cells, when the 
provirus fails to express its genome. Several factors establishing the latency stage 
are related to transcription repression, like chromatin environment at the integration 
site, availability of host transcription factors, transcriptional interference and 
epigenetic silencing (Colin and Van Lint 2009, Hakre et al. 2011). Alternatively, the 
virus may activate and start assembling viral particles in the cell, utilizing the cell’s 
machinery. Transcription activators like cellular NFkB and viral Tat protein trigger 
the process of transcription to viral mRNA. Tat acts by binding to a stem-loop 
region  (TAR)  present  near  the  5ƍ terminus  of  retroviral  mRNA  and  stabilizes  the  
elongation process by host RNA-polymerase II. Tat also recruits several cellular 
proteins for the transcription process. Multiple spliced mRNA is exported to the 
cytoplasm where early regulatory proteins Rev, Nef and Tat are translated, followed 
by the importation of Tat and Rev proteins into the nucleus where Tat enhances the 
transcription (Karn 1999, Romani et al. 2010). 
 
When Rev accumulates in the nucleus it binds to the viral Rev response element 
(RRE) that is present only in unspliced and singly spliced mRNA. Rev permits 
mRNA entry into the cytoplasm for translation and also enhances the unspliced 
mRNA encapsidation which directs it to the cell surface where assembly of new 
virus particles occurs (Brandt et al. 2007). Thus the later synthesis of Gag and Gag-
Pol proteins from full length mRNA and Env, Vpu, Vpr and Vif from singly spliced 
mRNA is enabled by accessory protein Rev (Turner and Summers 1999). The 
mechanism of Rev dependent nuclear export has been proposed to have evolved to 
prevent the translation of structural proteins in the early phase of virus replication as 
their presentation might result in CD8+ T cell recognition (Blissenbach et al. 2010).  
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Single mRNA chain encodes both Gag and Pol proteins. Gag precursor protein 
(p55) is synthesized first and then subsequent translational frameshift results in 
translation of Gag-Pol polyprotein (p160). HIV-1 Protease cleaves p55Gag into viral 
internal proteins matrix p17, capsid p24, nuceocapsid p7 and p6 and small peptides 
p2 and p1. Polyprotein p160GagPol cleavage products are three HIV-1 enzymes 
Integrase, RT and Protease (Frankel and Young 1998). 
 
The elusive role of Nef in viral replication and pathogenesis is linked to the 
capability of Nef to downregulate cell surface molecule CD4, which is suggested to 
facilitate the release of viral progeny by preventing Env-CD4 interactions at the 
time of  viral budding (Kim et al. 1999, Lundquist et al. 2002) and major 
histocompatibility (MHC) class I expression (Joseph et al. 2005, Piguet et al. 1999, 
Swann et al. 2001), which impedes the viral antigen presentation to CD8+ T cells. 
Nef enhances viral replication and infectivity also independently on CD4 
downregulation (Saksela et al. 1995). Nef enhances T cell activation and 
transcription response, thereby increasing the viral production in those cells (Foster 
and Garcia 2008, Simmons et al. 2001). By inducing FasL expression on infected 
cells, Nef augments bystander cell death by apoptosis, including CTL. Additionally, 
Nef protects HIV-1 infected cells from apoptosis (Joseph et al. 2005, Piguet et al. 
1999, Swann et al. 2001, Xu et al. 1997).  
 
New virions are assembled at the cell plasma membrane. The expressed Env 
precursor protein gp160 is glycosylated in the endoplasmic reticulum and cleaved in 
Golgi apparatus by the cellular protease furin. Cleaved protein products gp120 and 
gp41 are transported to the cell membrane, where they form trimeric structures. 
Myristoylation of p55Gag and p160GagPol polyprotein directs them to the cell 
membrane where two unspliced mRNA genomes are bound to Gag and thus packed 
into the new virion. p55Gag is the driving force in particle formation and release 
and is sufficient alone to form non-infectious virus-like particles (VLP). Maturation 
of the virus starts during the budding of the nascent virion from the plasma 
membrane, when HIV-1 Protease cleaves the Gag and Gag-Pol polyproteins into 
functional proteins. Gag domain p6 is used to hijack the components of the cellular 
endosomal sorting machinery, facilitating virus release (Frankel and Young 1998). 
 
Mature virion also contains accessory proteins Vif, Vpr and Vpu. Vpr  is  a  part  of  
pre-integration complex imported to nucleus and is able to arrest the cell cycle in the 
G2 phase and to induce apoptosis of infected cells. Vif and Vpu play important roles 
in HIV-1 pathogenesis by counteracting cellular antiviral factors (Gramberg et  al. 
2009). Vif is bound to the mRNA, stabilizing the viral core and inhibits the cellular 
antiviral protein APOBEC-3G (Zhang et  al. 2003). Vpu contributes to the 
degradation of cell surface CD4 along with Nef and Env and also reduces amount of 
MCH molecules on the cell surface, promotes the release of the virions and prevents 
endocytosis of nascent viral particles from the plasma membrane (Gramberg et al. 
2009, Piguet et  al. 1999). Finally, the mature virus contains the HIV-1 genome, 
structural  proteins and the proteins important for infectivity and for early phase of 
viral life cycle inside the new host cell. 
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2.1.3 Genetic variability and global distribution of HIV-1 
subtypes 
The hallmark for RNA viruses and especially for HIV-1 is the broad genetic 
variability, as every isolate of the virus and almost every virus in one population is 
different. Rapid turnover of virus replication in vivo and high mutation rate by error-
prone RT gives rise to HIV-1 quasispecies, virus particles with modified properties 
from transmitted founder virus, in a single infected individual (McMichael et al. 
2010, Onafuwa-Nuga and Telesnitsky 2009). In addition to point mutations, 
extensive recombination among quasispecies or among two separate strains in 
patients with HIV-1 coinfection efficiently generates variation. HIV-1 
recombination is a result of RT template switching between two viral RNA during 
provirus synthesis (Charpentier et al. 2006, Onafuwa-Nuga and Telesnitsky 2009, 
Temin 1993). The excessive selective pressure exerted both by the host’s immune 
system  and  antiretroviral  therapy  as  well  as  availability  of  different  target  cells  
further drives HIV-1 diversification and evolution. Even if the majority of genome 
mutations lead to depleted replicative capacity and viability of the virus, they also 
allow the virus to escape the host defense (Biesinger and Kimata 2008). 
 
HIV-1 is subdivided into four divergent phylogenetic subgroups, designated as M 
(main), O (outlier), N (non-M non-O) (Taylor and Hammer 2008) and a newly 
identified variant P, being distinct from previously established groups (Plantier et al. 
2009). Group O and N viruses are found at low frequencies mainly in Central 
Africa. HIV-1 group M is the predominant reason for the pandemic, accounting for 
more than 95% of infections worldwide. Group M consists of nine different genetic 
subtypes or clades (A, B, C, D, F, G, H, J and K), some of them further divided into 
sub-subtypes designated with numbers. Advances in the sequencing of HIV have 
also resulted in the identification of circulating and unique recombinant forms (CRF 
and URF). HIV-1 genetic forms are distributed over global geographic areas to 
varying extents. Clade C has become the dominant subtype in countries most 
heavily infected with HIV-1, like Southern Africa and India and currently accounts 
for nearly half of global HIV-1 infections. Clade A is predominantly found in 
Eastern and Central Africa and countries of the former Soviet Union in Eastern 
Europe.  In  Western  and  Central  Europe,  America  and  Australia  the  B  clade  is  
prevalent (Buonaguro et al. 2007). The degree of conservation in the different genes 
varies, pol encoding HIV-1 enzymes is most conserved (>90%), structural gene gag 
also possessing quite a high degree of conservation (>80%) while nef somewhat less 
(>70%) (Coplan et al. 2005, Rolland et al. 2007b). The greatest variability occurs in 
the gene encoding Env, which is the only viral protein presented on the surface of 
the viral particle and thus most predisposed to selective pressure. Env sequence can 
differ up to 35% between clades and 20% within a clade (Taylor and Hammer 
2008). Conserved sequences are usually related to viral fitness, the sequences that 
are crucial for viral infectivity and pathogenesis have least variability.  
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2.1.4 HIV-1 cell tropism 
HIV-1 productively infects cells expressing CD4+ receptor and chemokine co-
receptor, binding allowing HIV-1 to fuse with the cell membrane and infect the cell. 
Primary targets for HIV-1 are CD4+ T cells (Klatzmann et al. 1984), macrophages 
(Gartner et al. 1986) and dendritic cells (DC) (Knight and Macatonia 1988). 
Monocytes are quite refractory to infection and become more permissive upon 
differentiation into macrophages (Bergamaschi and Pancino 2010).  
 
HIV-1 strains vary in their host cell range, or tropism, according to co-receptor 
usage. Several members of chemokine co-receptors for HIV-1 have been identified 
(Calado et  al. 2010). During natural infection major HIV-1 co-receptors are 
considered to be CCR5, expressed mostly by cells of the monocyte/macrophage 
lineage, primary lymphocytes and DC (Alkhatib 2009, Deng et al. 1996) and 
CXCR4, expressed on many activated CD4+ T cells (Feng et al. 1996). According 
to this, HIV-1 variants have been broadly divided to M-tropic (R5 virus), T-tropic 
isolates (X4) and dual-tropic isolates (R5X4) respectively. R5-viruses infecting 
primary CD4+ T-lymphocytes and macrophages expressing CCR5 co-receptor are 
predominant during the early stages of HIV-1 infection, being mostly responsible 
for virus transmission and associated with slow disease progression (Calado et al. 
2010, Gorry et al. 2005). In about 40-50% of individuals infected with subtype B, 
the cell tropism is expanded through evolution of env gene and X4 and R5X4 virus 
variants emerge at later stages of the disease (Coetzer et al. 2008) but in the 
majority of infected individuals progressing to AIDS, R5 variants predominate 
throughout the disease. However, the classical linking together of phenotypic 
characteristics is not so straightforward, and the exact relationship between viral co-
receptor usage, cell tropism, syncytia induction and pathogenicity of HIV-1 remains 
elusive (Calado et  al. 2010, Coetzer et al. 2008, Goodenow and Collman 2006, 
Gorry et al. 2005). 
2.1.5 Course of infection 
HIV-1 transmission can occur by sexual transmission, via the parenteral route e.g. 
among drug users and vertically from mother to infant. The most common route of 
HIV-1 infection is sexual transmission across a mucosal surface (Biesinger and 
Kimata 2008, McMichael et al. 2010). During mucosal HIV-1 transmission, 
macrophages,  DC  and  a  subset  of  DC,  Langerhans  cells  (LC)  may  internalize  the  
virus by endocytosis, while intraepithelial CD4+ T cells are infected only through 
CD4 and CCR5 binding (Hladik et al. 2007, Pope and Haase 2003). Additionally, 
viral entry and migration to lymph nodes (LN) can occur as cell-associated virus, as 
myeloid DC (mDC) and macrophages allow HIV-1 to bind to their surface through 
c-type lectin named DC-SIGN, without internalization of the virus. DC-SIGN may 
also facilitate the infection of these cells (de Jong and Geijtenbeek 2010, Pope and 
Haase 2003). DC subsequently carry the virus to the draining lymph nodes where 
they interact with CD4+CCR5+ naive T cells, productively infecting them. LC 
express another c-type lectin, langerin and can efficiently prevent the infection by 
capturing HIV-1 through langerin and degrading incoming viruses in so-called 
Birbeck  granules  (de  Witte et al. 2007). Only when LC are activated by co-
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infections and inflammation, for example, by other sexually transmitted diseases, is 
langerin unable to capture the virus any more and LC become susceptible to HIV-1 
infection through CD4 and CCR5 receptors and start transmitting the virus (de Jong 
and Geijtenbeek 2010).  
 
The founder viruses have been shown to infect primary CD4+T cells with greater 
efficiency than monocytes and macrophages. In the acute phase the propagation first 
occurs in activated CD4+CCR5+ T cells in draining lymph nodes, soon followed by 
massive depletion of activated CD4+CCR5+ memory T cells in the gut-associated 
lymphoid tissue (GALT), which harbors the majority of T lymphocytes of the body. 
Within  a  few  weeks  after  transmission,  the  majority  of  CD4+CCR5+  T  cells  in  
GALT and vaginal mucosa become activated and die apoptotically or through direct 
viral killing or by HIV-1 specific cytotoxic CD8+ T cells when infected (Guadalupe 
et al. 2003, McMichael et al. 2010). Most infected individuals experience symptoms 
resembling influenza or mononucleosis at that time, severe and prolonged symptoms 
are correlated with rapid disease progression. High viral load in blood and viral 
seeding  to  the  central  nervous  system  are  observed  during  the  first  months  of  
infection, as well as large number of circulating functional HIV-1 specific cytotoxic 
CD8+  T  cells  and  anti-HIV  antibodies.  The  early  immune  responses  to  HIV-1  
infection are important for the subsequent clinical course of disease. By following 
the plasma viral load and CD4 counts within the first 6 to 12 months, the ultimate 
course of HIV infection can be predicted quite well. Usually at the time of peak 
viremia approximately a month after the transmission, the viral load is 106 - 107 
RNA copies / ml, but drops to 30, 000 copies / ml in the following months. CD4+ T 
cell counts are also restored to almost normal level in blood, but not in GALT. The 
higher this viral set-point is, more rapid disease progression will follow (Guadalupe 
et al. 2003, McMichael et al. 2010, Mellors et al. 1997).  
 
The constant activation of CD4+ and CD8+ T cells leads to T cell exhaustion and 
apoptosis during the chronic phase, effector memory T cells (TEM) rich in peripheral 
tissues especially are depleted or malfunctional (Groot et al. 2006, McMichael et al. 
2010). During the non-symptomatic chronic phase low but constant depletion of 
activated CD4+ T cells continues and finally blood count reaches the level of equal 
or less than 200 cells/mm3. This may be considered as the onset value for AIDS, as 
well as opportunistic infections emerging due to the weakened immune defense. The 
course of disease progression varies widely among infected, non-treated persons; 
AIDS can be developed within six months, while other individuals may remain 
asymptomatic for more than 25 years and are named long-term nonprogressors 
(LTNP). The virus still remains in latent reservoirs mainly in resting memory CD4+ 
T cells and full eradication of virus is still not possible today. Even if highly active 
antiretroviral therapy (HAART) can efficiently suppress viral replication, 
interrupting HAART leads to a rapid rebound of plasma viremia (Colin and Van 
Lint 2009, Hakre et al. 2011).  
 
The exact correlates of the progression or protection of AIDS have not been 
identified but are likely to be mediated by several factors of adaptive and innate 
immune responses, host genetic factors and viral pathogenicity. Long-term 
nonprogressors (LTNP) accounting for ~5-15% of HIV-1 infected individuals are 
able to preserve high CD4+ T cell levels and stay asymptomatic without any 
treatment for 7-10 years (Cao et al. 1995, Okulicz et al. 2009, Vesanen et al. 1996). 
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Another  small  subset,  <  1% of HIV-1 infected subjects not developing AIDS and 
additionally displaying more sustained control over viral replication (plasma HIV 
RNA levels of <50 copies/ml) are denoted elite controllers (Okulicz et al. 2009). 
These exceptional groups among HIV-1 infected individuals have yielded some 
insight into the mechanisms delaying the disease. Additionally, the sooty 
mangabeys  that  are  natural  hosts  for  related  SIV  infection,  do  not  develop  AIDS  
when infected. One explanation has been suggested to be the absence of chronic 
activation of the immune system that is detected in non-natural SIV hosts like rhesus 
macaques, and in human HIV-1 infection where the immunodeficiency is acquired 
(Mandl et al. 2008). In addition to the massive loss of T lymphocytes by direct viral 
killing, the driving force for AIDS progression is likely to be the chronic 
generalized immune activation, associated with elevated turnover rates of T cells 
and NK cells, polyclonal activation of B cells and decrease of peripheral DC 
number and reduced capability to regenerate immune cells by the primary lymphoid 
organs. 
2.2 Innate immunity and cytokines 
The immune system is composed of two major subdivisions, non-specific innate 
immunity and specific adaptive immunity. While the mucosal route is the most 
common for HIV-1 transmission, the mechanisms prevailing there have the greatest 
impact on protection from HIV-1. The mucosal layer is rich in cells of the immune 
system and antimicrobial agents produced by these cells. Innate immunity provides 
immediate first line defense against invading pathogens and is able to respond 
rapidly.  It  has  a  remarkable  role  in  primary  HIV-1  response,  as  adaptive  immune  
responses will be functional only when the HIV-1 infection is already well 
established.  
 
Cells working for innate immune responses during viral infection, such as tissue 
macrophages, blood monocytes, plasmocytoid DC (pDC), LC, NK and neutrophils 
can act by directly destroying the viral particles and infected cells or through the 
secretion of soluble factors like cytokines (Borrow et al. 2010, Chang and Altfeld 
2010). These cells use their pattern recognition receptors (PRR), such as toll-like 
receptors (TLR) for the recognition of structures specific for micro-organisms, 
called pathogen-associated molecular patterns (PAMPS), which activates cells to 
produce several cytokines and chemokines. These immunomodulators are the main 
controllers of the immune system linking the innate and adaptive immunity, turning 
on and off the inflammatory responses and directing immune cell differentiation, 
function and migration and having direct anti-viral effects (Alfano et al. 2008, 
Borrow et  al. 2010). Additionally, TLR-induced cytokine production upregulates 
the expression of multiple TLR receptors and enhances IFN production in a 
synergistic manner (Makela et  al. 2011). In viral infections structures such as 
double-stranded RNA (dsRNA), single-stranded RNA (ssRNA), unmethylated CpG-
oligodeoxynucleotide-containing DNA and certain viral proteins are recognized 
(Chang and Altfeld 2010, Mandl et al. 2008). Type I IFNs are a superfamily of 
innate cytokines including 13 IFN-Į subtypes, IFN-E,  -Z,  -H and  -N, triggered by 
virus infections through TLR stimulation. pDC stimulation by CpG DNA through 
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TLR-9 induces expression of several antiviral cytokines, such as IFN-Į, -E, -Z and 
IFN-Ȝ (Coccia et al. 2004).  
 
Cytokines are involved in HIV-1 pathogenesis, having an inhibitory effect on 
infectivity and replication on several stages of HIV-1 life cycle but also by 
enhancing the infection and leading to exacerbated responses. Their improper 
regulation during HIV-1 infection is one main effector for HIV-1 pathogenesis 
(Chang and Altfeld 2010, Mandl et al. 2008) and early cytokine storm in acute HIV-
1 has been well documented, associated with enhanced expressions of IFN-Į, IL-15, 
IL-6, IL-8, IL-18 and IFN-Ȗ (Chang and Altfeld 2010, Stacey et  al. 2009). A 
thorough understanding of the roles of each cytokine is also important when 
utilizing cytokines as immunopotentiators with vaccines or for antiretroviral therapy 
(Alfano et al. 2008, Borrow et al. 2010, Stacey et al. 2009).  
 
One well characterized innate defense mechanism against HIV-1 in humans and SIV 
infection in non-human primates is the cascade initiated by recognition of the viral 
HIV-1 ssRNA through TLR7 expressed by pDC, monocytes and B cells (Chang and 
Altfeld 2010, Mandl et al. 2008). HIV-1 endocytosis enhances pDC viability and 
maturation through TLR7 and activation leads to the production of several cytokines 
such as IFN-Į, TNF-Į, and proinflammatory chemokines and upregulates some 
maturation markers (CD83, CCR7) and costimulatory molecules (CD80, CD86) on 
pDC. HIV-1 activated pDC additionally contribute in mDC maturation, as mDC are 
not activated directly by HIV-1 (Fonteneau et al. 2004). Greater numbers of pDCs 
are found in HIV-infected individuals who are healthy, long-term survivors 
(Soumelis et al. 2001). Mucosal LC are the first DC subset to encounter HIV-1 and 
similar to pDC, they can detect ssRNA through intracellular TLR7. Additionally, 
LC work for innate immunity by internalizing and degrading the virus as described 
earlier (de Witte et al. 2007). 
 
NK cells can recognize HIV-1 infected cells that have downregulated MHC 
molecules and kill them by releasing apoptosis inducing proteins perforin and 
granzyme (Chang and Altfeld 2010, Pipkin and Lieberman 2007). NK cells also 
mediate non-cytolytic suppression of viral spread through the secretion of 
chemokines CCL3, CCL4, and CCL5 (also named MIP-1D and MIP-1E and 
RANTES) that can function as CCR5 ligands and thereby block the virus from 
entering  target  cells.  NK  cells  produce  cytokines  such  as  IFN-Ȗ,  TNF  and  
granulocyte/macrophage-stimulating factor (GM-CSF). NK contribution, especially 
by IFN-Ȗ production, has been emphasized in studies with seronegative individuals 
constantly exposed to HIV-1 (Fauci et al. 2005).  NK  cells  are  one  of  the  major  
effector cells for antibody dependent cellular cytotoxicity (ADCC), mechanism 
based on Fc receptors on NK cells, able to recognize and bind the Fc region of the 
antibody that is bound to the surface of the infected cells, thus recruiting NK cells. 
However, the role of ADCC in HIV-1 infection has not been extensively studied. In 
addition, IgG antibodies can bind proteins of the complement system, thereby 
leading to engagement of the complement system which plays a critical role in 
clearing and neutralizing HIV-1 virions. HIV-specific antibodies and complement 
deposited onto HIV lead to the inactivation of the virus and lysis of infected cells 
(Mascola and Montefiori 2010, Stoiber et al. 2008). However, the HIV-1 virus, 
having a broad range of strategies to avoid the host defense, also has a mechanism 
to avoid complement-mediated lysis and even take advantage of the system. 
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Mammalian cells are protected by the expression of cell membrane complement 
regulators such as CD55 and CD59 and HIV-1 can obtain these proteins on their 
surface when budding out of the cell and use them to escape the Ab-dependent, 
complement-mediated virolysis (Saifuddin et al. 1995). One specific intraepithelial 
lymphocyte type called Ȗį T cells bridges the innate and the adaptive immune 
system. They are mainly found in gut mucosa and thereby play a role in first line 
defence in HIV-1 infection, secreting chemokines, antiviral factors and killing 
infected cells through natural killer mechanism. Ȗį T cells are not dependent on the 
MHC antigen presentation (Agrati et  al. 2011). Additionally, another distict cell 
type  called  NKT  cells  share  characteristics  both  with  NK  cells  and  T  cell  
lymphocytes but little is known about their responses in HIV-1 infection (Borrow et 
al. 2010, Borrow et al. 2010). 
 
Innate and adaptive immune responses closely co-operate and the initial innate 
immune response can determine the quality of the forthcoming adaptive immune 
response. Cells of innate immunity can capture the foreign material and further 
present these antigens for lymphocytes in lymphoid organs. The cytokine and 
chemokine production also controls adaptive immune responses. Vaccines based on 
attenuated or killed pathogens contain pathogenic molecular patterns recognized by 
innate immunity and therefore induce strengthened specific immune responses. 
When applying highly purified vaccine antigens, the lack of these viral components 
result in weaker immune responses. For that reason the vaccine adjuvants are 
designed also to activate the innate immunity, further extrapolating the strength of 
the specific adaptive response (Chang and Altfeld 2010).  
2.3 Adaptive immunity 
While innate immunity provides rapid but unchanged response to antigen, the 
adaptive immune response takes days to evolve after the first encounter with the 
antigen. The highly specific surface receptors initiate tailored responses to the 
particular pathogen and, most importantly, the adaptive immune system remembers 
the antigen when repeatedly exposed. The re-encounter of the same antigen triggers 
significantly faster and more vigorous cellular and humoral immune responses 
driven by antigen specific memory T and B lymphocytes. The phenomenon of 
immunological memory is the basis for adaptive immunity, and the key to artificial 
acquired immunity achieved by vaccination.  
 
T lymphocytes maturing in the thymus and B lymphocytes maturing in bone 
marrow are the cells responsible for cell-mediated and humoral adaptive immunity 
respectively. They are highly adaptable to recognize wide variety of pathogens by 
generating a vast number of different antigen receptors. T and B cells can enter the 
secondary lymphoid organs including the spleen, lymph nodes and mucosal 
lymphoid tissue as naïve lymphocytes. Lymph nodes, the garrisons of immune cells, 
are the most important sites for antigen presentation and have a structure highly 
specific for their function (Banchereau and Steinman 1998).  
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2.3.1 Professional APC – The interphase between innate and 
acquired immunity 
Indispensable to adaptive immunity are the professional antigen presenting cells 
(APC) such as DC, macrophages and B cells that constantly screen their 
surroundings for self and non-self antigens. Professional APC can capture and 
engulf the extracellular molecules from the periphery, degrade them and present 
antigens on their surface to naive CD4+ and CD8+ T cells, the phenomenon called 
priming. Professional APC in the lymph nodes and spleen may also acquire antigen 
from circulating lymph fluid or blood respectively. DC and LC have an enormous 
capacity to induce strong T cell responses by small numbers of DC and low levels of 
antigen. Some lines of evidence suggest that macrophages could also be almost as 
efficient in priming T cell responses (Pozzi et al. 2005). Naive T and B cells can 
differentiate as effector, helper and regulatory cells and a small number of these 
antigen specific cells is maintained as memory cells once the pathogen has been 
eradicated.  
 
DC can be resident in tissues or circulate in the blood gathering antigens. In the 
initial immature state DC express only low levels of MHC class II molecules and 
costimulatory molecules needed for T cell activation, such as CD80 (B7-1) and 
CD86 (B7-2), but are instead highly phagocytic and effective in capturing antigens. 
After encountering the antigen, DC are activated and can migrate to secondary 
lymphoid organs where they maturate fully if receiveing the costimulation signal 
through CD40. Maturation is accompanied by increased expression of MHC class I 
and II molecules and the costimulatory molecules CD80, CD86, CD40 and CD83 
and by downregulation of antigen capture molecules such as Langerin and E-
cadherin on LC or DC-SIGN on DC. Migration to secondary lymphoid organs 
maximizes the probability of interaction with T and B cells and is directed by CCR7 
chemokine receptor on DC (Banchereau and Steinman 1998, de Jong and 
Geijtenbeek 2010, Guermonprez et al. 2002). DC can be divided into two subsets 
according to CD11c expression; myeloid DC (mDC) expressing CD11c+ and 
plasmocytoid CD11c- DC. CD11c+ DC include LC, dermal and interstitial DC and 
have additionally been subdivided into myeloid CD11b+CD11c+ DC and lymphoid 
CD8D+CD11c+ DC  with  different  T  cell  priming  capabilities  (Abadie et  al. 2009, 
Donaghy et al. 2001). During HIV-1 infection an inverse correlation has been 
observed between viral load and CD11c+ DC numbers, CD11c+ loss and shift to Th2 
type cytokines has shown to be concurrent (Donaghy et al. 2001).  
 
The migration patterns of naïve, effector and memory lymphocytes between 
lymphoid tissue and non-lymphoid tissue are consequence of differential expression 
of chemokine and adhesion receptors, such as integrins (Denucci et al. 2009, Muller 
and Lipp 2003). The precise migration capability of each cell type remains 
controversial  (Cose  2007).  Naïve  T  cell  and  central  memory  T cell  (TCM) homing 
receptors are such as L-selectin and CCR7, providing adhesion to lymph nodes, 
while activated effector T cells and effector memory T cells (TEM) express 
molecules such as CCR5 and CXCR3, directing cells to peripheral site of infection 
(Denucci et al. 2009). In general, the primary immune response is triggered during 
the first few days when DC prime the naïve T cells in the lymph nodes, leading to 
their clonal expansion. DC migration to the lymphoid tissue after s.c. inoculation 
has been shown to be more efficient than migration of macrophages. However, 
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when  these  APC  were  injected  i.v.,  both  cell  types  were  equally  presented  in  the  
spleen one day later (Pozzi et  al. 2005). The number of antigen-carrying DC in 
draining LN and in mucosal Peyer’s patches has been demonstrated to peak between 
4 hours and 2.5 days after skin contact with antigen (Abadie et al. 2009, Belyakov et 
al. 2004, Garg et al. 2003, Porgador et  al. 1998) and shown to persist for 
approximately two weeks (Akbari et al. 1999, Garg et al. 2003, Pozzi et al. 2005, 
Tuomela et al. 2005). For CD4+ T cells the clonal expansion has been apparent by 
day 2 and maximal on days 3 and 4. B cell expansion has been detected 3 days after 
immunization, reaching maximal level by day 5 and then declining (Garside et al. 
1998). 
2.3.2 Activation of humoral immune responses 
B cells act as professional APC, even if much less efficiently than DC. B cells can 
engulf and respond directly to some antigens but are partly dependent on antigen 
presentation by other APC, depending on the nature of the antigen. Antigens are 
recognized through B cell receptor by naïve B cells as intact antigens, being either 
soluble or membrane-bound. Activated CD4+ T cells play an important role in 
promoting B cell activation through CD40L/CD40 interactions although many non-
protein antigens, called T cell independent antigens, can stimulate antibody 
production independently of CD4+ T cells (Batista and Harwood 2009). Once CD4+ 
T cells are activated by DC priming, they are able to stimulate B cell responses. 
They express CD40L, downregulate CCR7 expression and upregulate CXCR5 
chemokine receptor that directs them to migrate from the T cell zone towards the 
follicle, augmented by follicular cells that secrete CXCR5 ligand. Conversely, 
activated B cells downregulate the CXCR5 and start to express CCR7, thus directing 
them toward the T-B interface and T cell zone. This leads to CD4+ T cell and B cell 
interaction and B cells can present the MHC class II-associated peptides to CD4+ T 
cells, thereby recruiting CD4+ T cell help which stimulates B cell proliferation, 
differentiation and antibody isotype switching (Muller and Lipp 2003, Okada et al. 
2002). Activated B cells can differentiate as antibody producing plasma cells or as 
memory B cells that provide long-lasting protection. The activated B cells require 
approximately two weeks to accomplish proper antibody response (Batista and 
Harwood 2009, Tahtinen et al. 2001, Tähtinen 2001).  
2.3.3 Activation of cellular immune responses  
Cell-mediated immune responses are mediated through cytotoxic CD8+ T 
lymphocytes (CTL) and CD4+ T helper (Th) lymphocytes. The subclass of Th cells, 
regulatory T cells (Treg) suppress the immune system and maintain the self-
tolerance. Naïve T cell are primed through T cell receptors (TCR) that recognize the 
peptide in the context of MHC molecules on APC. MHC molecule is additionally 
bound by another T cell co-receptor, either CD4 or CD8. T cell activation is 
successful if the second signal is received by a costimulatory molecule on the APC, 
interacting  with  the  specific  ligand  on  the  T  cell.  APC  can  use  CD80  (B7-1)  and  
CD86 (B7-2) molecules to either activate T cell through CD28 receptor or inhibit T 
cell responses through CTLA-4 binding (Alegre et al. 2001). The signaling cascade 
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in  the  T  cells  is  initiated  by  TCR,  associated  CD3 molecule  and  CD4 or  CD8 co-
receptor. The absence of costimulation leads to anergy or apoptosis of the T cell 
unable to respond to an antigen. Interactions with professional APC are essential for 
maintaining the T cell activity, also in the absence of foreign antigen presentation 
(Hochweller et al. 2010). Once activated, T cells start proliferation and differention. 
The division of antigen-activated T cells is very rapid and leads to >1000-fold 
expansion of the responding cells within a few days. At the end of the primary 
response >90% of the effector cells are destroyed, only few of them surviving as 
long-lived effector and central memory cells (D'Cruz et al. 2009, Williams and 
Bevan 2007). Induction of the polyfunctional CD4+ and CD8+ T cell responses is a 
highly desired goal for immunizations, referring to the ability of T cells to produce 
high levels of several soluble factors simultaneously, such as cytokines IFN-Ȗ, IL-2 
and TNF-D, chemokines like MIP-1E and cytotoxins. Degranulation indicating 
cytotoxic ability is measured as CD107a surface mobilization (Betts et al. 2006, 
Duvall et al. 2008). 
2.3.3.1 Cytotoxic T cells 
The effectors of the cellular immune system are CD8+ T cells that respond to 
peptides derived from proteins expressed inside the cell that can be derived either 
from self-proteins or during the viral infection, from viral proteins. These 
intracellular antigens are presented through MHC class I molecules, expressed not 
only on professional APC but on every nucleated cell of the body. However, 
stimulation of naive CD8+ T cells requires a costimulatory signal by professional 
APC  and  is  thus  dependent  on  these  cells.  In  the  case  of  direct priming, 
endogenously  synthesized  antigens  are  presented  on  MHC  class  I  molecule  (York  
and Rock 1996), while the cross-priming or cross-presentation refers to the ability 
of professional APC also to present exogenous antigens through MHC class I to 
CD8+ T cells (Corr et al. 1996, Corr et al. 1999, Giri et al. 2004, Jung et al. 2002, 
Norbury and Sigal 2003). DC and macrophages can process the internalized 
exogenous antigens for MHC class I cross-presentation mainly through phagosome-
to-cytosol or vacuolar pathways. A major source of cross-presented antigens are 
particulates, such as dying cells antigens, while cross-presentation of soluble 
proteins is less efficient (Rock et al. 2010). For MHC class I direct presentation the 
antigens are degraded by the cytosolic proteasome and cut into several small 
peptides which are transported to the endoplasmic reticulum (ER) for binding to 
MHC I  molecules.  A single  type  of  MHC I  molecule  can  bind  to  a  large  range  of  
different peptides with different affinities depending on the amino acid sequence. 
Additionally, the peptide binding groove is closed at both ends, limiting the length 
of the binding peptide. The peptides presented are usually 8 to 10 amino acids in 
length, the majority being nonamers. Occasionally longer peptides are 
accommodated but extending out of the groove may decrease the stability of 
interaction (Blanchard and Shastri 2008).  
 
Immunodominance is a central feature of cellular immune responses, reflecting the 
phenomenon that only a minor fraction of all potential immunogenic peptides 
derived from complex antigens are actually recognized. Which epitopes will be 
immunodominant in the individual is dependent on the expressed MHC allomorphs 
and their capability to bind and present the peptides. The immunogenicity of 
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subdominant determinants may be suppressed by the CD8+ T cells specific for 
immunodominant determinants (Manuel et al. 2009). A thorough understanding of 
the immunodominance phenomenon would be imperative for the designing of 
vaccines that elicit optimal CD8+ T cell responses (Yewdell and Bennink 1999, 
Yewdell 2006). 
 
The human equivalents of MHC are called human leukocyte antigens (HLA), class I 
encoded  by  three  HLA  genes  termed  HLA-A,  -B  and  –C.  HLA-A  and  HLA-B  
display greater polymorphic variation and are mainly responsible for presenting 
antigens. One individual can express up to six different class I molecules if 
heterozygous (Yewdell 2006, York and Rock 1996). The MHC genomic region in 
mouse is called H-2. Corresponding to human HLA-A, -B and –C, subtypes in mice 
are members of the classic MHC class I molecules, named H-2D, H-2K and H-2L. 
Like their human counterparts, these highly polymorphic genes are expressed 
widely and play an important role in presentation of non-self antigens to CD8+ 
CTL. Class I also has three non-classic subclasses that are similar in structure but 
not in function. Inbred laboratory mice strains are homozygous and have unique 
MHC haplotype, being H-2d for BALB/c (Ohtsuka et al. 2008, York and Rock 
1996).  
 
MHC molecules provide a mechanism to monitor the quality of antigens that cells 
produce. CD8+ T  cells  are  tolerant  of  healthy  self-antigen  presenting  cells,  while  
recognition of abnormal, such as tumorigenic or infected cells, leads to their 
elimination by CTL (Rock et al. 2010). Presentation of viral peptides on class I 
MHC molecules for CTL targets the infected cells for CTL mediated killing, usually 
by triggering apoptosis (Shastri et  al. 2002). Cytotoxic T cells and NK cells of 
innate immunity employ the same cytotoxic mechanism to initiate target cell 
apoptosis by releasing the contents of cytotoxic granules, perforin and serine 
proteases called granzymes into the target cell (Hersperger et al. 2010, Pipkin and 
Lieberman 2007). CD8+ T cells have additionally a non-cytolytic mechanism 
mediating strong antiviral immune responses involving several chemokines and 
secreting soluble CD8 cell antiviral factor (CAF) that suppresses HIV replication 
(Levy et  al. 1996).  A  broad  range  of  cytokines  (IFN-Ȗ,  TNF-D, IL-2, GM-CSF, 
CCL3, CCL4, and CCL5) may be also secreted by activated CD8+ T cells, although 
IFN-Ȗ predominates (Giri et al. 2004, Kristensen et al. 2004).  
2.3.3.2 Helper T cells  
CD4+ T helper cell activation is dependent on antigen presentation by another 
pathway mediated by MHC class II molecules that are expressed predominantly by 
professional APC. CD4+ T cells recognize antigens derived from exogenous and 
endogenous pathogens when antigens are presented by MHC class II molecules on 
professional APC. Most class II-associated antigens are exogenous, internalized by 
endocytosis or phagosytosis but also endogenous cytosolic and membrane proteins 
can enter the class II pathway. Antigens are processed to antigenic peptides, which 
are further bound to the binding groove of the MHC II molecule in specialized 
vesicles. MHC class II molecules have an open-ended binding groove allowing the 
display of considerably larger peptides of 15-20 amino acids (Moss et al. 2007). The 
MHC-II  /  peptide  complex  is  then  transported  to  the  cell  surface  where  it  can  
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present  the  antigen  for  CD4+ T cells.  Human HLA class  II  genes  are  encoded  by  
three loci, HLA-DP, HLA-DQ and HLA-DR. In mouse, I-A and I-E subregions 
encode several MCH class II proteins (Cosgrove et al. 1992, Matthews et al. 2000). 
 
When activated, helper T cells regulate and direct the immune responses by other 
immune cells by secreting several cytokines such as IFN-Ȗ, TNF-D, IL-2, GM-CSF, 
CCL3, CCL4, and CCL5 and by expressing co-stimulatory molecules on their 
surface that can be presented by cell-to-cell interactions. They start to proliferate 
and secrete IL-2 that acts in autocrine fashion through CD25 receptor that is 
simultanously upregulated on helper T cells. CD40L is expressed on the surface of 
activated CD4+ T-helper  cells  and  is  involved  in  their  activation  and  in  the  
development of their effector functions. Depending on cytokine environment they 
can differentiate into several subtypes, most importantly Th1, Th2 and more 
recently characterized Th17 and regulatory T cell (Treg), all having distinct patterns 
of cytokine secretion. Th1 cells direct the immune responses towards cellular 
immune responses by maximizing CTL and macrophage function through cytokines 
such as IFN-Ȗ, TNF-E and IL-2. Th2 cells stimulate humoral immune system by 
secreting cytokines IL-4, IL-5, IL-6, IL-10 and IL-13. Physiologically, Th1 
responses are thought to be important for defense against intracellular microbes and 
Th2 against multicellular parasites (Mosmann and Sad 1996). Th-17 cells regulate 
tissue inflammatory reactions by secreting proinflammatory cytokines IL-17 and IL-
22 that act against various infections, but no IFN-Ȗ or IL-4. They are also associated 
with tissue destruction during autoimmune diseases, thereby maintaining the right 
balance of Th17 cells is crucial (Brenchley et al. 2008, Lin et al. 2010, Park et  al. 
2005). By contrast, Treg cells function in an immunosuppressive manner by direct 
cell-to-cell contacts and by secreting inhibitory cytokines IL-10 and TGF-E, Treg 
cells also express FoxP3 transcription factor and disruption of FoxP3 function has 
been shown to lead to severe immune dysfunction and autoimmune diseases (Sojka 
et al. 2008). FoxP3+CD25+ Treg cells have been observed to be capable of down-
regulating  FoxP3  expression,  then  functioning  more  as  memory  and  effector  cells  
than as regulatory cells, demonstrating Th cell plasticity (Zhou et al. 2009). Th cells 
are essential for CD8+ T cell activation and for promoting protective memory cell 
development  and  thereby  the  induction  of  CD4+  T  cell  responses  is  also  very  
important for vaccines. 
2.3.3.3 Memory T cells 
The generation and retainment of T cell memory during natural infection is not very 
well  known.  However,  memory  T  cells  are  shown  to  emerge  during  the  
covalescence, in few weeks after the clearance of the pathogen (Tuuminen et  al. 
2007). Memory CD8+ T cells and memory CD4+ T cells can be subdivided into two 
distinct subsets, central memory cells (TCM), capable of regeneration and long-term 
maintenance and effector memory cells (TEM) cells, which are more prevalent in 
peripheral tissues and provide immediate effector functions (Baron et al. 2003). TCM 
cells express the CCR7 lymph node homing chemokine receptor and efficiently 
stimulate DC. Upon secondary antigen stimulation TCM can readily differentiate to 
TEM cells, expressing receptors that direct them to inflamed tissues (Sallusto et  al. 
1999). CD4+ memory  T cells  are  not  so  extensively  studied  than  CD8+ memory T 
cells (MacLeod et  al. 2009).  For vaccines the capability to elicit long-lasting 
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memory T cells is essential and immunization studies with rotavirus and influenza 
virus vaccines have yielded mounting evidence that IL-17 and IL-23 producing 
Th17 memory cells have an important role in long-lasting vaccine-induced memory 
T cell responses (Lin et al. 2010). 
2.3.4 Lessons learned from HIV-infected individuals and non-
human primates 
Adaptive immunity recognizes an enormous number of antigens but the capability 
of HIV-1 to escape these responses has still been overwhelming for the immune 
system. HIV-1 virus defeats the immune system by continuously introducing new 
variants of the immunogenic surface epitopes and simultaneously hiding the 
conserved parts from the immune system. Reports of superinfections, i.e. the re-
infection of an individual with a second heterologous strain of HIV-1, have 
demonstrated the major challenge for developing vaccines (Allen and Altfeld 2003). 
These cases demonstrate the inability of natural immune responses generated during 
primary infection to protect the individual from cross-clade or even same clade 
HIV-1 re-infection. However, even if the correlates of protection against HIV-1 
remain to be clarified, finding the factors likely to impede the progression of 
infection are crucial and may finally lead to overcoming the HIV-1 epidemic. 
2.3.4.1 The role of cytotoxic T cells in HIV-1 infection 
The correlation observed between the HIV-1 specific CTL response and disease 
progression has indicated the important role of cellular immunity in HIV-1 infection 
(Hersperger et al. 2011). Primary HIV-1 infection causes strong CD8+ T cell 
responses  that  are  able  to  initially  reduce  the  viremia  and  weaker  CD8+  T  cell  
responses have been linked to more severe disease progression (Koup et al. 1994, 
Musey et al. 1997, Streeck et  al. 2009). Similar observations have been made in 
nonhuman primates in vivo with SIV/SHIV models, demonstrating that the 
experimental depletion of CD8+ T cells leads to a striking decline in the capability 
to control the viral replication, even if not completely abolishing it (Amara et  al. 
2005, Schmitz et al. 2005). The polyfunctionality and proliferative ability of T cells 
are considered to be critical to the control of HIV-1 replication in vivo. 
 
The studies of immune responses of highly exposed seronegative persons, elite 
controllers and related animal models can provide valuable information. HIV-
exposed seronegative subjects have been studied intensively regarding their 
protective immunity since they were identified in late 80’s. Ranki et al. (Ranki et al. 
1989) reported in 1989 on the sex partners of HIV-positive men who remained HIV-
1 seronegative and virus-negative but had specific T cell responses to HIV-1 
envelope and core proteins, followed by other similar observations of exposed 
seronegative subjects (Berzofsky et al. 1991, Clerici et al. 1992, Ranki et al. 1997).  
Improved ability for antigen presentation and enhanced cell-mediated responses 
have been documented for these subjects. One of the best known examples are sex 
workers in Nairobi, having broadly cross-reactive cytotoxic CD8+ T cells against a 
wide range of HIV-1 subtypes in the absence of detectable HIV-1 infection 
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(Rowland-Jones et al. 1998). Significantly enhanced and more rapid perforin 
expression displayed by CD8+ T cells of elite controllers has been shown to 
correlate inversely with viral load (Hersperger et al. 2011). There is relationship 
between the MHC haplotype and its capability to present a specific antigen, also a 
relevant phenomenon when considering protection against HIV-1. Certain alleles, 
such as HLA-B*57, B*13, B*15, B*27, B*51, B*5801 and B*81 are found enriched 
in HIV-1 infected elite controllers indicating their capability to efficiently present 
protective epitopes (Emu et al. 2008, Frahm et al. 2006, Geldmacher et al. 2007, 
Honeyborne et al. 2007, Kiepiela et al. 2007), while some other HLA class I alleles 
are related to poor prognosis. Another genetic characteristic known to be related to 
natural protection or long-term non-progression is mutation of CCR5 receptor (Liu 
et al. 1996). 
 
All HIV-1 proteins have been shown to be targeted by CD8+ T cells in HIV-1 
infected individuals, the breadth and magnitude depending on the stage of the 
disease (Blazevic et al. 1995). Gag, Pol and Nef have been reported to be the most 
targeted proteins, while Vpu is considered least immunogenic, although the 
correlation with viral load is not always obvious (Addo et al. 2003). There are 
several studies both from clinical and non-clinical settings that clearly demonstrate 
the substantive role of Gag specific T cell responses in the containment of viremia 
(Geldmacher et al. 2007, Honeyborne et al. 2007, Kiepiela et  al. 2007). In elite 
controllers the durable control of HIV was shown to be strongly associated with the 
presence of Gag-specific CD4+IFN-Ȗ+IL-2+ T  cells  and  to  a  lesser  extent  Gag-
specific CD8+IFN-Ȗ+IL-2+ T cells (Emu et al. 2008). In HIV-1 infected non-
vaccinated individuals the cellular immune responses were also predominantly 
focused on HIV-1 Gag protein and less frequently on other proteins such as Nef and 
Pol (Coplan et al. 2005, Edwards et  al. 2002, Frahm et al. 2004). Nef has been 
reported to indicate substantial cross-reactivity, significantly more than Gag (Coplan 
et al. 2005). However, Gag specific responses have been associated most often with 
lower viremia, while responses specific to Env or accessory or regulatory proteins 
have been associated with higher viremia (Kiepiela et  al. 2007, Ngumbela et al. 
2008). Studies in rhesus macaques capable of exceptional control of the SIV virus 
infection showed that previously subdominant CD8+ T cell epitopes and broad Gag-
specific CD4+ T cell responses were mediating the control (Friedrich et  al. 2007, 
Martins et al. 2010). The viral containment of SIV has been shown to correlate with 
broad cellular immune responses against Vif and Gag and high T cell responses to 
Vpr, Nef, and Pol induced by T cell vaccine administration (Martins et al. 2010).  
2.3.4.2 The role of helper T cells in HIV-1 infection 
Due to  the  highly  multidimensional  role  of  CD4+ T cell  help,  the  fact  that  HIV-1  
already attacks CD4+ T cells virulently in the early phase of infection most 
seriously impedes the host’s ability to mount the proper immune response to virus. 
Additionally, CCR5 expression of effector cells makes them the principal target for 
destruction during acute HIV/SIV infection. The failure of effective memory cell 
proliferation has been linked to rapid disease progression (Kaech et al. 2002, Picker 
et al. 2004). The critical impact of CD4+ T cells on protection has been 
demonstrated by SIV model (Vaccari et al. 2008) and HIV-1 p24-specific CD4+ 
Th1 cells combined with gp41-specific IgG2 antibodies have been shown to 
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correlate with long-term non-progression (Martinez et  al. 2005). Vaccine induced 
Gag and Env specific CD4+ responses have been reported to correspond to 
containment of the viral replication after the SIV challenge (Hel et al. 2002).  
Despite their acknowledged role in protection, CD4+ T cell responses and related 
epitopes have been less studied than CD8+ T cell responses. However, similar to 
CD8+ T cells, the Gag-specific CD4+ T responses targeted at several epitopes have 
been shown to be associated with viral control in infected subjects (Ramduth et al. 
2009). Other HIV-1 antigens have also been shown to be recognized by CD4+ T 
cells but their correlation with viremia has not been established (Blazevic 1997, 
Ramduth et al. 2009).  
 
HIV-1 specific CD4+CD25+ Th17 cells detected in early HIV-1 infection are likely 
to increase the proinflammatory cytokine production. IL-17 secreting Th17 cells 
serve to maintain the integrity of the mucosal barrier and protection against invading 
pathogens. However, the preferential loss of Th17 cells in gastrointestinal mucosa 
during SIV and HIV-1 infection has been documented (Brenchley et al. 2008, Favre 
et al. 2009, Yue et al. 2008) and observed to occur simultaneously with increase in 
the  frequency  of  Treg  cells  in  SIV  (Favre et al. 2009). Treg cell may have a 
protective role in suppressing generalized T cell activation and negative 
inflammatory effects in HIV-1 infection but on the other hand, stronger HIV-1 
specific T cell responses detected in HIV-1 controllers may be explained by low 
Treg cell frequencies (Aandahl et al. 2004, Hunt et al. 2011).  
2.3.4.3 The role of antibodies in HIV-1 infection 
The impact of binding antibodies, neutralizing antibodies (nAb) or antibody-
dependent cell-mediated cytotoxicity (ADCC) on HIV-1 infection has remained 
controversial even if they may show great promise. A recent study on a rhesus 
macaque model has provided evidence of the importance of mucosal IgA and IgG 
non-neutralizing antibodies in protection (Bomsel et al. 2011). Additionally, cells 
expressing FcȖ receptor, such as monocytes, macrophages and DC can detect cell-
free HIV virus bound by antibodies, internalize them by endocytosis and degrade 
them (Mascola and Montefiori 2010). Binding of Env-specific nAb to free virus can 
prevent HIV-1 binding to the CD4 receptor, fusion with the cell and thereby block 
the viral transmission. The potential of nAb to provide sterilizing protection has 
been demonstrated by passive transfer in chimpanzee challenge studies, where 
protection against HIV-1 persistent infection seemed to correlate with the presence 
of anti-V3 domain antibody (Emini et  al. 1992). Similar observations have been 
made in macaques by SHIV challenge (Mascola et al. 1999). However, even if 
several broadly cross-reactive neutralizing human monoclonal antibodies have been 
highly effective against HIV-1 infection in vitro,  administering  them  to  HIV-1-
infected humans has only resulted in modest antiviral effects (Chen and Dimitrov 
2009). In natural infection, the development of cross-reactive nAb has been shown 
to require persistent HIV-1 replication, thus responses are seen only years after 
infection (Sather et al. 2009). Long-term non-progressors have been associated with 
slowly developing, low titer broad nAb responses, possibly a phenomenon that 
could be accelerated by vaccination (Pilgrim et al. 1997). The antibody dependent 
enhancement, referring to the higher susceptibility to HIV-1 infection by non-
neutralizing levels of anti-gp120 antibodies may take place in certain circumstances 
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(Willey et al. 2011) and should also be carefully considered in vaccination induced 
immune responses (Huisman et al. 2009). The induction of antibodies that could 
prevent the initial infection or limit early events of viral dissemination could have a 
significant role in protecting the host but as these antibodies should be targeted at 
the highly variable surface envelope glycoproteins, it has remained elusive.  
2.4 HIV-1 animal models  
2.4.1 Vaccine challenge studies 
A significant impediment to HIV-1 vaccine research is the fact that HIV-1 is highly 
specific to humans. Experimental HIV-1 infection of susceptible animals, including 
chimpanzees and pigtail macaques is generally non-pathogenic and thus does not 
resemble HIV infection or AIDS in humans (Fultz 1993). The scientific, economic 
and especially the ethical aspects make chimpanzees unsuitable models for AIDS 
research. Pigtail macaques, on the other hand, can usually resist the HIV-1 infection 
but by using a TRIM5 mutated strain and HIV-1 carrying the SIV Vif gene HIV-1 
infection has been established. However, infection still resembles only the HIV-1 
infection in LTNP group of humans (Hatziioannou et al. 2009).  
2.4.1.1 Non-human primate models  
Natural SIV hosts sooty mangabey and African green monkey lack the pathogenesis 
(Pandrea and Apetrei 2010), but instead, the experimental inoculation of SIV in 
several Asian macaque species, including rhesus, pigtailed and cynomolgus 
monkeys, causes a spectrum of pathological responses similar to HIV-1 infection in 
humans (Haigwood 2004). Studies with SIV or genetically engineered chimeric 
SHIV virus (Hu 2005, Li et al. 1992, Shibata et al. 1991) in rhesus macaque form 
the major approach for evaluating HIV vaccines and pathogenesis (Girard et al. 
2006).  
 
The relatively low sequence homology between HIV-1 and SIV (40-50%) (Hirsch et 
al. 1995) creates one major problem related to SIV challenge models, as the efficacy 
of  HIV-1-based  vaccines  cannot  be  directly  evaluated  in  the  SIV  model.  It  
necessitates the construction of homologous vaccine with SIV specificity for the 
challenge study, followed by extrapolation of the results to the different vaccine 
construct intended for use in humans. Chimeric SHIV, in turn, contains the HIV-1 
genes, such as tat, rev, vpu and env, thereby allowing direct testing of HIV-1 Env-
based vaccines (Hu 2005, Li et al. 1992, Shibata et al. 1991). Interpretation of non-
human primate challenge studies is made more complicated by the fact that several 
strains of these viruses with different virulence and pathogenesis characteristics are 
used for the challenge and even administered with variable routes and doses. This 
inevitably has a significant impact on how readily the protection is conferred in each 
model by immunization. In addition, the most commonly used high titer intravenous 
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challenge does not correspond to the natural route of infection (Benson et al. 1998, 
Haigwood 2004).  
 
In current vaccine research efforts, pre-clinical studies in non-human primates play 
a crucial role in evaluating the ability of alternative vaccination regimens to induce 
the effective immune responses and protection. There are several congruent results 
generated in non-human primates and in human phase I studies, thereby supporting 
the use of these animal models (Haigwood 2004). However, even if there are dozens 
of vaccines showing great promise for the prevention or even cure in non-human 
primates,  none  of  them  have  really  succeeded  in  human  clinical  trials.  The  
extrapolation of findings from non-human primates to a natural situation in humans 
is exacerbated by the incomplete understanding of the immunobiology of non-
human primates. In addition, the huge costs, poor availability and lack of 
standardization related to non-human primate models are the reasons why many 
experts in the field have concluded that prophylactic vaccines and therapeutic 
concepts should bypass primate models and instead test the vaccine candidates in 
other animal models and in clinical phase I or I/II trials (Hu 2005).  
2.4.1.2 Murine models  
While the HIV-1 cannot infect rodent cells or replicate in them, several humanized 
mouse models have been developed to complement present models in the study of 
viral pathogenesis, drug evaluation and immune-based therapies (Berges et  al. 
2010). Conventional xenotransplant models in mice enable the study of HIV-1 
pathogenesis,  such  as  Severe  Combines  Immunodeficiency  (SCID)  mice  that  are  
unable to produce functional B or T lymphocytes and thus allow engraftment of 
human tissue. Hu-PBL-SCID mice are transplanted with human peripheral blood 
leukocytes (Mosier et al. 1988) and SCID-hu mice with human thymus and liver 
tissue (McCune et al. 1988, Mosier 2000). Trimera mice are lethally irradiated 
normal BALB/c mice, reconstituted with murine SCID bone marrow and engrafted 
with human PBMC. HIV-1 infection in Trimera persists 4-6 weeks, accompanied by 
loss of the human CD4+ T cells, decrease in CD4/CD8 ratio, and increased T cell 
activation (Ayash-Rashkovsky et al. 2005). Recently improved humanized mouse 
models have been developed, displaying persistent viremia lasting over one year and 
continuous decline of CD4+ T cells, namely RAG-hu mice (Berges et  al. 2010). 
Transgenic mice (Browning et  al. 1997) and rats (Keppler et al. 2002) expressing 
the  appropriate  human  receptor  complex,  hCD4/hCCR5  are  candidates  as  a  small  
animal model for HIV-1 infection. However, only poor replication in CD4+ T cells 
and low viremia have been reported (Borkow 2005). These models are informative 
especially for analyzing the viral latency, long-term drug evaluation and immune-
based therapies; however, the lack of fully functional immune system and limited 
infectivity of the HIV-1 virus due to the species barriers impedes the efficient use of 
these models for vaccine efficacy evaluation. Instead of providing mice with HIV-1 
receptors, another approach has been taken by constructing HIV-1 species with 
receptors for mouse cells. Replacing the coding region of HIV-1 Gp120 with Gp80 
of MuLV has resulted in a chimeric virus that is able to infect mice systemically 
after one inoculation (Potash et  al. 2005). This virus has shown the potential for 
viral replication in lymphocytes and macrophages, induction of antiviral immune 
responses, neuroinvasiveness and elevated expression of inflammatory and antiviral 
 35
factors in the brain and has been used for the evaluation of the protective effect of 
HIV-1 multiclade vaccine VRC 4306 encoding gag, pol and nef (Saini et al. 2007). 
 
Various murine challenge models utilizing tumor cells (Fifis et al. 2004, Ni et al. 
2004, Thomson et al. 1998) or different viruses (Belyakov et al. 1998, Dittmer et al. 
2008, Gupta et al. 2005, Thomson et al. 1998) have been developed to enable rapid 
evaluation of vaccine immunogenicity and protective efficacy in mice, both in 
prophylactic (Colmenero et  al. 1999) and therapeutic (Ni et al. 2004) settings. In 
general, immunized mice are challenged by syngeneic tumor cells, such as P815 
(Colmenero et al. 1999) or EG7 (Fifis et al. 2004) cells or viruses, such as vaccinia 
(Belyakov et al. 1998), Friend virus (Dittmer et al. 2008) or murine leukemia virus 
(MuLV) (Hinkula et al. 2004), expressing the corresponding antigen. Challenges 
can be introduced via different routes and the vaccine induced protection is 
measured using variable parameters depending on the model. Considering tumor 
models, the protective effect can be evaluated by directly measuring tumor size 
(Fifis et  al. 2004, Ni et al. 2004), or weighting them after termination (Thomson 
1998). Viral models rely on detecting the virus in terminated mice (Belyakov et al. 
1998, Gupta et al. 2005). Tumor challenge models have been widely used for the 
evaluation of cancer therapies and for vaccine research in general, but not 
previously for HIV-1 DNA vaccines (Fifis et al. 2004, Ni et al. 2004, Rakhmilevich 
et al. 1996). On the contrary, viral challenge models are generally adapted for HIV-
1 vaccines protection studies. An approach utilizing HIV-1/MuLV pseudoviruses 
(Andang et al. 1999, Lusso et al. 1990, Spector et al. 1990) for mouse challenge has 
been developed in order to overcome the cellular tropism of HIV-1 (Hinkula et al. 
2004, Spetz et al. 2002) and used for evaluating several HIV-1 vaccine candidates 
(Bråve et al. 2007, Hinkula et al. 2004, Isaguliants et al. 2000, Ljungberg et  al. 
2002, Rollman et al. 2007). T-cell line Ampho-CEM-1B, dual infected with MuLV 
strain with broad host range (A4070) and different HIV-1 strains has been used to 
prepare HIV-1 virus pseudotyped with an amphotropic MuLV envelope (HIV-
1/MuLV) in vitro (Andang et al. 1999, Lusso et al. 1990, Spector et al. 1990). Dual 
infection of the cell line produces pseudoviruses possessing HIV-1 or MuLV 
genome surrounded by HIV-1 or MuLV envelope. Pseudovirus with MuLV 
envelope has been shown to productively infect primary murine splenocytes 
(Andang et  al. 1999, Lusso et al. 1990, Spector et  al. 1990) as denoted by 
continuous release of infectious HIV-1 particles and detection of HIV-1 RNA in 
vitro. After the challenge of synceneic host by intraperitoneal (i.p.) transplantation 
of HIV-1/MuLV in vitro infected splenocytes, infectious HIV-1 virus particles can 
be recoved from the ascites fluid for up to 14 days. However, the cell-free HIV-
1/MuLV pseudovirus does dot establish an infection and the viruses produced by 
inoculated infected cells are unable to reinfect new murine cells in vivo as they do 
not possess the MuLV envelope anymore (Hinkula et al. 2004). This experimental 
challenge model has been used to evaluate GTU-based HIV-1 vaccine as described 
in Paper III. 
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2.4.2 Vaccine immunogenicity studies 
Small animal models such as mouse, rat and guinea pig (Nkolola et al. 2010, Shu et 
al. 2007) have the advantage of short gestation time, well-characterized immune 
system, susceptibility to transgenic manipulation and wide availability for 
evaluating HIV-1 vaccine strategies and new drugs. They enable the use of larger 
group sizes for better statistical significance and a greater number of simultaneous 
experiments. In laboratory inbred strains the genetic background is simplified, 
which limits the possible immunological responses and their diversity. On the other 
hand, the use of inbred animals permits the transfer of immune cells between donor 
and recipient mice, a widely utilized method in immunological studies (Griffin 
2002). The most frequently used small animal models for HIV-1 vaccine 
immunogenicity studies are inbred mice, namely BALB/c with H-2d haplotype and 
C57BL/6 possessing H-2b haplotype (Collings et  al. 1999, Tahtinen et al. 2001). 
They are both widely used for immunological studies with well characterized 
features and immune system, the breeding history starting from the first part of the 
20th century. Rats are also used for immunogenicity studies even if less extensively 
(Moss 2009). Rats are frequently used for pharmacological studies such as for 
screening the toxicity and safety profiles of the vaccines and drugs (Tuomela et al. 
2005) and for studying the molecular mechanisms underlying HIV-related CNS 
pathology, while having a well-characterized central nervous system (Keppler et al. 
2002). The use of outbred animals offers the advantage of generating natural 
immune responses due to their expression of diverse heterozygous MHC molecules. 
Primates, ferrets, cats and rabbits are used selectively for immunological studies 
related to infectious diseases such as HIV-1, influenza and tuberculosis (Griffin 
2002). Domestic pigs are outbred animals with similar skin structure and body 
weight  to  humans,  and  have  also  been  used  to  study  GTU-MultiHIV vaccine 
immunogenicity (Molder et al. 2009). Selecting the most suitable animal model for 
human vaccine preclinical studies is a challenging task, as no animal model can ever 
totally mirror the outcome in a natural human host. Additionally, the immune 
system is very diverse and identifying the counterparts for certain immune cell types 
is not straightforward as the molecular markers and the cell functions may vary 
widely between different species.  
2.5 Immunization against HIV-1 
By active immunization the immune system is deliberately exposed to a foreign 
antigen through vaccination, thereby stimulating the adaptive immune system to 
generate immunity against the antigen that enable the recognition and fast response 
at the time of subsequent infection. An effective vaccine for active immunization 
holds the best promise to curtail the HIV-1 epidemic. Whereas the active 
immunization stimulates individuals’ own immune system, in passive immunization 
the person receives pre-synthesized antibodies, such as gamma globulin, or 
activated lymphocytes from another immune subject. Passive immunization 
provides rapid but temporary protection. Passive immunization with broadly nAb 
has been shown to protect against SHIV-1 challenge in animal models (Mascola et 
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al. 1999) and estimates for protective nAb titers have been gathered in HIV-1 
infected individuals (Trkola et al. 2008).  
 
HIV-1 vaccines are designed for both prophylactic and therapeutic settings. The 
ultimate goal of prophylactic immunization is to prevent in advance the infection of 
healthy individuals. Priming the immune system prepares the specific memory 
lymphocytes and when the virus is finally encountered, the acquired immunity can 
be efficiently harnessed to initiate a fast and efficient secondary response. Most viral 
vaccines can prevent the disease without preventing the initial infection, but in the 
case of HIV-1 this is not sufficient as the viral infection is established very rapidly 
once the virus has been transmitted. Consequently, sterilizing immunity would be 
required for the prevention of initial infection, but so far it remains an elusive goal. 
However, a prophylactic vaccine able to control the viremia, even if not preventing 
infection, is more achievable and still a much desired target. Therapeutic vaccines 
for infected individuals, on the other hand, are designed to limit the deleterious 
consequences and alleviate the symptoms caused by HIV-1 infection rather than to 
clear the virus completely. In the case of HIV-1, an effective therapeutic vaccine 
would be prominent as the current treatment with antiretroviral drugs has severe 
side effects and is functional only when rigorously followed throughout the lifetime. 
Also, the emergence of drug resistant genotypes of the virus is a serious and 
alarming consequence of the treatments. A therapeutic vaccine could be an option 
for antiretroviral drugs, strengthening the immune defence of the patient and 
reducing transmission to other individuals. The function of therapeutic vaccination 
strategy is based on stimulating host immune responses towards protecting epitopes 
instead of variable non-protecting epitopes, thus limiting HIV-1 replication and 
sequence variability (Hoffmann et al. 2008). Vaccines against variety of infectious 
viral diseases are licensed for human use, including live attenuated virus vaccines, 
inactivated virus vaccines and recombinant subtype vaccines (The National Institute 
for Health and Welfare (THL) 11/11/09, U.S. Food and Drug Administration (FDA) 
10/20/2010). Almost all of them rely on the production of neutralizing antibodies, 
while succesfull HIV-1 vaccine is likely to be strongly dependent on cellular 
immune responses as well.    
 
2.5.1 Virus-based and subunit vaccines 
Live virus vaccines are usually attenuated viruses lacking virulence due to 
mutagenesis or producing only asymptomatic infections. Another approach, using 
closely related but more benign virus to elicit cross-reacting immune responses, was 
introduced as the first universally applied vaccine in 1796 by Edward Jenner. He 
used the extracted material of cowpox lesions to generate immunity against another 
much more pathogenic virus causing the deadly disease of smallpox, and named the 
procedure vaccination (vacca is a latin word for cow). The advantage of live virus 
vaccine is the comprehensive induction of all components of the immune system 
and they have proven to be very successful vaccines. However, the risk of virulence 
precludes the use of attenuated vaccines in immunocompromised individuals. A 
major concern in using live attenuated lentivirus vaccines against HIV-1 is the 
genetic instability of the attenuation during manufacture or as a result of replication 
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in the vaccinated person (Berkhout et  al. 1999). Similar concerns are related to 
replication-deficient inactivated or killed HIV-1 virus vaccines, which might also 
have severe consequences e.g. in case of incomplete inactivation. Furthermore, they 
are potent humoral immune response activators but less efficient in inducing T cell 
responses.  
 
Subunit vaccines are recombinant HIV-1 proteins or synthetic peptides presenting 
an antigen to the immune system without introducing the viral particles. The first 
one of the two phase III efficacy studies completed so far with HIV-1 vaccine 
concepts utilized bivalent AIDSVAX (Vaxgen) purified monomeric HIV-1 Env 
gp120 proteins, aiming to generate virus-specific antibody responses. The vaccine 
was shown to induce the production of binding antibodies but no broadly reactive 
nAb and no protective efficacy was conferred by the vaccine (Pitisuttithum et  al. 
2006). Subunit vaccines aiming at eliciting Env-specific nAb responses have so far 
failed to exert selection pressure on the infecting HIV-1 strains (Arthur et al. 1989, 
Connor et al. 1998) and research has focused on generating immunogens more 
mimicking the native form of the viral trimeric glycoprotein. More recently, a 
structure based approach to construct vaccine immunogens based on the known 
neutralizing epitope may lead to more potent nAb inducing vaccine strategies in the 
future, together with more detailed knowledge of B cell stimulation (Stamatatos et 
al. 2009). Other challenges for protein based HIV-1 vaccine might be the selection 
of the correct immunogen and finding an economic production method. Peptide 
based  vaccines  are  usually  formulated  with  different  adjuvants  or  carriers  such  as  
alum (Lambert et  al. 2001), incomplete Freunds’ adjuvant (IFA) (Graham et  al. 
2010) or as lipopeptides (Gahery et  al. 2006), resulting in variable degrees of 
cellular and humoral immune responses. HIV-1 antigens can also be introduced in 
the  form of  VLPs.  Through VLP formation  epitopes  can  be  presented  in  the  same 
way as native infectious particles. Purified pseudovirions of HIV-1 proteins, such as 
Gag-Env pseudovirions, are used as a vaccine strategy (Chen et al. 2005). 
2.5.2 Viral vector vaccines 
Genetic vaccines represent a new generation of vaccines that have become available 
through the progress of molecular biology. Since the introduction of vaccination, 
smallpox has been eradicated worldwide and due to the vaccination prevalence has 
declined significantly for several other infectious diseases, such as polio, rubella, 
measles, diphtheria, mumps, tetanus and pertussis (Roush et al. 2007). However, 
some infectious pathogens like HIV-1 and some influenza viruses are extremely 
advanced in modifying their genetic composition and thus efficiently escape the 
immune defence elicited by vaccination. Genetic vaccines have several advantages 
when developing vaccines against these viruses, including the flexible and fast 
modification of their antigen content, safety and broad immune responses that can 
be targeted at several viral antigens. Genetic vaccines can be introduced as naked 
bacterial DNA plasmids or viral recombinant vectors can be used to delivere 
vaccine antigens to the cytoplasm. Viral vectors have been derived from several 
RNA and DNA viruses. Both replication competent and replication defective viral 
vectors have been used, the latter having the genes essential for replication deleted. 
As the vectors mainly retain the antigenic structural proteins, local and systemic 
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reactions can be elicited by innate immunity, thereby amplifying specific responses. 
However, immune responses targeted at the viral vector limit the immunization 
times that certain vector can be administrated. Additionally, the pre-existing vector-
specific immunity may reduce the immunogenicity and compromise the safety of 
the vaccine (Priddy et al. 2008).  
 
Many viral vectors for HIV are attenuated members of the poxvirus family, such as 
vaccinia, canarypox and fowlpox viruses that can also be used in 
immunocompromised hosts. The most recent, and so far most successful efficacy 
Phase III study in Thailand (RV 144) (Rerks-Ngarm et al. 2009) evaluated a 
recombinant canarypox vector expressing subtype B and E HIV-1 Env, Gag and 
parts of Pol and Nef proteins (ALVAC-HIV), boosted with a subunit vaccine gp120 
formulated in alum (AIDSVAX B/E, VaxGen). Subjects were healthy, primarily at 
heterosexual risk for HIV infection. The results of the first heterologous prime-boost 
efficacy study showed a modest benefit as a preventive vaccine but the exact 
mechanism of protection is not yet known (Haynes et al. 2010, Rerks-Ngarm et al. 
2009). This vaccination regimen showed 31% effectiveness in protection, setting the 
baseline for future HIV-1 vaccines evaluated in efficacy studies. Modified vaccinia 
virus Ankara (MVA) and another attenuated vaccinia strain, Copenhagen derived 
NYVAC, have been widely used as HIV-1 vaccine vector candidates and evaluated 
in clinical studies (Pantaleo et  al. 2010). MVA has been shown to trigger 
preferentially  CD8+  T  cell  responses,  as  NYVAC  stimulates  more  CD4+  T  cells  
(Gomez et al. 2008). A major problem related to attenuated poxviruses is the 
immunity generated to the antigenically complex vector backbone that restricts the 
number of doses. In addition, their large-scale production is difficult in primary cell 
lines and gene inserts are sometimes unstable. Overall the immunogenicity of 
poxvirus vector based HIV-1 vaccines has been quite variable (Pantaleo et al. 2010). 
 
Another widely used viral vaccine application is based on replication-incompetent 
adenovirus vectors. Despite several related advantages, pre-existing immunity has 
been recognized as a major challenge, especially in sub-Saharan Africa, where Ad5 
seroprevalence is >80% (Barouch and Korber 2010, Barouch 2010). The most 
obvious indication of that was obtained by the phase IIb clinical trial, known as 
STEP. The vaccinations with Merck’s Ad5-HIV vaccine, formulated as a trivalent 
mixture of rAd5 vectors expressing HIV-1 clade B Gag, Pol, and Env antigens, were 
unexpectedly terminated as primary endpoints were not met and an increase in HIV-
1 incidence was observed in vaccinated individuals with baseline Ad5-specific nAbs 
(Barouch and Korber 2010, Barouch 2010, McElrath et al. 2008). The HVTN 505 
trial initiated in October 2009 with Ad5 seronegative subjects evaluated the prime-
boost strategy (DNA prime, rAd5 boost Gag/Pol/EnvA/EnvB/EnvC) and 
additionally, other alternative serotypes as adenovirus vectors are currently being 
evaluated (Barouch and Korber 2010). In addition to attenuated vectors, non-
attenuated adenovirus serotypes 4 and 7 have been developed as HIV-1 candidate 
vaccines. However, the regulatory issues related to live replicating recombinant 
vaccine impedes their use even if they are claimed to be both safe and efficient 
(Peng et al. 2005).  
 
Alphavirus vectors, such as Venezuelan equine encephalitis virus (VEE), Sindbis 
virus and Semliki Forest virus (SFV) vectors, take advantage of the alphavirus 
replicon. Replicon is a minimal genome with replication origins and packaging 
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signals that can be used to encode the HIV-1 antigens. Replication-defective viral 
particles can be injected as plasmid DNA or as a naked RNA and, partly due to the 
tropism for dendritic cells, they are highly immunogenic. Other viruses engineered 
to serve as a vector for recombinant HIV-1 gene delivery include rhabdovirus 
vesicular stomatitis virus (VSV) (Rose et al. 2001) and adeno-associated virus 
(AAV).  
 
Table 1. Examples of experimental HIV-1 vaccine approaches in development 
FVP, fowlpox virus; HPV, Human papillomavirus; RV, rabies virus; AAV, adeno-associated virus; 
LV, lentivirus  
Clinical trials: (Clinical.Trials.gov)  1) (Clarke et al. 2006) 2) (Dai et al. 2009) 3) (Chin'ombe et al. 
2009) 4) (Chege et al. 2008) 5) (Wanjalla et al. 2010) 
 Vaccine Type Vaccine Vector Boost Phase Encoded Immunogens  
DNA plasmid vaccine    
HVTN 505 VRC DNA rAd5 Phase II Gag, Pol, Nef, Env  
HVTN205 pGA2/JS7 MVA Phase II Gag, Pol, Env, Tat, Rev,Vpu  
NCHECR-AE1 pHIS-HIV-AE rFPV Phase I/II Gag, Pol, Tat/Rev, Env  
HIV-001 PENNVAX™-G MVA Phase I Gag, Pol, Env 
- EnvDNA - Phase I Env  
Recombinant vector vaccine    
HVTN 503 Ad5 - Phase III Gag/Pol/Nef 
Ad26.ENVA.01 Ad26 - Phase I Env 
HVTN 078             
NYVAC-B 
rAd5 
rAd5 
NYVAC-B 
Phase I/II 
Env, Gag, Pol, Nef  
Gag/Pol fusion, Env  
PedVacc001 MVA - Phase I Gag, CD8+ Tc  epitopes 
RV144 Canarypox Gp120 prot. Phase III Env, Gag, Pro 
1) rVSV - Preclinical Gag, Env 
TGC 14F rAAV2  - Phase II Gag, PR, RT 
2) DC targeted LV - Preclinical Gag 
3) Salmonella - Preclinical Gag 
Subunit protein vaccine    
AIDSVAX Monomeric Gp120  - Phase III Env  
ISS T-002  Tat - Phase II Tat  
732461 Rec. fusion prot. -  Phase I/II rp24-Pol-RT-Nef-p17 
HVTN 064 Rec. prot. (DNA) Phase I Env, Gag, Pol, Vpu,Th epit. 
Peptide vaccine     
HIV-BIS AFO-18 - Phase I Gag, pol, Nef 
VLP     
4) Pr55-Gag VLP - Preclinical Gp120Env 
Cellular     
5) DC DC infected with  
live RV 
   - Preclinical Gag 
HIVDCVac Peptide pulsed DC    - Phase I Several CTL Epitopes  
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2.5.3 Genetic plasmid DNA vaccines 
Conventional vaccines based on the whole virus typically induce many immune 
responses against components of the virus that are irrelevant for protection and 
subunit vaccines mainly stimulate antibody responses. Furthermore, even if virus-
based vectors are widely used and efficient vectors, there are potential risks related 
to viral gene delivery. These risks can be avoided by using bacterial plasmid-based 
vectors, also called naked DNA vectors that can accommodate a combination of 
several antigenic regions from pathogens. The concept has many valuable features, 
including relative ease and flexibility of construction and manufacturing, the 
stability of the vaccines and safety as no handling of infectious agents is needed and 
the expression of DNA vaccines is transient. The local or systemic side-effects are 
minimal and in the absence of antivector immunity DNA vaccinations can be 
administrated repeatedly without adverse effects or diminishing the specific 
responses. Importantly, the production of the antigen by the host cell allows the 
antigen to be expressed and presented in a way that resembles natural viral 
infection.  This  has  been  shown  to  lead  to  balanced  CD4+  and  CD8+  T  cell  
responses, as well as antibody responses. The biggest challenge related to highly 
pure plasmid DNA immunization is the immunogenic potency of the naked DNA 
that has been overall fairly disappointing in humans. However, there are several 
factors affecting the immunogenicity of DNA vaccines, such as route of 
administration and dosing regimen, and various approaches can be utilized to 
improve the efficacy of these vaccines, such as heterologous prime-boost 
vaccination or co-administration with different immunopotentiators. Traditionally 
the same vaccines are given multiple times as homologous boosts, but the 
heterologous prime-boost immunization includes sequential delivery of different 
types of vaccines (Doria-Rose and Haigwood 2003, Harari et al. 2008, Seaman et al. 
2005, Shu et al. 2007).  
 
Naked DNA vaccines were introduced more than twenty years ago when mRNA 
and plasmid DNA encoded genes were shown to be expressed after intramuscular 
injection (Wolff et al. 1990), an observation followed shortly by several approaches 
utilizing naked DNA as a vaccine. Tang et al. observed the induction of antibody 
responses after DNA delivery by gene gun (Tang et al. 1992) and the induction of 
CTL responses was first reported by Ulmer et al. (Ulmer et al. 1993)  in  BALB/c  
mice, demonstrating the protective effect of influenza nucleoprotein specific CTL 
responses against heterologous influenza virus strain challenge. Since then, DNA 
vaccines as versatile vehicles against a variety of cancers and pathogens such as 
malaria parasite, human papilloma virus, dengue viruses, Ebola virus, 
cytomegalovirus (CMV), seasonal influenza viruses, SARS coronavirus and 
hepatitis B virus have been generated and evaluated in clinical trials. The almost 
limitless number of different possible approaches available for DNA vaccine 
development has generated numerous HIV-1 DNA vaccines and considerable 
preclinical and clinical experience has been accumulated during the years. However, 
no DNA vaccines have so far been licensed for human use. Three licensed animal 
DNA vaccines exist so far, against WNV virus that causes encephalitis in horses, 
against infectious hematopoietic necrosis virus in salmon and a therapeutic vaccine 
against skin cancer of dogs (Kutzler and Weiner 2008, Moss 2009).  
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2.5.3.1 Safety of DNA plasmid vaccines 
DNA vaccines have a well-tolerated safety profile in both preclinical and clinical 
trials. The concerns have been related to biodistribution and to the persistence of the 
genetic material in the body, potential integration into the host DNA especially has 
raised questions. Integration has been widely studied as reviewed by Schalk et al. 
(Schalk et al. 2006) showing that the risk of mutation due to plasmid integration is 
several orders below the spontaneous mutation rate. However, several factors can 
change  the  safety  profile,  such  as  different  delivery  methods  or  co-delivery  of  
adjuvants, and thus the risk cannot be neglected but must be evaluated case by case. 
Electroporation has been shown to increase the frequency of plasmid DNA 
association  with  genomic  DNA  in  some  cases  (Wang et al. 2004), while no such 
effect was detected with Biojector immunization, even if both methods have been 
shown to greatly increase the uptake of the plasmid in the cell (Manam et al. 2000). 
However, integration is not constantly detected even with electroporation and the 
use of intradermal electroporation instead of intramuscular electroporation may limit 
the invasiveness of the method (Bråve et al. 2010). Other concerns such as vertical 
transmission, induction of autoimmunity (anti-DNA antibody formation), induction 
of immunological tolerance and toxicity have been studied but no serious 
disadvantages related to the concept of DNA vaccines have been observed (Schalk 
et al. 2006). Even the maximum dose evaluated recently in macaques did not induce 
detectable integration or anti-DNA antibodies (Arrode-Bruses et al. 2010). 
2.5.3.2 Structural features of DNA plasmid vaccine 
Plasmid DNA vaccines are constructed to enable their efficient production in E. coli 
cells and to express the encoded antigen efficiently in the target tissue. The bacterial 
origin of replication and antibiotic resistance gene or some other selection system is 
incorporated for manufacturing purposes, while in mammalian cells DNA vaccines 
cannot replicate. Due to regulatory concerns, non-antibiotic selection systems have 
been developed (Krohn et  al. 2005).  The  expression  of  the  gene  encoding  the  
antigen of interest is driven by eukaryotic promoter allowing protein expression in 
mammalian cells (Garmory et  al. 2003). The promoter is selected considering the 
desired target cell type and expression level, while some promoters operate in a 
broad range of cells and some of them are more cell or tissue specific. Widely used 
strong classical promoters are the immediate early promoters/enhancers of human 
cytomegalovirus (CMV) and Rous sarcoma virus (RSV) promoter, CMV promoter 
often showing the highest expression. Intron A sequence has been shown to enhance 
the expression level by the CMV promoter. Downstream inclusion of 
polyadenylation (polyA) sequence, such as the bovine growth hormone (BGH) 
polyA sequence or rabbit ȕ-globin improves the expression by enhancing nuclear 
export, translation and mRNA stability (Garmory 2003). In addition to the promoter 
selected the codon optimization of lentiviral genes increases stability and export of 
nuclear mRNA and enhances translational efficiency in mammalian cells 
(Ngumbela et al. 2008). Codon optimization retains the natural amino acid sequence 
but the codons are synthetized according to human cell preference (Andre et  al. 
1998, Ramakrishna et al. 2004).  
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2.5.3.3 HIV-1  antigen selection for vaccine gene insert 
Several approaches have been assessed over the years in the search for the optimal 
way to elicit anti-HIV responses by genetic vaccines. As no absolute knowledge of 
correlates of protection so far exists, the antigen construction is more or less based 
on assumptions. Several issues need to be considered when evaluating how to 
construct the HIV-1 vaccine, such as if the vaccine is designed for the induction of 
nAb or broad cell-mediated responses, or ideally both, and what antigens and 
epitopes should be included and if it is enough to count on cross-clade reacting 
immune responses or if the vaccine should cover many clade specificities. The 
currently prevailing consensus idea is that all arms of immunity should be induced 
to achieve optimal protective effect for the vaccine, neither cellular nor humoral 
immune responses are likely to be enough by themselves (Virgin and Walker 2010). 
 
Current vaccine approaches are directed at multiple HIV-1 gene products, but 
enhanced nAb and cell-mediated immune responses with improved breadth are still 
pursued. nAb in HIV-1 infected individuals have been shown to be directed to 
different sites of Env-protein including CD4 binding site, glycans on the surface of 
gp120 and the membrane proximal region of gp41. This indicates that new vaccine 
antigens can be designed in various ways, using the most recent knowledge of Env 
and the CD4 binding site structure and of neutralizing epitopes (Mascola and 
Montefiori 2010, Sather et  al. 2009). Several HIV-1 vaccine constructs have been 
designed and evaluated in clinical studies targeting the Env protein, aiming at the 
induction of nAb but current HIV-1 vaccines are not able to routinely elicit broadly 
nAb (Haynes et al. 2010). Considering CD8+ T cells, even if there are several 
implications of the significant role of Gag-specific CTL responses for protection, it 
is likely that they will not be enough, but responses to other viral antigens will also 
be needed. Nef has both highly conserved, as well as highly variable domains and 
has been shown to contain several highly immunogenic regions and is frequently 
targeted in early infection. Anti-Nef cellular immune responses elicited after 
immunization have been observed to induce selective pressure on HIV-1 that was 
able to limit the variability of the virus in infected individuals (Hoffmann et al. 
2008). The degree of conservation can be one argument for antigen selection. 
However, the most conserved parts may not be very immunogenic, like most 
conserved gene pol,  with  comparatively  few  specific  CD8+  T  cell  responses  
recognized (Korber et al. 2009).  
 
Furthermore, the diversity of HIV-1 subclades must be considered when 
constructing the antigen (Taylor and Hammer 2008). The vaccine target population 
may guide the selection of the clade specificity. C-clade should be emphasized in 
vaccines introduced in South Africa, while the United States and Europe would 
benefit mostly from B clade specific constructs. The structure of the HIV-1 
phylogenetic trees is based on Gag or Env coding sequence similarity and shows the 
relationship of the M-group subtypes (Korber et al. 2009). Cross-clade protection 
has been shown to correlate with substantial protein sequence conservation observed 
for Gag and Nef (Coplan et al. 2005). One option is to select natural isolate 
resembling closest all the others and assume that sufficient magnitude of cross-clade 
reactions will be induced. However, many of the CD8+ T cell receptors are known 
to be sensitive even to single amino acid changes and additionally, there are several 
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indications of HIV-1 variants escaping the T cell responses by single mutation in 
epitopes (Lee et al. 2004).  
 
One way to overcome the wide diversity of HIV-1 is to combine several clades into 
one vaccine. The approach of using only narrow conserved elements concatenated 
together has been described by Rolland (Rolland et al. 2007b), the vaccine 
constituting 45 viral conserved segments across the M group of HIV-1 strains, with 
a minimum length of eight amino acids. The pressure against conserved regions has 
been suggested to lead to compromised viability of the virus. The induction of 
ineffectual and redundant immune responses is avoided by omitting the variable 
sequences of HIV-1 from the vaccine antigen. However, this approach does not 
generate any proteins resembling natural HIV-1 gene products. Despite several 
attempts to take the most conserved parts of the virus and compose an artificial 
polyepitope vaccine, no strong T cell responses have been generated in clinical 
phase I studies. When selecting longer conserved regions, the outcome may be 
improved as more epitopes can be presented, including epitopes in overlapping 
genomic regions (Barouch and Korber 2010). The “universal” HIV-1 vaccine was 
pursued by another group by assembling a gene encoding 14 most conserved 
regions  of  the  HIV-1  proteome,  each  segment  of  a  chimeric  protein  being  a  
consensus sequence from the major clades A, B, C and D (Letourneau et al. 2007). 
Furthermore, 'centralized' consensus and ancestor HIV gene sequences can be 
generated by phylogenetics-informed algorithm computer programs and designed to 
minimize the sequence difference between the vaccine and circulating virus isolates. 
Consensus sequences are designed by selecting the most common amino acid in 
each position in an alignment while highly variable regions may not be retained. 
Ancestral sequences are built by means of phylogenetic analysis. However, both 
consensus and ancestral sequences are artificially derived and their expression, 
antigenicity and biological activity must be carefully characterized. The proper 
folding might not be so relevant for eliciting cellular immune responses as it is for 
humoral antibody response (Ellenberger et al. 2002). Rolland et al. have 
reconstructed an ancestral HIV sequence utilizing the Center of Tree (COT) 
approach. COT sequences constituted the HIV-1 Gag, Tat and Nef proteins, which 
were shown to retain their biological functions and to be immunogenic in mice 
(Rolland et al. 2007a). So far they have proven immunogenic in mice. 
 
Polyvalent vaccines composed of a mixture of ‘mosaic’ immunogens have been 
suggested to maximize the coverage of potential T cell epitopes of the virus. They 
are assembled from fragments of natural sequences via a computational 
optimization, including common and excluding rare epitopes, but are still based on 
the generation of intact proteins (Fischer et al. 2007). Vaccines are also composed 
of a cocktail of immunogens derived from different clades (Seaman et al. 2005). 
One important aspect to consider with multiclade vaccines composed of several 
related immunogens as a cocktail is the immune interference, such as T cell epitope 
antagonism, immunodominance and original antigenic sin that has been observed to 
occur both in vitro and in vivo between closely related peptide sequences in the 
cocktail (Basu et  al. 1998, Larke et  al. 2007). Original antigenic sin refers to a 
phenomenon recognized for both humoral and cellular immunity, where the original 
exposure to a certain antigen by either infection or immunization induces 
immunological memory, which by a second encounter of related but not identical 
antigen results in immune response directed to the original antigen and induces only 
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an impaired immune response against the second antigen. T cell antagonism occurs 
when an existing memory T cell is functionally inactivated by presentation of a 
point mutant variant of its original cognate epitope on MHC class I molecule (Basu 
et al. 1998, Singh et al. 2002). By contrast, there is a line of evidence that the use of 
vaccines containing many mutant epitopes, even T cell antagonists, can tend to 
avoid some degree of immune interference generation (Singh et al. 2002). Similarly 
in HIV-1 infection, naturally arising virus variants may change the CTL epitopes so 
that they are able to engage the T cell receptor but fail to activate the T cell and 
further interfere with the recognition of the unmutated epitope (Klenerman et al. 
1996). 
2.5.4 Induction of immune responses with DNA vaccines   
In addition to the selection of antigens and vectors, the choice of delivery route, 
dose, timing, adjuvants and boosting agents influence the outcome of immunization, 
changing the magnitude and quality of immunity achieved. DNA molecules are 
highly susceptible to nuclease-mediated degradation that must be taken into account 
throughout the whole chain from DNA plasmid vaccine manufacturing process to 
delivery (Caputo et al. 2003). 
2.5.4.1 DNA immunization via variable routes  
When DNA is introduced into the body, the environment in which it is administered 
as well as the delivery technique affect the uptake of the DNA into the cell. Not all 
aspects of the cellular uptake are well known but both professional APC and non-
lymphoid cells such as myocytes and keratinocytes are known to participate and the 
route of administration affects which cell types are directly transfected. Parenteral 
DNA injection by needle is most often given intramuscularly (i.m.), intradermally 
(i.d.) or subcutaneously (s.c.), but intraperitoneal (i.p.) and intravenous (i.v.) routes 
have also been used. When DNA is injected i.m., antigen is primarily expressed by 
transfected muscle cells at the site of inoculation and can express the genes and 
present them through MHC class I molecules (Dupuis et al. 2000, Wolff et al. 
1990). Additionally, expressed, secreted proteins may directly stimulate B cells to 
produce antibodies. However, transfer of antigen from muscle cells to professional 
APC and their presentation to lymphocytes through MHC class I and II molecules 
by cross-priming is required for inducing primary T cell responses with optimal 
efficiency, as the muscle cells lack the costimulatory molecules and MHC class II 
molecules needed for CD4+ presentation (Agadjanyan et al. 1999, Corr et al. 1996). 
A similar cross-presentation is induced after i.d. injection (Corr et al. 1999). 
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Figure 2. Mechanism of antigen presentation by DNA vaccination. Adapted from Giri et al. 2004. 
 
The low prevalence of mature professional APC in the muscle or subcutaneous may 
explain the weak immunogenicity in humans when naked DNA is injected alone via 
i.m. or s.c. route (Liu et al. 2008, Sumida et al. 2004). The immune responses 
elicited can be much strengthened when DC are attracted by different means to the 
site of inoculation. The inclusion of factors that attract professional APC or signals 
that target the vaccine DNA to DC can be applied to improve vaccine 
immunogenicity (Nchinda et  al. 2008, Sumida et al. 2004). Furthermore, when 
DNA is introduced into an environment rich in professional APC, the antigen is 
efficiently transported to lymph nodes for presentation. DNA administration i.d. or 
transcutaneously therefore has an advantage over i.m. or s.c. injection as these 
tissues are rich in DC, macrophages and LC (Belyakov et  al. 2004). Recent 
evidence indicates that not only are DC in the skin much more abundant than in 
muscle, but additionally i.d. and i.m. administrations recruit different professional 
APC,  thereby  eliciting  both  CD4 and  CD8 cellular  immune responses  of  different  
quality and intensity. I.m. injection was shown to mobilize only DC, while i.d. 
injection also activated macrophages. Furthermore, the i.d. route was shown to lead 
to rapid transfer to lymph nodes draining the skin, peaking 4-48 hours after 
immunization, while after i.m. immunization only a very low number of antigen 
expressing professional APC were detected in the muscle draining lymph nodes. 
Macrophages may also play a bigger role than expected in certain circumstances and 
depending on the route of administration. This was shown by MVA immunization 
but probably the same mechanisms pertain to DNA vaccines in general (Abadie et 
al. 2009). Skin has turned out to be a successful route for vaccine delivery 
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(Mitragotri 2005). Needle-free jet delivery devices for i.m. or s.c. administration, 
such as Biojector device may improve the vaccine elicited immune responses and 
also reduce the risks of acquiring blood borne infections by needle. Jet-injection has 
been shown to significantly increase plasmid uptake (Bråve et al. 2010). Another 
needle-free route, mucosal DNA administration via intranasal, intravaginal, oral or 
anal routes has been assessed with DNA vaccines. Induction of mucosal immune 
response may be particularly important for protection, while the mucosal surface is 
the natural route for HIV-1 entry and is the site for large number of immune cells. 
Preventive vaccination should be able to generate a balanced CD8+ TEM cell 
response to provide efficient first line immune protection in the mucosal 
compartment and CD4+ and CD8+ TCM cell responses to prevent viral dissemination. 
Different prime-boost strategies combined with mucosal delivery as well as the 
presence of the right costimulatory signals can help the induction of these memory 
cell types (Ahlers and Belyakov 2010). 
2.5.4.2 Delivery methods enhancing vaccine immunogenicity  
Relatively weak immune responses in clinical and non-human primate studies with 
plain plasmid DNA have indicated the need to improve the potency of DNA 
vaccines. The large size and hydrophilic nature of naked DNA molecules does not 
allow them to enter cells efficiently. Several methods and different delivery devices 
have been developed to provide additional costimulation and enhance the cellular 
DNA uptake and direct transfection frequency and rely on more efficient 
professional APC recruitment (Al-Dosari and Gao 2009).  
 
The first device used for the administration of genetic vaccine was biolistic particle 
delivery by gene gun, which delivers DNA or RNA coated on gold microparticles 
into cells with a low pressure helium pulse enabling in vivo transfection (Tang et al. 
1992). Administration by gene gun device has been shown to directly transfect the 
dendritic cells of the skin, although keratinocytes are the main cell type found to be 
expressing the DNA-encoded proteins (Porgador et  al. 1998). Twenty-four hours 
following gene gun immunization, the total number of CD11c+ DC in the major 
draining lymph nodes has been shown to increase more than twofold, augmentation 
rather due to the bombardment than the plasmid DNA itself (Porgador et al. 1998). 
In addition, gene gun immunization reduces the required DNA dose hundred or even 
thousands-fold in mice, being the most powerful way to induce cellular and humoral 
immune responses (Doria-Rose and Haigwood 2003, Pertmer et al. 1995), although 
electroporation has been found a very effective delivery approach as well (Best et 
al. 2009).  Minute  amounts  of  DNA  have  also  been  shown  to  efficiently  induce  T  
and B cell immune responses in humans (Roy et al. 2000). However, biolistic 
immunization is not a very widely used method in clinical trials despite encouraging 
results (Al-Dosari and Gao 2009, Mitragotri 2005). Some studies have suggested 
that the route of administration may have an impact on how immunization will bias 
the response, namely that i.m. injection would preferably induce Th1 type response 
while g.g. would elicit more Th2 biased or balanced Th1/Th2 response (Barry and 
Johnston 1997, Pertmer et al. 1996, Tähtinen 2001). However, this is not frequently 
observed and is suggested to be more antigen dependent, although it is 
acknowledged that slight skin irritation in g.g. immunization may create more Th2 
responses (Doria-Rose and Haigwood 2003).  
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The potency of plasmid DNA i.m. and i.d. immunization has been significantly 
improved by in vivo electroporation, which has been shown to decrease DNA 
demand more than 10-fold in mice. Promisingly, electroporation has been shown to 
increase the strength, breadth and lead to more rapid onset and long duration of 
immune responses in non-human primates immunized with HIV-1 specific plasmid 
vaccines (Luckay et al. 2007, Martinon et  al. 2009). Electroporation involves the 
administration of electrical pulses to muscle or skin tissue following injection, 
increasing cell permeability, thus enhancing transfection of the cells. In addition, 
electroporation recruits large cellular infiltrates rich in DC, macrophages and 
lymphocytes to the site of inoculation. Electroporation has shown similar 
enhancement of the immune responses than molecular adjuvants, but the effect by 
electroporation was more durable and, importantly, was shown to generate more 
effector and central memory CD8+ T cell responses. Interestingly, for viral vectors 
the advantage is not so obvious, possibly due to the utilization of viral entry 
pathway into the cells and efficient innate immunity stimulation by the viral 
constitutes (Liu et  al. 2008). Insufficient dose has been proposed to explain the 
relative poor immunogenicity of DNA vaccines in humans and non-human primates 
compared to responses detected in mice. This was demonstrated by Arrode-Bruses 
and colleagues, who used an extremely high single dose for the induction of strong, 
long-lasting and polyfunctional CD8+ T cell responses in non-human primates. 
However, as the corresponding dose would not be feasible for human use, the use of 
electoroporation to achieve the same potency in humans was suggested (Arrode-
Bruses et al. 2010).  
2.5.4.3 Use of adjuvants for stronger recruitment of the immune system 
There is a wide range of molecular adjuvants that DC can recognize by specific 
receptors and respond to, such as proteins, lipids, nucleic acids, carbohydrates and 
chemical compounds (Kornbluth and Stone 2006). Molecular adjuvants such as 
cytokines, chemokines or T cell costimulatory molecules can be co-administered or 
their coding sequences can be integrated as a part of the vaccine and thus enhance 
the potency of either Th1 or Th2 type immune responses, as preferred (Calarota et 
al. 2001, Calarota and Weiner 2004, Sumida et al. 2004). The name adjuvant is 
derived from the latin word adjuvare meaning helping or aiding. Accordingly, 
adjuvant co-administration can enhance the immunogenicity of highly purified 
antigens and reduce the amount of antigen needed to elicit the proper immune 
responses. Adjuvants may be needed for efficient immunization of special groups 
like immuno-compromised individuals, newborns and the elderly (Aguilar and 
Rodriguez 2007). However, the broad range of activities modulated by cytokines 
carries a risk of also eliciting harmful effects. Stimulation of professional APC 
through TLR is critical in the initiation of immune response and the adjuvanticity of 
many TLR ligand molecules, such as heat-shock protein 70 and monophosphoryl 
lipid A, has been evaluated (Aguilar and Rodriguez 2007). The plasmids may also 
have co-stimulatory effects themselves, as the vaccine plasmids contain bacterial 
CpG motifs (Greenland and Letvin 2007, Klinman et al. 1999). The route of 
administration is critical not only for vaccine efficiency but also has a notable 
impact on adjuvant function. For example, the alum is generally used only i.m. and 
not  by  the  more  efficient  i.d.  or  s.c.  route,  due  to  its  local  toxicity  (Aguilar  and  
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Rodriguez 2007). The use of adjuvants can radically change the safety profile of a 
DNA vaccine, as the local and systemic adverse effects unfortunately usually 
correlate with the adjuvant potency. To enhance DNA uptake by the cells, vaccines 
can also be formulated with different chemical carriers, including liposomes, 
polymers, microparticles and nanoparticles. They may facilitate the permeation of 
the cell membrane, target the DNA for phagocytosis and protect and stabilize the 
DNA. 
 
The current HIV-1 vaccine research field emphasizes the need of broad and 
multifunctional immune responses. The candidates showing most promise are 
vaccines able to elicit highly multifunctional CD8+ T cell responses defined by 
determinants such as degranulation and expression of IFN-Ȗ, MIP-1ȕ, TNF-Į, and 
IL-2, thus emphasizing more the quality than the quantity of T cell responses as 
immune correlates (Arrode-Bruses et al. 2010, Betts et al. 2006). The almost 
limitless possibilities related to DNA vaccines show great promise for future HIV-1 
vaccine development, as long as the right combination of different components is 
developed and found for human use. It is likely that the most efficient vaccine 
regimen would target broadly both arms of immunity, which could be achieved e.g. 
by combining different vaccines within heterologous prime - boost vaccination 
regimens, further increasing the value of DNA vaccines.  
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3. Aims of the study 
The  aim  of  the  thesis  was  to  assess  the  immunogenicity  of  GTU DNA plasmids 
expressing HIV-1 multigene using different immunization regimens in a mouse 
model. Eliciting strong CD8+ T cell responses is a requirement for the vaccine to 
fight against the HIV-1 infection, thus two challenge models relying specifically on 
the action of cytotoxic lymphocytes were used to evaluate the protective efficacy of 
HIV-1 immunogens. The hypothesis that immune responses elicited by GTU 
plasmid vaccine were mediated by DC was briefly investigated. The specific 
objectives of this study were the following: 
 
I To evaluate the immunogenicity of GTU-MultiHIV B-clade/Han-2 and 
multiclade (A, B, C, FGH) Auxo-GTU-MultiHIVmix DNA in mice.  
 
II  To define the optimal immunization regimen for GTU based MultiHIV 
vaccine administration using g.g., i.d. and i.m. administration routes. 
 
III To assess the protective efficiency of the GTU based MultiHIV 
immunizations using two different experimental challenge models in mice.  
 
IV To briefly examine the role of DC in the generation of the immune response 
by GTU HIV-1 immunogen. 
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4. Materials and Methods 
4.1 GTU expression vector (I-IV) 
GTU platform  was  used  for  constructing  HIV-1  multigene  plasmids.  The  GTU 
expression vector consists of an expression cassette for a gene of a nuclear-
anchoring protein E2, a multimerized DNA sequence forming binding sites for E2 
and an expression cassette for the DNA sequence of interest.  
 
Protein E2 type 1 from bovine papillomavirus (BPV) is driven from the Rous 
sarcoma virus 5´ LTR (RSV LTR) promoter. Polyadenylation region of the bovine 
growth hormone is cloned at the end of the E2 transcription cassette from the 
pHook3 plasmid (Invitrogen). The vector carries ten copies of BPV1 binding sites 
for E2 (10E2BS). The gene of interest is driven by CMV immediate early promoter. 
The elements needed for the effective expression of the mRNA include HSV1 TK 
gene leader sequence, a rabbit E-globin gene sequence and an HSV TK gene 
polyadenylation signal region. A modified form of pMB1 replicon with ColE1 
origin of replication was included for propagation in E. coli cells. The patent 
application for GTU vector was filed on May 5, 2002 (PTC/FI02/00379). 
 
Auxo-GTU expression vector was constructed to enable antibiotic-free selection, 
utilizing L-ribulose-5-phosphate-4-epimerase encoding araD gene as a selection 
marker when plasmid is produced in a bacterial strain deficient in the araD gene. A 
patent application for araD based selection system was filed on September 15, 2004 
(PTC/FI2004/000540). 
4.1.1 HIV-1 multigene plasmid (I-IV)  
HIV-1 multiantigen, named MultiHIV (RNTp17/24CTL), is a fusion protein of 120 
kDa composed of full-length sequences of Rev, Nef , Tat, p17 and p24 proteins of 
Gag. C-terminus encodes for a stretch of eleven 17-45 aa long T cell epitope clusters 
of the reverse transcriptase and envelope sequences. The sequences were derived 
from Han-2 isolate of the HIV-1 strain. Strong murine H-2d restricted HIV-1 CTL 
epitope from env (RGPGRAFVTI) was included at C terminus. GTU-MultiHIV 
encodes for MultiHIV derived from HIV-1 B-clade HAN2 isolate. 
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Figure 3. Schematic diagram of the GTU-MultiHIV vector. Reprinted from the original article (I), 
copyright (2006), with kind permission of Mary Ann Liebert. 
4.1.2 HIV-1 multiclade plasmids (II-III) 
Four different MultiHIV plasmids were constructed on Auxo-GTU backbone to 
theoretically cover 95% of the variability of known HIV-1 sequences when mixed 
(HIV-1 Sequence Database, Los Alamos National Laboratory, assessed August 
2002). Three vectors express the consensus sequence of the HIV clades A, B and C 
and  one  is  based  on  ancestor  sequences  of  the  clades  F,  G and  H.  Four  plasmids,  
encoding 1053-1079 aa long MultiHIV polypeptides, were mixed in equal amounts 
for a multiclade vaccine (MultiHIVmix).  
4.1.3 Control vectors (I, IV) 
Conventional eukaryotic vector CMV-MultiHIV (6545 bp) was constructed by 
removing E2 expression cassette and 10E2BS from GTU-MultiHIV vector. GTU-
LacZ vector encoding E-galactosidase was used as a negative control DNA for 
expression studies (I). GTU-GFP was derived from GTU vector backbone and a 
destabilized form of enhanced GFP derived from vector pd1EGFP-N1 (Clontech 
Laboratories) (IV).  
4.1.4 Plasmid production and analysis (I-IV) 
GTU based plasmids were produced in Escherichia coli cells using kanamycin 
resistance gene as a selection marker. Auxo-GTU based plasmids were produced in 
E. coli cells in the presence of arabinose and selected using the araD selection 
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system. Plasmids were purified by Qiagen Endofree Plasmid kits (Hilden Germany) 
according to the manufacturer’s instructions and dissolved in sterile, endotoxin-free 
PBS. The quality of the plasmid products used for immunization studies was 
confirmed by concentration measurement, restriction enzyme analyses, sequencing, 
plasmid homology and impurity analyses, the latter comprising of E. coli genomic 
DNA, RNA, endotoxins, kanamycin and bioburden analyses.  
4.1.5 Expression studies (I, IV) 
The expression properties of GTU-MultiHIV were analyzed by Western 
Immunolotting after in vitro transfections of the Jurkat, Cos-7 and RD cell lines by 
electroporation. 0.5 µg or 3 µg of DNA was used for electroporation. Equimolar 
quantities, 0.27 µg and 2.2 µg, of CMV-MultiHIV control DNA were additionally 
transfected into RD cell line for comparison. 3 µg of GTU-LacZ was used for 
transfection of negative control cells. Two and five days posttransfection the cells 
were lysed with lysis buffer (50 mM Tris–HCl, pH 6.8, 2% SDS, 0.1% 
bromophenol blue, 100 mM dithiothreitol, and 10% (v/v) glycerol) and samples 
were run on a 10% sodium dodecyl sulfate–polyacrylamide gel (SDS–PAGE). 
Proteins were transferred on nitrocellulose membrane and MultiHIV expression was 
analyzed after membrane blocking by incubation with monoclonal anti-p24 antibody 
(05-001, FIT Biotech, Tampere, Finland), followed by HRP-conjugated goat 
antimouse IgG (LabAs, Tartu, Estonia) and visualization using an ECL 
chemoluminesence detection system (Amersham Pharmacia Biotech, Uppsala, 
Sweden).  
 
GTU-MultiHIV  and  CMV-MultiHIV  transfected  RD  cells  were  lysed  and  the  
fusion protein expression was quantified by ELISA as described in Chapter 4.11.3, 
on the rNef coated plate using biotinylated anti-p24 antibody (05-001) and TMB 
substrate for detection. Subcellular localization of the MultiHIV antigen encoded by 
GTU-MultiHIV  was  analyzed  in  Cos-7  cells,  transfected  with  2  µg  of  GTU-
MultiHIV DNA, by immunofluorescent staining with anti-Nef (01-001, FIT 
Biotech) or anti-p24 antibodies and detected by fluorescein isothiocyanate (FITC)-
conjugated goat antimouse secondary antibody (LabAs). 
 
GFP expression from GTU-GFP (IV) was verified in vitro by fluorescence flow 
cytometry analysis after transfecting Jurkat cells using Cellfectin® Reagent 
(Invitrogen). For the in vivo expression study, mice were immunized twice, 24 hours 
apart, with 250 Pg of GTU®-GFP plasmid intradermally. On the third day mice were 
sacrificed and lumbar and sacral LN of the experimental mice and control mice were 
collected and pooled. As a control, mice immunized with the plasmid lacking GFP 
were used. Cells were digested from the tissues by incubating with Collagenase D 
(Sigma). Collected DC were enriched by density gradient centrifugation using 
Optiprep (Axis-Shield PoC AS, Oslo, Norway) according to manufacturer’s 
instructions. DC were washed and labeled with R-PE-conjugated anti-mouse CD11c 
antibody  or  PE  anti-mouse  IgG1 as a control (BD Biosciences Pharmingen, San 
Jose, CA, USA). Non-specific binding to DC CD16 and CD32 was blocked with 
Mouse Fc BlockTM (BD Biosciences Pharmingen). DC were washed and samples 
were run with FACSCalibur. CD11c+ cells were gated on FSC/FL2 scatter and 
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analyzed by FlowJo (Tree Star, OR, USA). The percentage of the GFP+ cells in the 
gated population was determined. 
4.2 P815-MultiHIV cells (II) 
P815 mastocytoma cell line, possessing H-2d MHC class I  molecules was used for 
challenging DBA/2 mice in the tumor challenge study (II). A plasmid where 
MultiHIV Han-2 expression was driven by strong hybrid SRD-promoter (Takebe et 
al. 1988) was ligated with another plasmid, carrying an expression cassette for 
puromycin acetyl transferase and E-hCG hormone. Puromycin acetyl transferase 
was used as a selection marker in the presence of puromycin and E-hCG hormone 
was used monitoring the tumor development as it was shown to correlate positively 
with the tumor load (Shih et al. 2000). P815 cells were stable transfected by 
electroporation and one day later puromycin (0.75 µg/ml) was added onto the cells. 
After one week of cultivation with antibiotic cells were subcloned by limiting 
dilution method and the subclones were analyzed by western immunoblotting. For 
positive clones the E-hCG hormone secretion was analyzed with Free E HCG 
ELISA kit (DRG Instruments GmbH, Germany) and presentation of MultiHIV was 
assessed with ELISPOT IFN-J assay  using  the  splenocytes  of  MultiHIV  DNA  
immunized mice. As a control for challenge, similarly analyzed wild type (wt) P815 
cells were used.  
 
The  capability  of  P815-MultiHIV  cell  line  to  present  MultiHIV  antigen  was  
analyzed in vitro using these cells as APC in ELISPOT IFN-J and  Cr51 release 
assay. For ELISPOT, splenocytes of GTU-MultiHIV Han-2 immunized mice were 
in vitro stimulated with mitomycin C treated P185-MultiHIV and P815-wt cells, 
followed by IFN-J secreting cell enumeration as described in Chapter 4.11.2. 
Similarly, both P185-MultiHIV and P815-wt cell lines were used as target cells in 
Cr51 assay (Chapter 4.11.4). 
 
Before  the  challenge,  the  tumorigenicity  of  the  P185-MultiHIV and  P815-wt  cells  
was assessed in vivo in DBA/2 mice. 1×106 tumor cells were inoculated s.c. into the 
right flank and the tumor growth was followed and tumor diameter measured with 
an electric calliper every second day. The size (mm2) was calculated as longest 
diameter × shortest diameter. Mouse welfare was followed and mice were sacrificed 
when the diameter reached 10 mm. 
4.3 HIV-1/MuLV pseudovirus infected cells (III) 
HIV-1/MuLV pseudotype viruses were prepared in neomycin-resistant cell line 
Ampho-CEM-1B as previously described (Spector et  al. 1990) (III) at Karolinska 
Institutet, Stockholm, Sweden. CEM-1B cells were cultured in 10% FCS-RPMI 
1640 (Invitrogen, Gibco, Carlsbad, CA) supplemented with antibiotics (Sigma-
Aldrich,  St.  Louis,  MO) until  infected with the subtype B LAI HIV-1 strain or the 
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primary Kenyan subtype A 9284 HIV-1 isolate. Every 3-4 days culture supernatants 
were collected, screened for p24 antigen (Vironostika, Bio-Mérieux, Boxtel, France) 
and  stored  at  -70°C  on  testing  positive  for  p24.  Splenocytes  of  C57BL/6  were  
infected as previously described (Andang et al. 1999).  In  brief,  splenocytes  were  
activated with Con A for 24 h, washed and 50×106 cells in one ml were infected 
with stored pseudoviral supernatant by overnight incubation. One day after infection 
the amount of p24 protein per 106 splenocytes was determined (Devito et al. 2000).  
4.4 Animals (I-IV) 
Inbred female mice, ca. 8 weeks old at the beginning of the experiments were used 
for all studies. All immunizations and challenges were performed under general 
anesthesia. Animal welfare and health were followed throughout the study and mice 
were weighed at the beginning and at the end of the studies. BALB/cOlaHsd (H-2d) 
mice were used for the immunogenicity studies (I, III, IV). The tumor challenge 
model  was  made  with  DBA/2OlaHsd  (H-2d) mice, syngeneic for P815 cells, both 
strains obtained from Harlan (Italy and Netherlands). All procedures were carried 
out according to the national guidelines and permission of the County 
Administrative Board of Tampere and of Laboratory Animal Board of Tampere 
University Medical Faculty, Finland. For HIV-1/MuLV pseudotype virus challenge 
C57BL/6 (H-2b) strain transgenic for HLA-A201 (Hinkula et al. 2004, Vitiello et al. 
1991) was used. Animal care and experimental procedures were approved by the 
animal research ethical committee of the Karolinska Institutet and The Swedish 
Institute of Infectious Disease Control, Solna, Sweden.  
4.5 Immunization routes 
4.5.1 Gene gun (I-III) 
For gene gun administration, plasmids dissolved in PBS were coated on gold 
particles (Bio-Rad, Richmond, CA) according to manufacturer’s instructions. DNA-
coated gold particles were administered to shaved abdominal skin by Helios Gene 
Gun (Bio-Rad) using a pressure of 400 psi and 0.5 mg gold/cartridge (Collings et al. 
1999). 
4.5.2 Intradermal and intramuscular injections (I-IV) 
For i.d. and i.m. injections the plasmids were formulated in sterile, endotoxin-free 
PBS and given by 0.3 ml insulin needle. I.d. injections were administered just 
beneath of the skin at the base of the tail, dorsal side of the mouse. I.m. injections 
were given into the quadriceps femoris of the hind leg. For DC immunization (IV), 
enriched DC suspended in PBS, were administered i.d. by needle. 
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4.6 DNA immunogenicity studies 
4.6.1 GTU-MultiHIV (I) 
A comparison of GTU and CMV expression vector was done by immunizing 
groups of 5 BALB/c mice at days 0, 7 and 21 with three different doses of both 
MultiHIV expressing plasmids. For GTU-MultiHIV DNA total  doses were 24 ng 
(g.g.), 300 ng (g.g.) and 750 µg (i.d.). Equimolar doses used for CMV-MultiHIV 
DNA were 17.4 ng (g.g.), 220 ng (g.g.) and 546 µg (i.d.). Mice were sacrificed two 
weeks after the last immunization. 
 
To analyze the dose-dependence of the immune responses, mice were immunized 
with GTU-MultiHIV (I) by g.g. three times (days 0, 7 and 21) with a total amount 
of 24 ng, 120 ng, 600 ng, or 3 µg DNA/mouse. Total DNA doses for i.m. and i.d. 
immunizations were 6, 30, 150, or 750 µg. One third of the dose was given at one 
immunization time and the mice were terminated on day 31.  
 
In another set  of experiments,  the 0-3 doses (1 µg) of GTU-MultiHIV DNA was 
administered by g.g. once (day 0), twice (days 0 and 7) or three times (days 0, 7 and 
21). Mice were terminated five weeks after the first immunization. Next, duration of 
the immune responses was followed in 3 × 1 µg immunized groups of mice by 
terminating groups 2, 6, 10, 14 and 22 weeks after the last immunization on day 21. 
Boost immunization ten weeks after the third dose was also given in one group. 
These mice were terminated four weeks later. 
 
Similarly, the effect of fourth booster immunization (at wk 13) by i.m. or i.d 
immunization routes was assessed in mice immunized on days 0, 7 and 21 (wk 0, 1 
and 3) with 50 µg/injection of GTU-MultiHIV. CTL responses were analyzed by 
ELISPOT IFN-J four weeks after the boost (wk 17). 
 
Each experimental group consisted of 5-10 animals. Negative control mice were 
immunized with DNA carrier only. Individual spleen and blood samples were 
collected. Splenocytes were preserved in aliquots in liquid nitrogen and serum 
samples at -20°C until analyzed. 
4.6.2 Auxo-GTU-MultiHIVmix (III) 
Auxo-GTU-MultiHIVmix immunogenicity was evaluated first with long-term 
immunization schedules. Total dose of 8, 40, 200, or 1000 ng DNA was given by 
g.g. at weeks 0, 4 and 12.  
 
Next, the short term immunization with Auxo-GTU-MultiHIVmix at weeks 0, 1 and 
3 was used to assess g.g. (3×1 µg), i.m. and i.d. (3×50 µg) administration routes and 
the persistence of the cellular immune response induced by i.m. and i.d. injections 
was followed two and fourteen weeks after the last immunization.  
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Finally, mice were immunized 3×40 ng by g.g. with 1) the MultiHIVmix or with 2) 
the individual constructs alone or with 3) all different combinations of three of the 
constructs, combined in equal amounts. Negative control mice were immunized i.m. 
with PBS only. Mice were sacrificed 2 weeks after the third immunization, 
splenocytes and serum samples were stored until used for ELISPOT IFN-J and 
ELISA analysis respectively.  
4.7 Tumor challenge model (II) 
Both GTU-MultiHIV and Auxo-GTU-MultiHIVmix were  evaluated  in  a  tumor  
challenge  model.  First,  DBA/2  mice  were  immunized  (n  =  9)  at  weeks  0,  1  and  3  
with  1  µg  of  GTU-MultiHIV  DNA  by  g.g.  After  two  weeks  (wk  5)  immunized  
mice were challenged either with 1×106 P815-MultiHIV or 1×106 P815-wt tumor 
cells. Non-immunized control groups were equally challenged.  
 
In the second set of experiments mice were challenged with different cell numbers; 
0.2 ×106, 0.4 ×106 and 0.8 ×106 of  P815-MultiHIV  cells.  Immunizations  were  
performed similarly but using Auxo-GTU-MultiHIVmix. The immunized but not 
challenged control group was terminated at the time of challenge for evaluation of 
MultiHIV specific cellular and humoral immune responses at the time of challenge 
by ELISPOT and ELISA. A group of naïve mice was included as a control. Groups 
of eight mice were divided randomly into two groups terminated at two different 
time points; 9 and 15 days after the high cell number challenge and 15 and 22 days 
later for groups challenged with 0.2-0.4 ×106 cells. Individual serum samples were 
stored at -20°C, splenocytes in liquid nitrogen until used. 
 
P815-MultiHIV and P815-wt cells were grown in RPMI 1640 (Sigma–Aldrich, St. 
Louis, MO) supplemented with 100 U/ml penicillin–streptomycin (Sigma–Aldrich), 
L-glutamine (BioWhittaker, Verviers, Belgium), 10% FBS (BioWhittaker) at 37qC 
with  5%  CO2.  P185  cells  used  for  the  challenge  in  the  tumor  study  (II)  were  
suspended in sterile PBS and injected in 50 µl s.c. in the shaved right flank by 23-
gauge needle. Tumor growth was recorded every 2-3 days. For E-hCG hormone 
determination urine samples were collected for a few mice in each group on days 6 
and 20. Mice were terminated when the longest diameter of the tumor reached 15 
mm,  or  vertical  growth  >10  mm,  or  at  the  latest  on  day  26  and  samples  were  
collected and stored as previously described until analyzed. 
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4.8 HIV-1/MuLV challenge model (III) 
Groups of twelve C57BL/6.A201 mice were immunized with Auxo-GTU-
MultiHIVmix at weeks 0, 1 and 3, one group by g.g. (3×1 µg), the other 
intramuscularly (3×50 µg). The control group was i.m. injected with sterile PBS. 
Two weeks after the last immunization, at week 5, mice were bled for pre-challenge 
immunity by PBMC ELISPOT and antibody analysis. PBMC were pooled 
groupwise for the analysis. 
 
Five  weeks  after  the  last  immunization  (at  wk  8)  mice  were  challenged  by  
intraperitoneal injection of splenocytes of syngeneic mice, infected in vitro with 
HIV-1/MuLV pseudovirus (Chapter 4.3.). 1×106 subtype B LAI HIV-1/MuLV 
infected cells expressing approximately 1 ng p24 protein, or 3×106 subtype A 9284 
HIV-1/MuLV infected cells were used for the challenge. Ten days post-challenge, 
the ascites of each animal were collected and cells were co-cultured with activated 
human  PBMC  or  Jurkat  Tat  cells.  Every  3  days,  50%  of  the  culture  medium  was  
changed and HIV-1 p24 secretion was analyzed (Devito et al. 2000). If the 
supernatant was positive at more than one time point in at least one of the isolation 
systems (Jurkat Tat or hPBMC), the animal was regarded as unprotected by 
immunization. Splenocytes and serum samples were collected. 
4.9 DC immunization (IV) 
BALB/c mice were immunized twice on consecutive days i.d. with 250 µg of Auxo-
GTU®-MultiHIV-B plasmid. On the third day, lumbar and sacral LN and spleens 
were collected separately. DC were enriched using the gradient as described above 
(4.1.5.) and further used for immunization. This procedure was done twice with one 
week interval for two sets of mice, to accomplish DC transfer immunizations at 
weeks 0 and 1.   
  
A group of naïve BALB/c mice were injected twice with 4 × 105 LN DC/mouse and 
another group of mice twice with 8 × 105 spleen DC/mouse, i.d.  in the base of the 
tail. Tail blood samples were collected at weeks 1, 2 and 3 and mice were 
terminated three weeks after the second DC transfer (week 4). Splenocytes and 
serum samples were stored and analyzed later. 
4.10 Sample preparations (I-IV) 
The spleens were dispersed in a single cell suspension and washed splenocytes were 
resuspended in RPMI1640 supplemented with 40% FBS + 10% DMSO. Cells were 
cryopreserved by freezing to -80°C for a few days and then stored in liquid nitrogen 
(LN). For analysis the splenocytes were thawed and suspended in culture media 
(CM): RPMI 1640 (BioWhittaker, Verviers, Belgium) supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin-streptomycin, and 50 µM 2-mercaptoethanol (all 
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from BioWhittaker). For CD8+ T cell depletion magnetic beads (MagCellect, R&D 
Systems, Minneapolis, MN) were used following the manufacturer’s instructions. 
The whole blood was collected at the time of termination and serum was obtained 
by centrifugation at 1300 g 10 min after incubating the blood at RT ~2 h. Serum was 
collected and stored at -20°C until analyzed. 
4.11 Immunoassays  
4.11.1 Recombinant proteins and peptides (I-IV) 
Glutathione S-transferase (GST)-tagged HIV-1 (Han-2) Nef and GST proteins were 
affinity purified from lysates from E. coli BL21 (DE3) cells which were transformed 
with a pGex-Nef-GST or pGex-GST plasmids using Pharmacia (Piscataway, NJ) 
reagents. Coding sequences of HIV-1 Rev, Tat, p17/24, CTL and E2 were cloned 
into pET24d vector and purified from E. coli lysate using Ni-NTA Agarose 
(Qiagen).  
 
H-2d-restricted HIV-1 gp120 (Env) 10-mer peptide (aa 311–320; RGPGRAFVTI) 
(Takahashi 1988) and 9-mer HIV-1 Gag peptide (aa 65–73; AMQMLKETI) (Qiu 
1999) were purchased from Sigma-Genosys (Cambridge, UK) as t95% pure. 15-
mer peptide pools of Rev (29 peptides), Nef (51 peptides), Tat (25 peptides), Gag 
(91 peptides) and CTL (67 peptides) were purchased from Sigma-Genosys and were 
t85% pure. The peptides in the pools were 15 aa in length, overlapping by 11 aa, 
covering the MultiHIV B consensus sequence. 
 
For C57BL/6.A201 mice (III) EnvB.gp120 15-mer peptide pool overlapping by 8 
amino acids (ThermoHybaid, Ulm, Germany) and GagB.p24 peptide pool 
containing 15-mer peptides overlapping by 10 (ThermoHybaid, Ulm, Germany) 
were used. 20-mer herpes simplex virus (HSV) peptide 
(RRHTQKAPKRIRLPHIREAD) was used as a negative control. Peptide pools were 
used at a final concentration of 2.5 µg/ml of each peptide whereas single peptide 
was used at 1 µg/ml. 
4.11.2 ELISPOT IFN-J assay (I-IV) 
CTL responses of BALB/c and DBA/2 mice were measured by quantification of 
IFN-J producing cells using mouse ELISpot IFN-J assay kit (R&D Systems, MN, 
USA) on liquid nitrogen stored frozen cells (I-IV). Polyvinylidene difluoride-backed 
96-well plates were pre-coated with IFN-J specific monoclonal antibody. 105 cells  
per well were plated and restimulated for 24 h at 37°C and 5% CO2.  
 
Cells were incubated with culture media (CM), T lymphocyte mitogen concanavalin 
A (Con A, 5µg/ml, Pharmacia) or with HIV-1 specific peptides and peptide pools. 
Single short peptides Env and Gag were used at a final concentration of 1 µg/ml and 
 60
five peptide pools specific for Rev, Nef, Tat, Gag and CTL were used at a final 
concentration of 2 µg/ml of each peptide (Chapter 4.11.1). P815-MultiHIV and 
P815-wt cells were used similarly for stimulation in tumor challenge model (II). 
Secreted IFN-J was detected by incubating with biotinylated antibody, following 
streptavidin-alkaline phosphatase conjugate and finally the BCIP/NBT substrate 
incubation. Spot forming cells (SFC) were counted using an automated plate reader 
(ImmunoSpot™ analyzer, CTL Europe, Germany). The results were expressed as 
mean SFC/106 splenocytes of duplicate wells and were considered positive if both 
replica wells were !50 SFC/106 above  the  control  (unstimulated  cells)  and  twice  
above the control. All CM values were <30 SFC/106 cells, Con A values typically 
between 2500-8000 SFC/106 cells. 
 
C57BL/6.A201 mice PBMC and splenocytes were also analyzed using IFN-J 
ELISpot kit of Mabtech AB (Stockholm, Sweden), with the similar protocol. Cells 
were stimulated with EnvB.gp120 pool, GagB.p24 pool and HSV peptide 
ThermoHybaid) in addition to MultiHIV specific CTL pool. Peptide pools were 
used at a final concentration of 2.5 µg/ml of each peptide whereas single peptide 
was used at 1 µg/ml. Spots were counted by an AID ELISPOT reader (Autoimmune 
Diagnostika GmbH, Germany). 
4.11.3 Antibody IgG ELISA (I-IV) 
4.11.3.1 MultiHIV-specific antibodies (I-IV) 
HIV-1 Rev, Nef, Tat, p17/24, CTL, and E2-specific antibodies were assayed in 
1:100 or 1:400 PBS-BSA diluted sera by ELISA. HIV-1 Rev-, Nef-, Tat-, p17/24-, 
CTL-,  and  BPV-1 E2-specific  monoclonal  antibodies  (FIT Biotech  Oy)  were  used  
as  positive  controls.  The  serum  samples  and  controls  were  plated  as  duplicates  to  
protein-coated, blocked 96-well microplates (Nunc MaxiSorp) and incubated either 
at RT for 2 h or at 4°C overnight. After extensive washes the plates were incubated 
at RT for 2 h with 1:500 diluted peroxidase-conjugated antimouse Ig (P0447, 
DAKO, Glostrup, Denmark) or IgG (P0161, DAKO). After washing the substrate 
was added; either the 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) 
in phosphate-citrate buffer or tetramethylbenzidine (TMB peroxidase EIA Substrate 
Kit, BioRad, München, Germany) was used for detection of bound antibodies. The 
absorbance of the ABTS substrate was measured at 405 nm. Reaction with TMB 
was stopped with 0.2 M sulphuric acid and optical absorbance read at 450 nm. The 
photometric analysis was performed by ELISA plate reader (Labsystems, Helsinki, 
Finland). Mean blank optical density (OD) value was subtracted from sample OD 
values.  An  OD  above  the  mean  of  naïve  sera  plus  3  standard  deviations  was  
regarded as positive (Cut-off value = mean OD of the negative control group × 3 SD 
of negative control group).  
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4.11.3.2 Anti-double strand (ds) DNA antibodies (I) 
Anti-dsDNA antibody levels were assayed by ELISA using ɉ phage dsDNA antigen, 
bounded on poly-L-lysine coated plates (I). Sera of immunized mice, positive 
control mice (MRL/MpJ-Faslpr,  a  generous  gift  from  Dr.  Gene  Shearer,  NIH  
Bethesda, MD, USA), and negative control mice (DNA carrier immunized mice) 
were diluted 1:10, 1:50, 1:250 and 1:1250 and antibodies were assayed as described 
above, using the ABTS susbstrate. 
4.11.4  Chromium51 release assay (I, II) 
Thawed splenocytes of g.g. 3 × 1 µg GTU-MultiHIV immunized mice were used 
to generate HIV-1 Env-specific effector cells by stimulating cells in vitro with the 
gp120 10-mer peptide (2 µg/ml) and recombinant IL-2 (25 U/ml, Boehringer 
Mannheim, Indianapolis, IN, USA) for 5 days, to be used in Cr51 release assay 
(Townsend et al. 2006). As target cells, peptide pulsed (1 µg/ml; 2 h at 37°C), MHC 
I restricted syngeneic P815 cells (Tobery and Siliciano 1997) were used, while 
control target cells were P815 cells incubated without the peptide (I). For evaluating 
stable transfected p815-MultiHIV APC function, mitomycin treated P815-MultiHIV 
or P815-wt (control) were used as target cells (II). The target cells were prepared by 
incubating for 1.5 - 2.5 h at 37°C in medium containing 150 µCi Na2 51CrO4 (New 
England Nuclear, Boston, MA). After washing target cells were mixed with the 
effector cells at ratios (E:T) of 50:1, 25:1, 12.5:1. Assays were done in 
quadruplicate, 5000 targets/well. Supernatants were collected after 5 h incubation 
and radioactivity measured by a E-counter (Wallac Oy, Turku, Finland).  
 
Nonspecific  lysis  of  the  control  targets  was  subtracted  from  the  specific  lysis  and  
results were expressed as mean percent lysis of quadruplicate determinations. 
Results were calculated by the following formula: (experimental release - 
spontaneous media release) / (maximum detergent release - spontaneous media 
release) × 100. Experimental release represents the mean count per minute released 
by target cells in the presence of effector cells. Maximum release represents the 
radioactivity released after lysis of target cells with 5% Triton X-100. Spontaneous 
release represents the radioactivity present in medium derived from target cells 
alone. 
4.12 Statistical analyses 
Differences in mean values were tested by paired and unpaired two-tailed Student’s 
t-test (two-tailed for equal variance assumed); p values 0.05 were considered 
significant.  The software GraphPad Prism software was used for analyses of HIV-
1/MuLV challenge protection (III). The log rank survival analysis was used for 
comparison  of  time to  infection  between the  challenged  mouse  groups  both  in  the  
overall test and in the post hoc pairwise comparisons between the naïve group and 
the various vaccinated groups. 
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5. Results 
5.1 High expression of GTU® vector encoded protein 
was detected in vitro and in vivo  
5.1.1 Expression by GTU® vector in vitro (I) 
Expression properties of GTU vector and conventional CMV vector were 
compared in vitro by transfecting RD cell lines with equimolar quantities of GTU 
and CMV vectors expressing MultiHIV fusion protein. Western blot showed 
considerably lower MultiHIV fusion protein (120 kD) production by CMV vector 
than  by  GTU vector  as  detected  by  monoclonal  anti-p24  antibody.  Only  GTU-
MultiHIV expressed the protein on a detectable level by a less sensitive ELISA 
assay. Localization of the fusion protein was shown to be cytoplasmic by anti-Nef 
specific immunofluorescent staining of GTU-MultiHIV transfected Cos-7 cells.  
5.1.2 Expression by GTU® vector in vivo (IV) 
After verifying the GFP expression of GTU-GFP vector in vitro by flow cytometry 
analysis of transfected Jurkat cells, the expression was assessed in in vivo. GTU®-
GFP  plasmid  was  injected  in  mice  twice  on  two  consecutive  days  i.d.  and  on  the  
third day lumbar and sacral LN were collected and pooled LN DC enriched by 
gradient.  GFP  expression  was  observed  by  flow  cytometry  analysis  of  CD11c+ 
labelled DC. GTU-MultiHIV immunized mice LN DC were used as controls. 25% 
of the gated CD11c+ DC were shown to express GFP protein (Fig 4). 
 
 
 
 
Figure 4. GFP expression in 
lymph node CD11c+ DC. GTU-
GFP  (grey  line)  and  GTU-
MultiHIV (black line) immunized 
mice lymph node DC were 
CD11c–PE labeled and analysed 
by flow cytometer. Reprinted from 
the original article (IV), copyright 
(2011), with kind permission of 
Springer Science and Business 
Media. 
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5.2 GTU® HIV-1 multigene vaccination induces HIV-1 
specific cellular and humoral immune responses  
5.2.1 Comparison of GTU-MultiHIV and CMV-MultiHIV 
immunogenicity (I) 
BALB/c mice were immunized three times with total GTU-MultiHIV DNA dose 
of 24 ng (g.g.), 300 ng (g.g.) or 750 µg (i.d.) and with equimolar amounts of CMV-
MultiHIV and assayed for antigen specific immunity. When immunized with g.g. 
the GTU-MultiHIV DNA was observed to induce significantly stronger cellular 
IFN-J responses than CMV-MultiHIV. When high DNA doses were administrated 
intradermally, the advantage of GTU was no longer seen (Fig. 5 A). Anti-Nef and 
anti-p17/24 antibody production detected after higher dose g.g. immunization was 
significantly higher with GTU vector (Fig. 5 B). 
 
 
A      B 
 
 
Figure 5. GTU-MultiHIV and CMV-MultiHIV induced cellular and humoral immune responses. A) 
Mean HIV-1 gp120 peptide-specific IFN-J production as shown by ELISPOT assay. B) HIV-1 Nef- 
and p17/24- specific antibody responses after g.g. higher immunization dose. *Significant responses 
(p 0.05) Figure B reprinted from the original article (I), copyright (2006), with kind permission of 
Mary Ann Liebert, Inc. 
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Table 2. Comparison of immune responses induced by GTU-MultiHIV and CMV-MultiHIV 
immunizations by g.g. (ng doses) or i.d. (µg doses) as shown by mean SFC/106 splenocytes in 
ELISPOT IFN-Ȗ assay. 
Peptide pools
DNA plasmid (total dose) CM Rev Nef Tat Gag CTL Con A
GTU-MultiHIV (24 ng) 2 67 2 12 43 150 2030
CMV-MultiHIV (17.4 ng) 0 0 0 3 2 0 2577
GTU-MultiHIV (300 ng) 0 80 320 51 296 1145 2003
CMV-MultiHIV (220 ng) 4 13 115 31 274 1008 2088
GTU-MultiHIV (750 Pg) 0 15 105 10 78 455 2102
CMV-MultiHIV (546 Pg) 0 30 60 20 77 643 2443
 
5.2.2 GTU-MultiHIV dose escalation immunization (I) 
Mice were immunized with four escalating doses of GTU-MultiHIV plasmid 
following a short-term schedule (wk 0, 1 and 3). Total DNA doses given by g.g. 
were 24 ng, 120 ng, 600 ng or 3 µg. Intramuscularly or intradermaly total doses of 
6, 30, 150 or 750 µg were administrated. Two weeks after the final immunization 
CTL responses were assessed by IFN-J ELISPOT and HIV-1 specific antibodies 
analyzed.  
 
G.g. delivery induced strong IFN-J responses also with low DNA doses,  while the 
highest dose of 750 µg was needed for i.d. administration to provide adequate 
stimulus for the cells. I.m. injection elicited only minor IFN-J responses with the 
highest doses given. Strongest responses were generated against gp120 peptide 
(RGPGRAFVTI)  shown  in  Figure  6.  However,  all  components  of  MultiHIV  
induced specific responses after g.g. immunization as tested with Rev, Nef, Tat, 
p17/24 and CTL peptide pools. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. HIV-1 specific IFN-J responses with escalating MultiHIV DNA doses. A) CD8+ responses 
against H-2d restricted gp120 peptide. Reprinted from the original article (I), copyright (2006), with 
kind permission of Mary Ann Liebert, Inc.  
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Dose-dependent humoral responses to Nef and p17/24 proteins were observed after 
g.g. and i.d. administrations, the majority of the high dose immunized mice had 
developed HIV-1 specific antibodies, g.g. administration inducing strongest 
responses.  Low antibody production was induced in a few mice against Rev, Tat 
and CTL proteins. Low doses or intramuscular immunization with any of the DNA 
doses used did not result in detectable HIV-1 specific antibodies. No E2-specific 
antibodies were generated by immunization with GTU plasmid.  
5.2.3 Immunization frequency and duration of immune 
responses (I) 
To examine the effect of the immunization frequency on humoral immunity, mice 
were immunized once, twice or three times and anti-Nef antibodies were analyzed 
by ELISA assay. Clear dose dependence was detected, indicating that a third 
immunization is needed for optimal antibody response induction (Fig. 7) 
                            
Figure 7. HIV-1 Nef antibodies after immunizing mice 0-3 × 1 µg with GTU-MultiHIV DNA. 
Reprinted from the original article (I), copyright (2006), with kind permission of Mary Ann Liebert, 
Inc. 
 
Mice were immunized 3 × 1 µg of GTU-MultiHIV  on  days  0,  7  and  21  and  
duration of CMI responses was followed by terminating groups of mice at several 
time points. Samples were analyzed by IFN-J ELISPOT  using  H-2d restricted 
peptides gp120 (Env) and Gag for stimulation. All mice showed positive HIV-1 
specific  responses  two  weeks  after  the  immunization  period,  when  the  strength  of  
the gp120 response was also significantly greater than detected at later time points. 
However, the IFN-J response was shown to be maintained at a constant level 
throughout the study (Fig. 8A). The effect of boost immunization ten weeks after the 
third immunization was evaluated and addressed to be capable to restore the IFN-J 
response back on the highest level (Fig. 8B). 
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Figure 8. Long-term persistence of the IFN-J immune responses after g.g. immunization. A) 
Duration of the immune responses was followed 2, 6, 10, 14 and 22 weeks after the last 
immunization. B) Boost immunization 10 weeks after the last immunization regenerated the high 
response detected earlier. Reprinted from the original article (I), copyright (2006), with kind 
permission of Mary Ann Liebert, Inc. 
 
 
Similarly, the boost effect 10 weeks after the third immunization was evaluated with 
i.d. and i.m. immunization routes, a single dose being 50 µg. CD8+ responses were 
evaluated four weeks later by IFN-J ELISPOT, however, no elevation in CTL 
responses following the boost immunization was detected with this immunization 
schedule.  
 
After depletion of CD8+ T cells by magnetic beads, <4% CD8+ T cells remained as 
shown by flow cytometry. The depletion of CD8+ T cells inhibited ELISPOT IFN-J 
responses towards Gag peptide completely and 60% of the gp120 peptide-specific 
responses. Residual CD8+ T  cells  may  primarily  account  for  the  40%  of  the  
responses against very immunodominant H-2d restricted 10-mer epitope gp120. 
 
HIV-1 specific IFN-J producing CD8+ T cells induced by GTU-MultiHIV 
immunization were demonstrated to be capable of functioning as cytotoxic T cells 
by lysing the target cells. Some of the mice immunized with 3 µg dose by g.g. were 
analyzed additionally with Cr51 release assay. CTL capability to kill the target cells 
was shown to correlate positively with IFN-J responses measured by ELISPOT 
assay (SFC/106 cells), as shown in Fig 9.  
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Figure 9. HIV-1 specific cytolytic activity of GTU-MultiHIV immunized mice. Frozen splenocytes 
were cultured in vitro in the presence of the gp120 (Env) peptide and assayed for specific lysis 
against the gp120 peptide pulsed P815 target cells. Spontaneous release of 51Cr from the targets did 
not exceed 25% of the maximum release. Reprinted from the original article (I), copyright (2006), 
with kind permission of Mary Ann Liebert, Inc. 
5.2.4 Auxo-GTU-MultiHIVmix induced immune responses (III) 
Auxo-GTU-MultiHIVmix induced cell-mediated and humoral immune responses 
were assessed with two different schedules. First, three immunizations were 
administrated by g.g. at intervals of one and three months, using total doses of 8, 40, 
200, or 1000 ng of DNA. Gp120 and gag specific CD8+ responses were assessed 
two weeks later by IFN-J ELISPOT. All doses induced strong CTL responses 
against gp120 peptide, while dose-response against Gag was more distinct (Fig. 
10A). Next, CMI responses induced by immunization on days 0, 7 and 21 were 
evaluated by g.g., i.m. and i.d. routes. In addition to usual screening after two weeks 
time, groups of i.m. and i.d. immunized mice were sacrificed 14 weeks after the 
third immunization. 
 
Similar to what was seen with follow-up of GTU-MultiHIV g.g. immunized mice, 
strong gp120-specific response was detected after i.d. immunization, slightly lower 
magnitude but still persisting twelve weeks later. On the contrary, this time the 
immunization of the 150 µg total dose did not induce detectable response in five 
weeks, however, the response was observed twelve weeks late, at week 17 (Fig. 
10B).  
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Figure 10. IFN-J specific responses induced by Auxo-GTU-MultiHIVmix immunization. A) 95% of 
mice responded to both epitopes tested after g.g. delivery of four different DNA doses. B)  gp120 and 
Gag specific responses were detected two and 14 weeks after the last DNA administration via i.d. and 
i.m. routes. G.g. immunization was not followed here. Dose (µg) per immunization time is shown. 
Reprinted from the original article (III), copyright (2005), with kind permission of Mary Ann Liebert, 
Inc. 
 
 
To address possible interference of the individual clade components of the 
MultiHIVmix, mice were immunized with four different plasmids of Auxo-GTU-
MultiHIVmix, i.e. MultiHIV-A, MultiHIV-B, MultiHIV-C and MultiHIV-FGH 
individually, in different combinations of three plasmids and in MultiHIVmix. The 
dose for each immunization was 3×40 ng by g.g. at intervals of one and two weeks. 
Two weeks after the last immunization, T cell responses were assessed against 
gp120 and Gag peptides in ELISPOT assay. Gp120 sequence (RGPGRAFVTI) is 
coded by all four plasmids and could be used here as a control, to ensure equal 
dosing of different plasmids and plasmid mixtures. Gag epitope (AMQMLKETI) is 
MultiHIV-B specific and altered for three other plasmids (AMQMLDETI). As 
expected, the Gag responses detected corresponded to the amount of B-clade 
plasmid administered (either 100%, 33.3%, 25% or 0% of the dose), even though 
the response induced by MultiHIVmix was lower than expected. However,  no signs 
of  inhibition  towards  Gag  B-clade  sequence  were  seen  when  MultiHIV-B  was  
mixed with two other plasmids (Fig 11). 
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Figure 11. IFN-J production induced by clade-specific plasmids administered individually and in 
different mixtures. A) gp120 sequence was equally present in each immunization dose resulting in 
equal gp120 specific T cell responses. B) B-clade specific Gag epitope was recognized only in B-
clade immunized mice but not after immunization by other clades, with epitope differing by one 
amino acid. Reprinted from the original article (III), copyright (2005), with kind permission of Mary 
Ann Liebert, Inc.   
5.3 MultiHIV immunization protected DBA/2 mice from 
tumor cell challenge (II) 
5.3.1 P815-MultiHIV cells as APC  
Before the challenge study, MultiHIV presentation by P815-MultiHIV cells was 
attested  by  ELISPOT  IFN-J and  Cr51 release  assay.  Both  GTU-MultiHIV and 
Auxo-GTU-MultiHIVmix immunized BALB/c mouse splenocytes responded 
strongly to P815-MultiHIV cells but not to P815-wt cells by IFN-J secretion (Fig. 
12A) and by lysing the P815-MultiHIV target cells (Fig. 12B). In addition, the 
capability of P815-MultiHIV and P815-wt cells to form tumors by inoculating 
1×106 tumor cells in non-immunized DBA/2 mice was attested before starting the 
challenge study. 
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Figure 12. MultiHIV-immunized mouse cell responses to P815-MultiHIV cells. A) IFN-J response 
to P815-MultiHIV cells and P815-wt was assessed by ELISPOT. B) Lysis of the P815-MultiHIV 
target  cells  by  the  CTL in  Cr51 release assay. The lysis of wild type P815-wt target cells (%) was 
subtracted from the MultiHIV-specific lysis. Reprinted from the original article (II), copyright 
(2007), with kind permission of Elsevier. 
5.3.2 Protection conferred by GTU-MultiHIV  
The first challenge experiment was done with DBA/2 mice immunized with GTU-
MultiHIV by inoculating 1×106 P815-MultiHIV or 1×106 P815-wt tumor cells able 
to form palpable tumors when injected s.c. Immunizations were given by g.g. 
following a short-term schedule (days 0, 7, 21) and mice challenged two weeks 
later. As a control, groups of PBS immunized mice were similarly challenged.  
 
GTU-MultiHIV immunization was able to delay the P815-MultiHIV tumor 
growth. A significant difference (p<0.05) was seen in immunized and non-
immunized P815-MultiHIV challenged groups until day 12, when tumor regression 
was observed in non-immunized groups and additionally a deliberate tumor growth 
started in the immunized group (Fig. 13A). Urinary E–hCG measurement indicated 
the loss of transfected insert from P815-MultiHIV cells or overgrowth of non-
transfected P815 cells after the regression, while the hormone was clearly detected 
in day 6 samples but not on day 20, when the tumor mass had redeveloped to equal 
size. Wild type challenge resulted in aggressive tumor growth independently of 
immunization. In non-immunized groups, inoculation of both cell types resulted in 
equally aggressive tumors within one week. However, at 12 days a regression of 
P815-MultiHIV tumors was observed, while P815-wt tumors either grew or 
remained constant until termination time. Immune responses at the time of 
termination varying according to tumor growth are depicted in Fig. 13B. 
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Figure 13. GTU-MultiHIV, 3x1 µg by g.g. immunized, and non-immunized DBA/2 mice were 
challenged with 106 stable transfected P815-MultiHIV cells or wild type P815 cells. A) Tumor 
growth as measured after the challenge at day 0. B) Cellular and humoral immune responses in 
different treatment groups at the termination time. Reprinted from the original article (II), copyright 
(2007), with kind permission of Elsevier. 
5.3.3 Protection conferred by Auxo-GTU-MultiHIVmix   
In the second experiment, Auxo-GTU-MultiHIVmix immunized mice were 
challenged with 0.2×106, 0.4×106 or 0.8×106 of P815-MultiHIV cells. Two different 
termination days were applied for challenged mice to assess the progression of the 
immune responses. Low and medium challenge dose groups were terminated on 
days 15 and 22 and the group with highest challenge dose at days 9 and 15. A group 
of immunized mice was sacrificed at the time of challenge to measure the immune 
responses in DBA/2 mice and a group of naïve mice was included as a control.  
 
Auxo-GTU-MultiHIVmix immunization was shown to delay tumor growth in all 
challenge doses used when compared to corresponding non-immunized groups (Fig. 
14). One out of eight mice challenged with the 0.2×106 cells, and two out of eight 
mice challenged with the 0.4×106  cells stayed completely tumor free until the end of 
the study (day 22). 
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Figure 14. Tumor growth in immunized and non-immunized mice after 0.2×106,  0.4×106 or 0.8×106 
P815-MultiHIV tumor cells. Reprinted from the original article (II), copyright (2007), with kind 
permission of Elsevier. 
 
ELISPOT IFN-J responses were analyzed against gp120, Gag, P815-MultiHIV and 
P815-wt cells. In general, responses were more marked at the first termination time 
point. Only immunized mice recognized the Gag epitope, while gp120 and P185-
MultiHIV stimulation also induced dose-dependent response in non-immunized 
P815-MultiHIV challenged mice. Wild type P815 cells did not induce any responses 
(Fig. 15A-C). 
 
Auxo-GTU-MultiHIVmix DNA immunogenicity in DBA/2 mice was evaluated two 
weeks  after  immunizations  on  days  0,  7  and  21,  by  ELISPOT  IFN-J and  ELISA.  
Immune responses observed in DBA/2 corresponded with BALB/c mice; 
immunized mice responded strongly to gp120 and Gag peptides and P815-MultiHIV 
stimulation, but not to P815-wt in IFN-J ELISPOT (Fig. 15D). Gag-specific 
responses measured after the challenge (Fig. 15B) were significantly lower (p < 
0.05) than at the time of the challenge in the immunized control mice (Fig. 15D).  
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Figure 15. IFN-J CD8+ responses at two selected time points after the challenge and at the time of 
the challenge. A) Gp120-peptide, B) Gag-peptide and C) P815-MultiHIV cell induced responses in 
immunized and non-immunized challenged groups. D) IFN-J responses at the time of the challenge 
in immunized control group. (*) values above 50 SFC/106 cells were considered positive. Reprinted 
from the original article (II), copyright (2007), with kind permission of Elsevier. 
 
 
Auxo-GTU-MultiHIVmix immunization generated very high B-clade Gag-specific 
antibody response in DBA/2 mice, persisting until the last termination time but 
dropping significantly after the challenge (Fig. 16). Only few low Nef-specific 
responses were induced by immunization. 
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Figure 16. HIV-1 specific antibodies induced in DBA/2 mice by immunization or P815-MultiHIV 
challenge. A) Gag-specific antibodies at two different post-challenge termination time points in 
immunized and non-immunized DBA/2 mice, inoculated with P815-MultiHIV cells. Immunized and 
P815-MultiHIV challenged groups had Gag-specific antibodies, while P815-MultiHIV challenge 
alone did not induce humoral response. B) Anti-Gag and anti-Nef antibodies two weeks after the last 
immunization, at the time of the challenge. Reprinted from the original article (II), copyright (2007), 
with kind permission of Elsevier. 
5.4 Protection against HIV-1/MuLV pseudovirus 
challenge was provided by Auxo-GTU-MultiHIVmix 
immunization (III)  
The protective effect of Auxo-GTU-MultiHIVmix DNA given via two 
immunization routes, g.g. (3×1 µg) and i.m. (3×50 µg) was evaluated against HIV-
1/MuLV challenge in C57BL/6.A201 mice. Sterile PBS i.m. injections were given 
to control animals. Ten days after the last immunization, blood samples were 
collected for PBMC ELISPOT analysis and mice challenged i.p. either with 1×106 
subtype B or 3×106 subtype A HIV-1/MuLV infected cells. After ten days ascites 
were collected for co-cultivation with hPBMC or Jurkat Tat cells susceptible to 
HIV-1 infection and supernatants were analyzed for HIV p24 over a 21-day period. 
 
Each challenged group consisted of six mice. G.g. immunization protected all mice 
from subtype B and five mice from subtype A challenge. In i.m. immunized groups 
four mice were protected from subtype B and three mice from subtype A infection. 
In the control group, one subtype B infected mouse was spontaneously protected 
while subtype A infected all control mice (Fig. 17). 
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Figure 17. Protection of Auxo-GTU-MultiHIVmix g.g., i.m. and PBS immunized mice from subtype 
A and B HIV-1/MuLV pseudovirus challenge. A) HIV-1 p24 content as measured from mouse post-
challenge ascites and hPBMC or Jurkat Tat co-culture supernatant. B) A mouse was considered 
infected if isolation was p24 positive in two or more time points at least in other test system. 
Protection against subtype B challenge was 100% by g.g. and 66% by i.m. and against subtype A 
challenge 83% by g.g. and 50% by i.m. Spontaneous protection of control mice  was 16% for subtype 
B and 0% for subtype A challenge. Reprinted from the original article (III), copyright (2005), with 
kind permission of Mary Ann Liebert, Inc.  
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Cellular immune responses were measured by ELISPOT against EnvB.gp120 pool, 
CTL pool (corresponding to the subtype B MultiHIV CTL) and GagB.p24 pool, 
atigens matching for C57BL/6.A201 mice, having different genetics than BALB/c. 
IFN-J responses were measured from mPBMC pre-challenge samples and post-
challenge splenocytes. In general, g.g. immunization resulted in more frequent and 
stronger cell mediated immune responses. However, post-challenge responses were 
quite similar in both g.g. and i.m. immunized groups. The most striking observation 
was the switching from pre-challenge gag-specificity to post-challenge env-
specificity. 
 
Before the challenge groupwise pooled mPBMCs of g.g. immunized mice 
responded to Gag-specific stimulation strongly (max. 231 SFC/106 cells for the 
group to be challenged with clade B virus / 583 SFC/106 cells for the group to be 
challenged with clade A virus), while EnvB.gp120 stimulation induced only weak 
responses (max. 20 SFC/106 cells B clade challenged group / 27 SFC/106 cells A 
clade challenge group). Only weak EnvB.gp120 response (30 SFC/106 cells) was 
detected after i.m. immunization.  
 
The post-challenge ELISPOT analysis of splenocytes showed that after the 
challenge, Gag-specific responses had declined in the g.g. immunized groups, being 
13-30 SFC/106 cells (2 responders in both groups). A similar weak response to Gag 
was also detected this time in few mice of i.m. immunized groups. On the contrary, 
Env stimulation elicited better responses post-challenge both in g.g. and i.m. 
immunized groups. One mouse in both g.g. immunized groups responded to 
EnvB.gp120 (50 / 100 SFC/106 cells). Four responders in B subtype challenged 
group (25-70 SFC/106 cells) and five responders in A subtype challenged group (25-
165 SFC/106 cells) were detected after CTL pool stimulation. In i.m. immunized 
groups EnvB.gp120 peptides were recognized in three mice (13-103) after subtype 
B challenge and in one mouse (73 SFC/106 cells) after subtype A challenge. 
Responses to CTL pool were not analyzed for i.m. immunized groups. No specific 
responses were detected in control mice. 
 
Antibodies  against  recombinant  Gag  A-,  B-,  C-,  and  FGH  -clade  proteins  were  
detected at the time of the challenge in g.g. immunized mice. Challenge with HIV-
1/MuLV infected cells raised the anti-Gag antibodies in all treated groups, also in 
the control group. Only low antibody levels were detected overall. 
5.5 Immunization with in vivo transfected DC induced 
HIV-1 specific immune responses (IV) 
T cells of BALB/c mice were primed by immunization on days 1 and 2 with Auxo-
GTU®-MultiHIV-B. On the third day draining LN and spleens were collected and 
dendritic cells enriched by gradient. DC were used further for immunizing naïve 
groups  of  mice,  one  group  with  LN  DC  and  the  other  with  spleen  DC.  DC  
immunization was given with freshly isolated, in vivo transfected DC, twice at one 
week intervals. Blood samples were collected weekly for antibody measurement. 
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Mice were terminated three weeks after the last DC immunization and CMI 
responses analyzed using in vitro stimulated splenocytes in ELISPOT IFN-J. 
   
IFN-J responses were measured against Rev, Nef, Tat, p17/24 and CTL pool; all 
antigens were recognized by LN DC immunized lymphocytes, Nef, p17/24 and CTL 
by spleen immunized lymphocytes. CTL and Gag peptide pools elicited the 
strongest responses, while Tat was least immunogenic (Fig. 18). Naïve control mice 
did not respond to any peptide pools used for stimulation. Low anti-Nef and anti-
Gag  antibody  responses  were  detected  after  DC  transfer,  slowly  already  elevating  
one week after the first DC immunization. Approximately half of the mice in both 
groups generated Nef specific antibodies, while Gag specific responses were less 
frequent. 
 
 
                              
                   
Figure 18. HIV-1 specific IFN-J responses after 6 days in vitro stimulation of splenocytes. Non-
specific (CM) SFC values were subtracted from the relevant peptide SFC values. The result was 
considered positive (*) when the SFC with the relevant peptide exceeded the mean of the SFC from 
the negative antigen wells + 3 × SD. Values obtained with the Con A stimulation were similar for all 
groups analyzed (>5000 SFC/106 splenocytes). Reprinted from the original article (IV), copyright 
(2011), with kind permission of Springer Science and Business Media.   
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6. Discussion 
6.1 GTU is a potent DNA vaccine vector 
With the two DNA vectors used, MultiHIV antigen is expressed as a fusion protein 
with a molecular mass of approximately 120 kDa in the cytoplasm of transfected 
cells. Significantly higher MultiHIV protein expression level was observed when 
expressed from GTU vector, compared to expression from regular eukaryotic 
CMV vector. This observation is in agreement with the results obtained in other 
studies  with  GTU-GFP, addressing the improved maintenance of the vector in 
dividing cells, as well as enhanced transcription (Krohn et al. 2005, Martinon et al. 
2009). The advantage of GTU vector comes from the expressed BPV-1 E2 protein 
(Abroi et al. 2004, Silla et  al. 2010, Ustav et al. 1993) which attaches to multiple 
oligomerized binding sites of the vector, thereby acting as a transcription activator 
for the gene of interest. Secondly, E2 has a natural chromatin binding function 
accomplishing the GTU vector segregation function leading the plasmid to the 
progeny of cells during mitosis. This is a valuable aspect while the major 
impediment with DNA vaccine development is related to the relatively low and 
transient immune responses generated in humans (Estcourt et al. 2004), most 
probably largely due to too low dose of the vector in the expressing cells and to the 
rapid loss of non-replicating vector during cell division (Arrode-Bruses et al. 2010). 
The  expression  level  of  the  MultiHIV  gene  by  the  GTU vector enables more 
efficient immune responses with smaller DNA doses. This was demonstrated when 
the HIV-1 specific immune responses were compared after GTU or CMV based 
MultiHIV immunization. Low doses (24 ng and 300 ng of GTU and equimolar 
amount of CMV) administered showed the significant superiority of GTU vector, 
while with high dose immunization (750 µg of GTU and equimolar amount of 
CMV) the advantage was no longer observed, possibly due to saturation. Similarly, 
the less immunogenic antigens such as Rev were more efficiently recognized after 
GTU immunization. 
 
There are concerns related to anti-vector immune responses with the use of naked 
DNA vaccines, even if not so striking as in case of viral genetic vaccines (Schalk et 
al. 2006).  However,  we  detected  no  antibodies  to  dsDNA  in  the  sera  of  GTU 
immunized mice, neither have others reported anti-dsDNA antibodies after repeated 
DNA immunizations (Giri et  al. 2004, Parker et al. 2001, Schalk et al. 2006). 
Previously GTU-MultiHIV general safety, biodistribution, persistence and 
tolerability have been studied in rats and no concerns were observed (Tuomela et al. 
2005). GTU based HIV-1 vaccines have been found safe and well-tolerated in 
several clinical trials conducted both on healthy volunteers and HIV-1 infected 
subjects (Krohn et al. 2005, Vardas and Stanescu,I, Valtavaara,M, Kuntonen,T, 
Gray,C, Leionen,M, Ustav,M, Reijonen, K 2010). 
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6.2 Evaluation of vaccine immunogenicity 
The strength of DNA vaccines is to direct the expressed immunogen for MHC class 
I and II presentation, making them especially suitable inducers of cellular immune 
responses. GTU- MultiHIV is designed to elicit cellular immune responses to HIV-
1 regulatory proteins Rev, Nef and Tat expressed at an early phase of the viral life 
cycle, (Blazevic 1997, Ranki et al. 1994) as well as to highly immunogenic 
structural proteins p17 and p24. Furthermore, the 17-45 amino acid long stretches 
containing T cell epitope clusters included can elicit RT and Env specific CD8+ and 
CD4+ T cell responses. The essential role in viral infectivity and expression early in 
the viral life cycle makes the regulatory proteins Rev, Nef and Tat attractive 
antigens to be included in vaccine (Blazevic 1997). The immunological pressure 
towards these antigens leading to detrimental changes in their function could 
effectively reduce the acute phase viral burden. Nef has been reported to be the most 
targeted HIV-1 antigen in early stage of HIV-1 infection (Masemola et  al. 2004) 
even if these immune responses have not been shown to correlate with viral load. 
The role of cellular immune responses against Gag, also expressed by the MultiHIV 
sequence, has an indisputable effect on HIV-1 viral load. Rev and Tat are not so 
frequently recognized by the immune systems of HIV-1 infected individuals, likely 
due to their nuclear location and low expression level. But the importance of 
responses generated to these antigens cannot be ignored until the correlates of 
protection related to vaccination are better known. It may be possible that even if 
there is no evidence of the efficacy of non–Gag-specific CD8+ T-cell responses in 
HIV infected individuals, such responses may mediate control of viremia if 
vaccinated HIV-negative individual subsequently becomes HIV infected. Several 
groups are also working with DNA vaccine constructs encoding full-length Env 
proteins capable of inducing nAb (Estcourt et  al. 2004, Haynes et al. 2010). 
However, as MultiHIV does not encode the full envelope sequence and hence not 
capable of inducing nAb, the humoral immune responses to encoded proteins were 
of secondary interest.  
6.2.1 Use of inbred mice for vaccine immunogenicity evaluation 
In the experimental work we used murine models for evaluating the immunogenicity 
and protective efficacy of GTU based MultiHIV DNA plasmids. The mouse strain 
used for immunogenicity studies is BALB/c of H-2d haplotype, the same haplotype 
as the DBA/2 mice used for the tumor challenge study. Using the inbred mouse for 
immunogenicity studies has the advantage of more reproducible results as the 
variation due to the MHC class diversity in outbred animals and humans is 
bypassed. The advantage of inbred laboratory mice is obvious when preliminary 
studies are performed. When evaluating the immunogenicity of different vaccine 
constructs, variable routes or time schedules, the less variation the test system itself 
generates, the easier it is to detect the differences related to the different vaccine 
constructs. Also, good knowledge of the immunodominant epitopes in these animals 
facilitates the characterization of immune responses and permits the inclusion of the 
epitopes for screening purposes. This approach has been utilized when constructing 
the MultiHIV sequence, carrying H-2d-restricted highly immunodominant HIV-1 
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epitopes gp120 (aa 311–320; RGPGRAFVTI) (Takahashi et al. 1988) and Gag 
peptide (aa 65–73; AMQMLKETI) (Qiu et al. 1999). Their presence in the vaccine 
constructs facilitates the screening of MultiHIV expression, presentation and 
immunogenicity in mice. However, the immunodominance of these sequences in H-
2d mice may reduce the immune responses targeted at other less immunogenic 
epitopes, thereby possibly hampering the induction of broader responses in mice. 
Yet it must be conceded that the homozygous H-2 haplotype of inbred mice creates 
restrictions not corresponding to the natural human host (Griffin 2002). Although 
there are limitations and differences in the ability of H-2 and HLA molecules to 
present variable peptides, several identical CD4+ and CD8+ T cell epitopes are still 
recognized both in mice and humans, permitting the evaluation of vaccine 
immunogenicity in mice prior to moving to non-human primate or clinical studies 
(Berzofsky et al. 1991, Hosmalin et al. 1990). The inbred mouse model is the first 
level  model  when  a  vaccine  construct  is  evaluated  and  the  real  breadth  of  the  
immune responses in humans can be evaluated only in clinical trials. Although the 
mouse system utilized may not be a perfect model for less predictable human 
antiviral responses, it obviously provides useful knowledge that can subsequently be 
used as an experimental hypothesis setup. 
6.2.2 Effect of the immunization regimen  
The immunization regimen, including the route, dose and frequency of 
administrations has a crucial role in how efficiently the immune response is 
generated. The routes used for evaluating the GTU-MultiHIV vaccine in BALB/c 
were g.g., i.m. and i.d. Each route was assessed with four escalating doses and 
GTU-MultiHIV immunogenicity was evaluated by measuring the MultiHIV-
specific IFN-Ȗ production of immunized mice splenocytes using ELISPOT assay. 
Three immunizations were given at intervals of one and two weeks and mice were 
terminated 10-14 days after the last immunization to allow both cellular and 
humoral immune responses enough time to develop following the boost. Consistent 
with previously published studies demonstrating the superiority of gene gun 
immunization over needle injections (Barry and Johnston 1997, Cohen et al. 1998, 
Pertmer et  al. 1995, Trimble et  al. 2003), the g.g. administration resulted in 
extremely high gp120 epitope specific responses in the order of magnitude of >2000 
SFC / million splenocytes. G.g. immunization is known to already induce strong cell 
activation with minute DNA doses administered (Pertmer et al. 1995), and using the 
highly immunodominant gp120 10-mer for screening, dose dependency after GTU-
MultiHIV immunization was observed only by the lowest dose (24 ng), while all 
other doses (120 ng, 600 ng and 3000 ng) induced equally strong “saturated” 
responses. A similar study performed with multiclade vaccine by the same route and 
doses resulted in equally high gp120–specific responses with all doses. However, 
the gag-specific dose dependency was clear, indicating that the smallest doses by 
g.g. are probably not effective in inducing cellular immune responses to less 
immundominant epitopes of MultiHIV vaccine. 
 
Earlier research has demonstrated that i.d. and i.m. routes are efficient inducers only 
with high antigen doses, likely due to the inefficient uptake of the plasmid (Barry 
and Johnston 1997, Caputo et al. 2003). Here, the highest total dose of 750 µg was 
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able to efficiently induce IFN-Ȗ response via i.d. route, while high dose i.m. 
injection elicited only moderate cellular immune responses. I.m. needle injection has 
been  found  by  others,  too,  to  be  an  inefficient  delivery  route  for  naked  DNA  
vaccination (Hinkula et  al. 1997) and was unable to elicit detectable humoral 
immune responses against the MultiHIV proteins. Induction of humoral immune 
responses requires more DNA than cellular immune responses (Barry and Johnston 
1997, Tähtinen 2001) and consistently, antibodies were induced only after high dose 
g.g. and i.d. administrations. A more feasible approach for the induction of 
antibodies might be administration of heterologous boost with the viral vector 
(Bråve et al. 2007). Using a g.g. immunization, we demonstrated the need for at 
least one boost to elicit humoral responses, while the third boost is needed to elicit 
high level of antibodies, which is in agreement with previously published results 
(Hinkula et al. 1997).  
 
The duration of induced immune responses is a critical parameter for vaccine 
efficacy, as vaccination is supposed to create immunological memory cells able to 
confer protection for subsequent encounters with related pathogen later in life. We 
evaluated the kinetics and duration of the cellular immune responses in g.g. 
immunized mice and demonstrated the persistent cellular response up to 22 weeks 
following the last immunization, being highest two weeks after the third 
immunization and then staying at constant lower level throughout the study. The 
fourth boost immunization ten weeks after the third immunization was able to 
restore the strong IFN-Ȗ response, demonstrating the efficient priming of the 
immune system and capability of homologous boost to induce high responses. 
Additionally, the HIV-1/MuLV challenge was given 5 weeks after the third g.g. or 
i.m. immunization and addressed the emergence of highly effective, protective 
CD8+ T cells. The recovery of the cellular immune response even one year after 
immunization of BALB/c has been demonstrated by others  (Bråve et al. 2007). In 
addition  they  showed  that  DNA  immunization  resulted  in  the  generation  of  CD8+ 
memory T cells, while MVA immunization elicited CD4+ memory T cells. It was 
also demonstrated that the DNA primed cellular immune response can be biased to 
CD4+ or CD8+ T cells according to the boosting agent selected. This further adds to 
the value of DNA vaccines as stand-alone vaccines or as efficient priming agents for 
heterologous immunization.  
 
We also determined whether the immune responses induced via i.m. or i.d. 
injections could be similarly enhanced by a fourth boost immunization, with the 
single dose of 50 µg. Even if the fourth boost injection resulted in the restoration of 
earlier immune responses, thereby resembling the results by g.g. immunization, only 
fairly low responses were induced. An interesting observation was made when mice 
immunized with MultiHIV multiclade vaccine via i.m. and i.d. route were followed 
2 weeks and 17 weeks after the third immunization. In the i.m. immunized groups 
gp120-specific IFN-Ȗ responses were detected only at a later time point, suggesting 
that the kinetics of the immune responses after i.m. route are different and the 
response develops only later. In light of recent evidence this may be expected to 
happen as a result of differences between the intrinsic structure of skin and muscle 
tissues  and  their  ability  to  be  infiltrated  by  innate  immune cells,  especially  by  DC 
and macrophages (Abadie et al. 2009). The plasmid is readily carried for presenting 
DC by i.d. injection, while i.m. immunization mainly transfects muscle cells capable 
of expressing the antigen but the lack of resident professional APC in muscle is 
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likely  to  delay  and  decrease  the  efficiency  of  immune  response  induction.  On  the  
contrary, a biodistribution study demonstrated the longer persistence of the GTU 
plasmid in the skin than in muscle, but assessed only the existence of the plasmid in 
tissue, not the kinetics of antigen presentation (Tuomela et  al. 2005). These 
observations indicate that a different delivery route might preferably not be 
compared head-to-head but the tissue structure related variables should be 
considered as they might affect the kinetics and quality of the immune responses 
induced. However, similar to what is generally acknowledged, and based on the 
results generated here, it can be concluded that plasmid DNA delivery through i.m. 
injection is not optimal but needs to be augmented with more invasive delivery 
devices, boosting agents or immunomodulators to induce proper responses (Sumida 
et al. 2004). In line with earlier reports, the success of plain DNA vaccination is 
dependent on a high dose of DNA and many booster immunizations (~100 µg in 
mice, up to 2-4 mg in non-human primates and humans) (Caputo et al. 2003).  
 
In addition, given that mice are known to generate elevated immune responses by 
DNA immunization than larger animals or humans, the injection of pure naked 
DNA alone is probably not enough to induce proper responses in humans. More 
invasive delivery methods such as electroporation or gene gun delivery and other 
means to enhance the immune system responses are needed. 
6.2.3 Immunogenicity of different HIV-1 antigenic components of 
MultiHIV   
There are several indications of the protective role of Gag specific cellular immune 
responses (Geldmacher et al. 2007, Honeyborne et al. 2007, Kiepiela et al. 2007) 
but  it  is  not  known  how  big  role  immune  responses  to  this  or  other  antigens  will  
finally play in vaccine induced HIV-1 viral suppression. Thus the goal of many 
HIV-1 vaccine approaches is currently to induce broad responses to several HIV-1 
antigens. Concerns may be raised that competition between CTL responses directed 
against different HIV-1 antigens would result in diminished responses, but on the 
contrary, a recent study of HIV-1 infected individuals showed that in hosts 
responding to a broad range of epitopes, the average epitope-specific response is 
rather larger than smaller (Fryer et  al. 2009). All MultiHIV components including 
Rev, Nef, Tat, p17/24 (Gag) and CTL epitopes were appropriately presented and 
recognized by mice splenocytes, as assayed with five MultiHIV peptide pools or 
single peptides. IFN-Ȗ responses of variable magnitude were detected, and as 
expected, the strongest immune responses were generated towards H-2d restricted 
epitopes gp120 and Gag. IFN-Ȗ responses to Rev, Nef and Tat were analyzed using 
respective 15-mer peptide pools that were all recognized, despite their non-optimal 
length for CD8+ T cell presentation (as discussed later in this chapter) (Betts et al. 
2001, Tarosso et  al. 2010). Both Rev and Nef specific responses were shown to 
have significant benefit of GTU expression vector compared to CMV vector. Tat 
must be considered as a fairly poor immunogen, as only low positive responses to 
Tat were elicited. This concurs with what others have reported, independently of Tat 
being administered alone (Tahtinen et al. 2001) or as a part of multiantigen DNA 
vaccine. Vaccine evaluated by Burgers et al, encoding gag, RT, tat, nef and env 
genes, induced similarly strong gag-specific and weak tat-specific responses 
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(Burgers et al. 2009). Studies in HIV-1 infected individuals have also shown a 
similar distribution of CD8+ T cell responses towards different HIV-1 proteins, Tat 
being one of the least targeted proteins while Nef was more immunogenic than Rev 
and Tat (Masemola et  al. 2004). However, in macaques immunized intradermally 
with MultiHIV plasmid, T cell responses induced were quite equally distributed 
against Gag, Tat and Nef (Martinon et  al. 2009), demonstrating the immunogenic 
potential of all MultiHIV antigens.  
 
As mentioned, the immunodominance of gp120 and gag epitopes in BALB/c may 
reduce the immune responses to other epitopes, further restricted by the 
homozygous haplotype of inbred mice. As a consequence, it may be questionable 
how well inbred H-2d mice are suited to their purpose when evaluating the breadth 
of immune responses (Griffin 2002). However, it is of importance to show that each 
antigenic part of the MultiHIV is properly expressed and efficiently processed for 
presentation in vivo. Similarly, all MultiHIV components have been found 
immunogenic in clinical trials, when the GTU-MultiHIV vaccine has been 
administered  via  i.d.  or  i.m.  delivery,  even  though the  level  of  responses  has  been  
low especially in healthy volunteers (Krohn et  al. 2005). The immunogenicity of 
MultiHIV vaccine has also recently been evaluated in non-human primates 
(Martinon et al. 2009) and outbred pigs (Molder et al. 2009), which were shown to 
recognize several immunogenic epitopes. Even if the response in BALB/c mice is 
strongly biased to two H-2d restricted epitopes that elicit considerably higher IFN-Ȗ 
responses in ELISPOT than achieved with any other model (pigs, macaques, 
human), still relatively many of the epitopes recognized by pigs have also been 
shown to be immunogenic in BALB/c mice, when they were evaluated with 15-mer 
overlapping MultiHIV specific peptide pools in matrix (non published data). 
Similarly, the Gag immunogenicity is frequently seen in all animals used for 
evaluation as well as in humans. Antibodies were predominantly targeted at Nef and 
p17/24 proteins, emerging after g.g. and i.d. immunization with high dose. Low 
level of antibodies against other MultiHIV antigens Rev, Tat and CTL were detected 
only occasionally. CTL protein is entirely artificial and only included for the 
induction of cellular responses. The absence of Rev and Tat specific antibodies has 
been reported also previously (Caputo et  al. 2003, Tahtinen et al. 2001), when the 
Nef, Rev and Tat were introduced individually in mice. Only Nef was found to be 
highly immunogenic, while Rev induced proliferation and cytotoxic responses but 
no antibodies, and all Tat-specific immune responses were almost absent (Tahtinen 
et al. 2001). Additionally, the expression of the MultiHIV sequence as a fusion 
protein is not likely to support the efficient presentation of all MultiHIV 
components to B cells, which are dependent on the intact antigen on their activation. 
 
As a methodological aspect, the general use of overlapping 15-mer peptides for 
assaying the cytokine production has been criticized for underestimating the specific 
CD8+ T cell responses (Betts et al. 2001, Tarosso et al. 2010). Betts et al. reported 
nearly equal responses to 15-mer and 20-mer overlapping pools by CD4+ T cells, 
while CD8+ T cells recognized more frequently 15-mer pools and furthermore, 
when compared to optimized 8- to 11-mers, they observed clear preference for 
shorter peptides. Despite the fact that overlapping 15-mers can detect both CD4- and 
CD8- mediated T cells, MHC class I restricted minimal short peptides are expected 
to elicit only CD8+ T cell response. Similarly Tarosso et al. reported similarly on 
higher cellular responses detected with short optimal peptides (Tarosso et al. 2010). 
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This  is  likely  to  be  related  to  peptide  overhang  length  and  the  location  of  the  
immunogenic epitope within the longer peptide sequence. The critical impact of the 
optimal epitope presentation has also been demonstrated by our group when 9-mer 
gag epitope (AMQMLKETI) was compared to the corresponding most 
immunogenic 15-mer (HQAAMQMLKETINEE) in the overlapping Gag pool. The 
IFN-Ȗ production, mainly produced by CD8+ T cells, was considerably higher when 
stimulated  with  9-mer  than  with  15-mer,  whereas  CD4+  T  cell  related  IL-2  
production was induced on higher level with the longer peptide (unpublished data). 
Thus the use of optimal length of peptides for analysis may improve the readouts 
and whenever feasible, the careful optimization of peptides used should be done.    
6.2.4 HIV-1 multiclade consensus / ancestral vaccine approach   
The subtype specific MultiHIV sequences were constructed by consensus (A, B, C) 
or ancestral (FGH) lineages as described in more detail by Krohn et al. (Krohn et al. 
2005), to represent wide variation within the clades. The Auxo-GTU-MultiHIV B 
consensus plasmid has been observed to induce responses in mice comparable to 
GTU-MultiHIV B Han-2 plasmid. We aimed to detect the effect of mixing four 
plasmids together and compared these to the responses induced by single clade 
immunizations. To demonstrate the equal success of immunizations with all four 
individual constructs, we assayed IFN-Ȗ responses directed to gp120 epitope 
(RGPGRAFVTI) that is found identically in all four constructs. However, the strict 
epitope sequence specificity related to T cell activation through MHC presentation 
(Lee et al. 2004) was elucidated by one amino acid difference found between the B-
clade  Gag  epitope  (AMQMLKETI)  and  other  three  constructs  A,  C  and  FGH   
(AMQMLDETI).  The  immunization  with  the  B-clade  specific  plasmid  was  shown 
to virtually solely contribute to the immune responses to the Gag peptide in the 
cocktail, while CD8+ T cell activated by immunization with other constructs could 
not efficiently recognize the sequence differing by one amino acid. This 
demonstrates that even minimal change in the epitope made the sequence 
suboptimal for H-2d mice recognition. 
 
Although cross-reactivity of murine CD8+ T cells does not directly translate to 
humans, the possible immune interference between the four plasmids in a cocktail 
was also briefly investigated by comparing the IFN-Ȗ responses induced by 
immunization with different mixtures of three plasmids and the cocktail of four 
plasmids (MultiHIVmix). Mixing the plasmids was not observed to result in 
competition or enhancement, but the gag-specific response was directly dependent 
on the amount of the identical construct in the cocktail. It would be of value to have 
several immunogenic clade specific epitopes analyzed for a broader picture of the 
phenomenon, but the use of inbred mice may be the optimal model for this. By 
contrats, when MultiHIV vaccine (g.g.) was co-administrated with gp160Env 
encoding plasmid (Biojector)  in  BALB/c,  CD8+  T  cell  immune  responses  were  
observed to be slightly compromised (Brave et al. 2009). This might have been 
avoided by using some other combination of immunization routes, utilizing different 
draining lymph nodes. Other research groups working with multiclade plasmid 
cocktail vaccines have ended up with contradictory results when studying the 
immune interference. Kong et al. (Kong et  al. 2003) evaluated the immune 
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interference in complex multiantigen (Env and Gag-Pol-Nef) and multiclade 
(A/B/C) plasmid mixture and despite mixing various components the combining of 
individual genes with each other was shown not to cause interference. Furthermore, 
the simultaneous administration of mutant epitopes has been suggested to even 
avoid the induction of immune interference (Singh et al. 2002). However, others 
have ended up with severe immune interference. Larke et al. compared the single A, 
B and C clade vaccines alone or in dual-clade formulation in BALB/c. The encoded 
immunogens  were  Gag,  RT  and  Nef  and  five  H-2d epitopes,  two  of  which  were  
identical in all clades used. As results of mixing the plasmids, they reported 
immunodominance, “original antigenic sin” and T cell antagonism. They also point 
out that using peptide pools for analysis would mask the effect of immune 
interference. The administration of individual clade vaccines to anatomically 
separated sites was shown to overcome the antagonism (Larke et  al. 2007). With 
multiclade constructs there undoubtedly is a need for careful assessment of the 
immune interference and analysis should be designed individually for each vaccine 
modality and based on thorough selection of appropriate peptide epitopes to be used 
for screening. The induction of immune interference is related to several variables 
such as immunization sites, routes of administration and essentially on antigen 
design, thus in light of the current knowledge of this phenomenon, the occurrence of 
immune interferance cannot be extrapolated from results with other vaccine 
regimens. Finally, it can be concluded that the extreme complexity of the immune 
responses combined with the versatile HIV-1 virus and huge variability that can be 
included in vaccine constructs sets the requirements for immune response analysis 
extremely high. Complex studies are demanded to carefully estimate the outcome of 
administration of such complex vaccines as many of the current HIV-1 vaccine 
candidates are.  
6.2.5 Read-outs for cellular immune responses 
There is compelling evidence that CD8+ T cells play a crucial role in the control of 
HIV-1 infection and broad activation of this cell type is also one major goal of 
GTU-MultiHIV immunization. So far, the functional characterization of activated 
CD8+ T cells has mainly relied on the measurement of IFN-Ȗ, which is the 
predominating cytokine secreted by activated CTL, the activator for immune system 
cells and furthermore significantly and inversely has correlated with viral load in 
several studies (Betts et  al. 2001, Masemola et al. 2004, McMichael 1998, 
McMichael et al. 2010). Additionally, the role of granzyme B and perforin in CTL 
activity is acknowledged (Kuerten et al. 2008). Despite the unquestionable 
requirement for cytokine measurement as a tool for evaluating the cellular immune 
responses, it would be of importance to supplement them with assays measuring the 
direct antiviral function. Additionally, it has been reported that CD8+ T cells 
showing high antigen specific IFN-Ȗ activation in ELISPOT have not been able to 
suppress the viral replication (Addo et al. 2002, Addo et al. 2003, Chung et al. 
2007, Martins et  al. 2010). However, cellular immune responses are versatile and 
currently the idea prevails that broad and polyfunctional CD8+ as well as CD4+ T 
cell  responses  are  a  requirement  for  the  efficient  containment  of  the  HIV-1  virus.  
Hence  the  use  of  more  sensitive  assays  to  carefully  measure  all  characteristics  of  
cellular immunity, such as proliferative capacity, cytotoxicity and cytokine 
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expression profile would be needed (Arrode-Bruses et al. 2010, Betts et al. 2006). 
While lacking clearly defined correlates of protection, it cannot be known for certain 
which characteristics are the most valuable to be monitored and until they are 
clarified, comprehensive immunomonitoring is the only way to properly define the 
immunogenicity of vaccine candidates. The immunogenicity of a certain antigen is 
always limited by the technology available for detecting the responses, but 
fortunately immunological techniques have developed enormously. 
 
For the work presented in this thesis, the main readout used for measuring the 
cellular immune responses was IFN-Ȗ secretion by splenocytes, analyzed at single 
cell level by ELISPOT assay. The IFN-Ȗ production was demonstrated to be 
produced by CD8+ T cells, by assessing CD8+ T cell depleted samples in ELISPOT 
assay. The use of short 9-mer and 10-mer peptides and restricts the presentation to 
CD8+  T  cells.  We  elucidated  the  correlation  between  IFN-Ȗ production  and  
cytotoxic activity by utilizing the cytotoxic T lymphocyte assay to demonstrate that 
the  CD8+  T  cells  with  higher  IFN-Ȗ secretion  were  more  efficient  to  lyse  the  
peptide-pulsed P815 target cells. Recently, we have frequently also assessed the IL-
2 as a cytokine marker for CD4+ T cells by ELISPOT in immunological studies and 
correlation between IL-2 and IFN-Ȗ production has been observed. However, it 
would be valuable to include a broader range of assays, such as multiparametric 
flow cytometric analysis, to have more detailed information on the expression 
profile of the activated cells, and the cell types mounting the immune responses and 
immunological memory.  
6.3 Tumor challenge model 
There is a need for small animal models measuring vaccine protective efficacy in 
vivo. Vaccine immunogenicity is constantly evaluated in mice but measuring 
cellular immune responses and their cytotoxic capability by in vitro assays does not 
fully represent the function of cytotoxic cells in their natural surroundings with all 
constituents  of  the  immune  system.  To  meet  this  need,  we  developed  a  tumor  
challenge model where MultiHIV immunized DBA/2 H-2d mice were challenged 
with syngeneic P815 tumor cells stable transfected with MultiHIV B-clade Han-2 
isolate  antigen.  The  P815-MultiHIV  cells  were  evaluated  for  their  MultiHIV  
presentation in vitro by using them as target cells for immunized BALB/c effector 
cells and additionally, their tumorigenicity in DBA/2 mice was assessed in pilot 
study.  
 
Mastocytoma P815 cell line is a well-characterized and therefore an affordable 
model to also adapt for HIV-1 vaccine protection studies. Wild type P815 express 
high level of MHC class I molecules, explaining their high capacity to work as APC 
in in vivo assays, but not MHC class II molecules, thereby stimulating only CD8+ T 
cells. Wild type P815 cells are known to possess a low degree of immunogenicity, 
leading to anti-tumor immunity when inoculated several times in syngeneic mice 
(Chen et al. 1994) and even if partial immune rejection of the tumor by the host is 
generally  observed,  it  very  rarely  results  in  the  complete  elimination  of  the  tumor  
cells. Additionally, the generation of protective CTL responses has been shown to 
be largely dependent on the mode of P815 tumor injection, with 600 P815 cells by 
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i.p. injection already leading consistently to tumor growth (Uyttenhowe 1983), 
whereas injecting s.c. 106 cells in the footpad leads to progressive tumors in only 
30-40% of cases (Brichard et  al. 1995). P815 cells injected s.c. in the flank have 
been reported to lead to progressive tumor growth in 85% of the mice (Colmenero et 
al. 1999) being thus a more suitable route for a challenge model.  
 
In the first experimental setup evaluating the GTU-MultiHIV B-clade g.g. 
immunization, the vaccine antigen sequence was identical with that encoded by 
transfected P815 cells. A protective effect was clearly observable by delayed and 
low P815-MultiHIV tumor growth in immunized mice when compared to 
aggressive tumor growth in non-immunized mice or P815 wild type challenged 
mice. However, the P815-MultiHIV induced tumors in non-immunized mice 
showed regression  on  day  12,  while  tumor  mass  temporarily  diminished  radically.  
This has been suggested to be consequence of antigenic MultiHIV sequence that is 
presented by P815 cells, thereby leading to CTL activation during the first week and 
subsequent killing of P815-MultiHIV cells. Additionally, the slow growth of P815-
MultiHIV tumors observed in immunized mice after the first week is likely to be 
another consequence of the immunological pressure by CTL, constraining the tumor 
cells to lose the transfected antigen. This hypothesis was further strengthened by 
beta-hCG measurement, which also indicated the loss of insert from the cells 
forming the tumors after regression. The same phenomenon by CTL pressure has 
been shown also to take place in i.p. injected wild-type P815-cells, losing some of 
their antigenic determinants. Additionally in our model, a small number of non-
transfected cells may be already present in the challenge cell suspension, initiating 
the slow tumor growth. The slow P815-MultiHIV tumor escape in immunized mice 
and the regression in non-immunized mice occur consistently with the time needed 
for effective cellular immune responses to emerge. Immunity is likely to be induced 
by cross-priming as P815 cells lacking costimulatory (B7) molecules cannot prime 
naïve T cells. Additionally, anti-tumor immune responses have been demonstrated 
to be mostly dependent on CD8+ T cell, being effective without the help of CD4+ T 
cells. Similar kinetics for the development of anti-tumor immunity has also been 
reported by others utilizing immunogenic tumor cells (Chen et al. 1994, La Motte et 
al. 1999).  Furthermore,  the  analysis  of  cellular  and  humoral  immune  responses  at  
the time of termination revealed MultiHIV specific cellular immune responses not 
only in immunized mice, but also in non-immunized mice, where P815-MultiHIV 
was inoculated, demonstrating the induction of MultiHIV specific immunity by 
transfected tumor cells.  
 
In the second set of experiments we wanted to evaluate protection by Auxo-GTU-
MultiHIVmix immunization, thereby assessing the cross-clade protection by utilizing 
consensus/ancestral multiclade vaccine and Han-2 subtype specific challenge. We 
demonstrated that cellular immune responses induced by MultiHIV vaccine in 
DBA/2 by the time of the challenge were directed largely to Gag epitope and less 
extensively to gp120, showing a difference to BALB/c mice invariably reacting 
most strongly to gp120 epitope (Env). Similarly, very high Gag-specific humoral 
response was observed. Three escalating P815-MultiHIV doses were used for the 
challenge and similarly to an earlier study, a clear delay by MultiHIV immunization 
was observed in each group when compared to the respective non-immunized 
control groups and tumor regression in non-immunized mice emerged by day 12. 
However, the analysis of post-challenge immune responses indicated that P815-
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MultiHIV cells present the gp120 epitope most efficiently, as high dose challenge in 
non-immunized mice induced high gp120-specific cellular response but no Gag-
specific responses. Moreover, strong Gag-specific responses elicited by 
immunization were depleted more strikingly after the challenge, while gp120-
specific responses were maintained longer. 
 
As a conclusion, both tumor challenge studies successfully attested the protective 
efficacy of MultiHIV specific CD8+ T cells induced by immunization with a minor 
dose  of  GTU-MultiHIV vaccines administered by gene. Importantly we 
demonstrated the correlation between strong specific IFN-Ȗ responses and cytotoxic 
in vivo activity of these cells. The cross-clade protection evaluated by considerable 
sequence diversity between immunizing antigen and the challenging antigen showed 
some promise for vaccine development against highly variable HIV-1, although this 
challenge model is evidently highly simplified to answer that question in its real 
depth. The advantage of our tumor model is its feasibility; there is no need to work 
with infectious material and monitoring the tumor growth is effortless. Importantly, 
the evaluation of protection by following subcutaneous tumor growth enables 
follow-up of the protection, while several other challenge models require 
termination of mice to measure the protection, thereby giving the answer only for 
that particular day (Gupta et al. 2005, Thomson et al. 1998, Trimble et al. 2003). 
The utilization of beta-hCG hormone adds more value for the model, strengthening 
the tumor size measurements, although it may be valuable to include a control cell 
line of P815 cells stable transfected with irrelevant plasmid encoding beta-hCG, to 
exclude any effect by inclusion of the coding gene. 
6.4 HIV-1/MuLV challenge model 
Protection conferred by i.m. or g.g. Auxo-GTU-MultiHIVmix vaccine 
immunization was assessed by pseudotype HIV-1/murine leukemia virus 
(HIV/MuLV) challenge model. As the model requires a syngeneic mouse strain for 
HIV-1/MuLV pseudovirus to be used, C57Bl/6.A201 mice were used in the study. 
After g.g. immunization cellular immune responses were directed to Gag and with 
less extent to Env, while i.m. immunization elicited only low Env response as 
observed by mPBMC ELISPOT IFN-Ȗ pre-challenge samples. Consistently, 
protection was shown to be conferred more efficiently by g.g. immunization than by 
i.m. injection. Two HIV-1 strains were used for the challenge, both deviating from 
the sequences of MultiHIVmix vaccine sequences, thereby indicating the cross-
protective efficacy of the vaccine. G.g. immunization was able to protect 100% of 
B-clade challenged mice and 83% of A-clade challenged mice, while the 
corresponding values for i.m. immunized mice were 66% and 50% respectively. 
Antibody responses before the challenge were detected only to Gag after g.g. 
immunization. However, based on the previous data they are not presumed to be 
critical for mediating protection towards the pseudovirus challenge that is primarily 
based on cytotoxic effect by CD8+ T cells (Hinkula et  al. 2004, Rollman et  al. 
2007).  
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IFN-Ȗ responses after the challenge revealed that cellular immune responses had 
been shifted to Env, while Gag responses had radically decreased in g.g. immunized 
group. Also, i.m. immunized mice showed higher Env-specific response at the time 
of termination (week 9) than four weeks earlier before the challenge, which might 
reflect the longer time needed for immune response to develop after i.m. 
immunization (Abadie et al. 2009). On the other hand, inoculation of HIV-1/MuLV 
infected splenocytes i.p. has been shown to efficiently induce cellular immune 
responses to p24Gag, gp160Env, Nef, Tat and Rev (Hinkula et  al. 2004), thereby 
the immune responses after the challenge are boosted by the pseudovirus antigens 
which may partly explain the difference in immune responses detected. An 
interesting observation is the fact that a similar change from pre-challenge Gag 
response to post-challenge Env response was detected both in the tumor model and 
here. Whether it is only related to more efficient Env presentation by challenging 
cells or related to other mechanism cannot be known. However, the initial Gag 
specific cellular immune responses detected before the challenge in g.g. immunized 
mice can be speculated to be responsible for the clearance of the HIV-1/MuLV 
particles and their high activation may explain their further depletion observed later 
at termination. The important role of Gag-specific cellular immune responses 
contributing to the protection in this model has also been emphasized by others, 
while no correlation with other vaccine constituents, Env or Tat was detected (Bråve 
et al. 2007). However, the mechanism of protection in this model is not very well 
known and some contradictory results have been seen when the correlation between 
immune responses and protection has been evaluated (Rollman et al. 2007). No 
absolute answer was provided either in our challenge study, but it strongly suggests 
that high cytotoxic cell activation elicited by g.g. GTU-MultiHIVmix immunization 
was the main provider of the protection. DNA plasmid immunization has been 
demonstrated to be crucial for protection in this model, while protein was shown to 
serve efficiently as boosting agent, but not as stand-alone vaccine, which elicits 
mainly high antibody responses (Bråve et al. 2007). 
 
Methodologically, the HIV-1/MuLV pseudovirus challenge model possesses the 
clear advantage of utilizing the total HIV-1 genome in the challenged host. This 
model thus resembles more natural HIV-1 infection, whereas several other models, 
including our tumor challenge model include shorter parts of HIV-1 in the 
challenging agent, usually closely or totally identical with the vaccine antigen.  
However, HIV-1/MuLV infected splenocytes used for the challenge produce viruses 
lacking the MuLV envelope and thereby infectivity in mice, this model is still rather 
distinct from the actual HIV-1 infection model. The drawback is related to 
biosafety, while this model involves the handling of the live HIV-1 virus and the 
work must therefore be performed following high-level safety regulations (Spector 
et al. 1990). Additionally, the short-term infectivity of inoculated HIV-1/MuLV 
infected cells (~10 days) (Hinkula et  al. 2004) in mice restricts the possibility to 
follow-up the development of protection which is likely not to be identical in each 
animal. The weakness of both the tumor model and HIV-1/MuLV is related to the 
challenging route that might not be considered relevant, compared to HIV-1 which 
is transmitted usually through mucosal surfaces. Some other challenge models, like 
recombinant vaccinia challenge can be given through mucosal surfaces (Belyakov et 
al. 1998, Gupta et al. 2005). However, as the correlates of protection in HIV-1 are 
not known, eliciting systemic immune responses by vaccination can be considered 
equally important. 
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Furthermore, from the results obtained it can be concluded that Auxo-GTU-
MultiHIVmix vaccine was shown to be able to elicit highly cross-protective cellular 
immune responses when administrated via efficient route, as g.g. has been shown to 
be. Weaker CD8+ T cell responses elicited by i.m. immunization are not enough to 
confer protection, indicating the important role of these cells and the necessity to 
use either stronger vaccine delivery methods or other immunopotentiators. Mixing 
of several MultiHIV plasmids with variable clade-specificity (A, B, C, FGH) 
(Krohn et al. 2005) as a cocktail immunogen was not observed to result in immune 
interference in this model. 
6.5 Immunization with in vivo MultiHIV transfected DC  
With  this  brief  study,  we  wanted  to  demonstrate  the  high  potential  of  GTU-
MultiHIV DNA for eliciting immune responses by activating CD11c+ DC, the main 
players in inducing immune responses and additionally, we wanted to provide a new 
approach for studying the DC function in immunization. The fact that DC play a 
critical role in CD8+ T cell priming following DNA vaccination is generally 
acknowledged (Akbari et al. 1999, Corr et al. 1996, Corr et al. 1999) but here we 
provided a novel way to study the mechanism related to immune response 
generation. DC cellular immunization is a widely applied method but these studies 
are done constantly utilizing in vitro antigen loaded DC and thereby are not 
comparable to the present study, even though providing useful information on the 
related mechanisms. The research of DC is highly relevant; recent studies have 
indicated the existence of highly heterogenous subtypes of DC with different 
locations and with variable efficiency to work for generation of immune response, 
however, constantly emphasizing their crucial role in eliciting immune responses. 
Their participation in antigen presentation has been demonstrated to involve much 
higher  numbers  of  DC  than  earlier  assumed  and  the  efficiency  of  DC  recruitment  
has been shown to be essentially related to the mode of vaccine delivery. The exact 
role in T cell priming of two CD11c+ subtypes, CD11b+CD11c+ myeloid DC and 
CD8D+CD11c+ lymphoid DC is still very controversial and often they are treated as 
one CD11c+ population. 
 
We first demonstrated the expression of GTU encoded antigen in abdominal 
draining lymph nodes one day after the two i.d. injections on sequential days, 
showing that 25% of myeloid or lymphoid CD11c+ DC  were  expressing  GFP. 
Previously, Garg et al. utilizing Cre/loxP recombination strategy (Sauer 1998) 
reported that 60 hours after g.g. immunization, 12% of the purified lymph node DC 
were antigen-bearing CD11c+ DC,  a  higher  number  than  reported  earlier,  but  still  
less  than  what  we  observed  (Garg et  al. 2003). However, the recent study 
demonstrated the peak of antigen expressing DC and macrophages (CD11c-) in 
lymph nodes already four hours after i.d. injection followed by a rapid decline, 
being less than one tenth at 24 hours or 48 hours after injection (Abadie et al. 2009), 
indicating that an even higher percentage of expressing cells could have been 
detected  at  an  earlier  time  point  in  our  study,  and  partly  explaining  the  lower  
number in Garg et al. (Garg et  al. 2003) We continued with GTU-MultiHIV 
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immunization, using the same immunization regimen and this time enriched DC 
both from draining lymph nodes and spleen and used these in vivo transfected DC to 
immunize naïve mice. Because of the minimal size of lymph nodes we were able to 
use 0.4×106 lymph node cells per one i.d. injection and correspondingly, we used a 
twice  larger  quantity  of  spleen  DC.  This  was  consistent  with  the  fact  that  i.d.  
injection is known to direct the professional APC mostly to draining lymph nodes 
and less efficiently to spleen (Pozzi et al. 2005). Accordingly, quite similar immune 
responses were detected in both lymph node DC immunized and spleen DC 
immunized groups, irrespective of the difference in cell numbers used. Lymph node 
DC induced somewhat broader cellular immune responses as IFN-Ȗ responses 
towards Rev, Nef, p17/24Gag and CTL 15-mer peptide pools were detected, while 
spleen DC immunized mice developed slightly higher Rev, p17/24Gag and CTL 
specific immune responses. No positive responses to Tat were detected. Overall the 
immune responses observed after DC immunization were complementary to the 
responses generated by DNA MultiHIV immunization, demonstrating that the 
efficient presentation of most MultiHIV antigens is mediated by enriched in vivo 
transfected DC.  
 
This model has much potential to be developed further for studying mechanisms 
related to immunization and cell types involved in induction of immune responses, 
on a level of basic research that forms the basis for the whole field of immunology 
and vaccinology. More valuable control for GTU expression in lymph nodes would 
be the use of GTU-MultiHIV vaccine instead of GTU-GFP, although the result is 
presumed to be the same. The DC isolation from the lymph nodes and spleen before 
transfer immunization could be improved by use of FACS sorting or magnetic bead 
separation and the purity and the cell types involved could be verified by flow 
cytometric assays using additional specific markers for different skin DC subtypes. 
The impact of using apoptotic DC for transfer immunization could further clarify 
the role of donor versus recipient mouse DC in inducing immunity and the role of 
cross-presentation, even though previous studies have argued that the viability of 
DC is crucial for triggering T cell responses (Kleindienst and Brocker 2003). 
Furthermore, the use of in vitro MultiHIV pulsed DC as a control immunization 
could yield a more precise estimation of the magnitude and efficiency of in vivo 
transfected DC assessed here. 
6.6 Future perspectives 
Here, the immunogenicity and protective efficacy of GTU based MultiHIV DNA 
plasmids were demonstrated in mice. The final goal, however, is to develop a 
vaccine that could be used as a therapeutic agent in HIV-1 infected individuals alone 
or in addition to highly active antiviral treatment. The mouse model is a valuable 
test model for the first line screening of the immunogenicity of the vaccine 
constructs. Even if immune responses generated in mice predict neither the quantity 
nor quality of vaccine immunogenicity in humans, they still serve as a fairly reliable 
predictor  of  immunogenicity  overall  and  are  to  be  recommended  for  use  as  a  test  
model before moving to the larger outbred animals and further to clinical trials. As 
an example, Gag specific immune responses elicited in mice by the GTU-
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MultiHIV immunization have subsequently also been shown to be induced in pigs 
(Molder et al. 2009), in non-human primates (Martinon et al. 2009) and in humans 
(Vardas and Stanescu,I, Valtavaara,M, Kuntonen,T, Gray,C, Leionen,M, Ustav,M, 
Reijonen, K 2010), demonstrating that immunogenicity of Gag antigen is not 
species restricted.   
 
In light of the results obtained here, GTU vector encoding MultiHIV antigen can 
be seen as a potent HIV-1 DNA plasmid vaccine candidate. Several different 
vaccines including various DNA plasmid constructs are being evaluated in clinical 
trials and more data is being gathered on their effects and modes of action in 
humans. It is not currently exactly known which mechanisms are induced when 
HIV-1 infected individuals are immunized with HIV-1 antigens, but the goal is to 
induce and maintain strong cellular and humoral virus-specific immune responses, 
probably against antigens with higher protective capability. Targeting the immune 
responses in infected individuals against several HIV-1 antigens can be considered a 
way to counteract the variability of the virus. MultiHIV DNA plasmid vaccine is 
able to induce strong cellular immune responses against several HIV-1 antigens. 
Whether these responses will be effective in humans can be ascertained only in 
clinical trials. According to current knowledge, the HIV-1 vaccine should target all 
parts of the immune system and GTU-MultiHIV DNA plasmid vaccines can be 
seen as promising agents at least for priming the immune responses, while co-
administration with another vaccine inducing neutralizing antibodies may be needed 
to cover the humoral part efficiently.  
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7. Conclusions 
The  aim  of  this  thesis  was  to  assess  the  immunogenicity  of  GTU-MultiHIV-B 
DNA and multiclade Auxo-GTU-MultiHIVmix DNA and to  evaluate  the  different  
modes of DNA delivery, including g.g. administration, i.m. and i.d. injection in 
mice. The protective efficacy of these immune responses was moreover analyzed by 
two experimental murine challenge models. We also provided an insight into the 
mechanism responsible for eliciting immune response by GTU-MultiHIV 
immunization, emphasizing the DC role. The results generated led us to the 
following conclusions: 
 
- All antigens expressed by MultiHIV antigen are immunogenic in mice, 
denoting their efficient expression and presentation to the immune system. 
In mouse, two H-2d restricted immunodominant epitopes specific for Gp120 
and Gag induce the greatest responses, but additionally Rev and Nef have 
been shown to be highly immunogenic, while only low and frequent 
responses were induced against Tat. GTU vector backbone adds to the 
value of the MultiHIV vaccine approach by significantly improving the 
expression level and the broadness and magnitude of cellular and humoral 
immune responses (I). 
 
- The route of administration is one of the main determinants for the success 
of GTU-MultiHIV immunization.  Gene  gun  delivery  enables  the  use  of  a  
minute amount of DNA for inducing robust cellular and humoral immune 
responses. Intradermal administration can be an efficient inducer of T cells 
and antibody producing cells if a sufficiently high DNA dose is given. 
Intramuscular injection by naked DNA alone elicits slowly developing, low 
cellular immune responses and almost negligible antibody responses. 
Whereas g.g. may not be available for clinical use, other approaches to 
improve the potency of GTU-MultiHIV DNA vaccine, such as modulation 
of DNA delivery are recommendable as high doses are neither profitable nor 
feasible (I, III).  
 
- Both immunization schedules applied were equally effective in inducing 
cellular immune responses in mice, short term immunizations at one and 
two-week intervals (I, II, III) and longer schedule immunizations at one and 
two-month intervals (III). Induced CD8+ T cells mounted strong HIV-1 
specific IFN-Ȗ responses that were shown to correlate with efficient cytolytic 
activity. The third boost immunization was shown to elevate the humoral 
responses significantly, while two administrations were the minimum. The 
cellular immune response was shown to be highest two weeks after the last 
immunization, declining rapidly during the following month. The boost 
immunization at ten weeks following the last immunization by g.g. was 
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demonstrated to restore the high response, indicating the efficient priming of 
the T lymphocytes (I). 
 
- GTU-MultiHIV i.d. immunization was able to confer protection by 
delaying the tumor challenge by P815 cells stable transfected with MultiHIV 
antigen. Auxo-GTU-MultiHIVmix in turn, was evaluated both in tumor 
model and in HIV-1/MuLV model, inducing cross-reactive, protective 
immune responses. Corresponding to the immunogenicity studies, g.g. was 
shown to confer almost total protection in the HIV-1/MuLV challenge 
model while i.m. induced immune responses cleared the virus from 
approximately half of the animals. The tumor model developed by us was 
proven to be a safe and feasible small animal model for HIV-1 vaccine 
efficacy studies. The multiclade MultiHIV vaccine was found to be a more 
efficient inducer of MultiHIV immune responses than single clade vaccine, 
showing no signs of immune interference. The cross-protective potential 
attested was promising, even though more detailed studies would be needed 
to collect more substantial data on the multiclade approach (II, III). 
 
- Immunization by i.d. delivery with GTU-MultiHIV can efficiently transfect 
the DC of the skin in vivo, enabling them to act as professional antigen 
presenting cells. The good potential of antigen presentation by the MultiHIV 
transfected DC, enriched from lymph nodes and spleen was demonstrated by 
their ability to induce MultiHIV specific immune responses in naïve 
recipient mice. 
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ABSTRACT
A multiHIV fusion gene expressing an antigenic fusion protein composed of regulatory HIV-1 proteins Rev,
Nef, and Tat, as well as Gag p17/p24 and a stretch of 11 cytotoxic T lymphocyte (CTL) epitope clusters from
Pol and Env, was cloned into a novel DNA vector named the Gene Transport Unit (GTU). A mouse H-2d-re-
stricted HIV-1 gp120 epitope (RGPGRAFVTI) was cloned into the fusion gene as well. In addition to the HIV-
1 genes the GTU codes for a nuclear anchoring protein (bovine papilloma virus E2), ensuring the long main-
tenance of the vector and a high expression level of the selected immunogens. BALB/c mice were immunized
with the GTU-MultiHIV DNA construct by different routes and regimens of immunization to assess the im-
munogenicity of the DNA vaccine in vivo. Mice developed strong CD8 CTL responses to HIV-1 Env and Gag
measured by an ELISPOT-IFN- assay and chromium release assay. In addition, T cell responses to regula-
tory proteins Rev, Nef, and Tat were induced. Antibody responses were detected to each of the HIV antigens
encoded by the DNA construct. Minimal doses of the GTU-MultiHIV DNA delivered by gene gun were po-
tent in inducing significant HIV-specific CTL responses. The equivalent doses of the conventional plasmid ex-
pressing MultiHIV DNA delivered by gene gun failed to do so. An ideal DNA vaccine should yield high ex-
pression of the viral antigens for a prolonged period of time, and expression of the multiple viral antigens is
probably required for the induction of a broad and protective immune response. The GTU-MultiHIV DNA
vaccine described is a good vaccine candidate that meets the above criteria.
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INTRODUCTION
DESPITE THE EFFORTS, to date there is neither a curative anti-viral drug1,2 nor a safe and effective vaccine against HIV-
1 infection. The correlates of immune protection in HIV infec-
tion remain to be elucidated, however, the ability to induce
strong HIV-1-specific CD8 T cell responses is considered to
be the main feature of an effective HIV vaccine.3 It has been
demonstrated that cytotoxic T lymphocyte (CTL) responses in
long-term nonprogressors correlate with reduced viral loads.4,5
In addition, CTL responses in HIV-exposed uninfected indi-
viduals suggest immunological control of limited infection.6 In-
deed, in vivo studies show that CD8 CTL are crucial for con-
trolling SIV/HIV replication and delaying disease progression.7
There are indications that a CTL response directed against HIV
regulatory proteins could prevent the release of infectious viri-
ons by destroying infected cells and clearing the infection at an
early stage.8–10
The high degree of vaccine efficacy induced by live attenu-
ated vaccines11 indicated that multiple viral proteins were re-
quired as antigens to stimulate a protective immune response.
However, the use of live attenuated retroviral vaccine has not
considered for human use due to safety concerns. DNA vaccine
mimics the live vaccine but without the pathogenic potential of
the virus. Furthermore, DNA vaccination may provide a nat-
ural mode of antigen presentation, especially to the cellular im-
mune system, as it allows in vivo production and processing of
the vaccine-encoded gene products within the cell. DNA vac-
cination has been shown to induce both cellular and humoral
immune responses in mice, nonhuman primates, and hu-
1FIT Biotech Oyj Plc., Tampere, Finland.
2FIT Biotech Oyj Plc., Tartu, Estonia.
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mans.12–14 However, the route of administration, dose, time
schedule, as well as usage of different booster regimens and ad-
juvants are not yet defined for optimal DNA immunization in
humans. Data published recently indicate that viral escape from
CTL recognition may be a major limitation of the vaccines
based on the protective role of T cells.15 However, this might
be a limitation of HIV-1 vaccines that are based on very few
viral antigens. Here, we describe a novel strategy for the con-
struction of an HIV-1 DNA vaccine antigen with multiple HIV-
1 immunodominant regions expressed under a single promoter.
We believe that by combining structural and regulatory proteins
of HIV-1 the resulting DNA vaccine could induce an array of
CTL responses that would lyse infected cells at various stages
of viral replication and, furthermore, by this approach the
chance of immune escape may be minimized.
Eukaryotic expression vectors that are most widely used for
DNA vaccinations16 have a limited capacity for transcription
and a limited period of persistence. To achieve a long lasting
and high expression level of the immunogenic protein we have
developed a novel Gene Transport Unit (GTU), a naked DNA
plasmid with the key distinguishing feature of utilization of the
bovine papilloma virus type 1 (BPV-1) multidomain E2 pro-
tein in a manner that results in substantial enhancement of gene
expression compared to other DNA plasmids.17 In the GTU-
MultiHIV DNA plasmid the coded multiantigen is a fusion pro-
tein composed of full length sequences of Rev, Nef, Tat, p17,
and p24 encoded by the Gag gene and a stretch named CTL
composed of 11 CTL epitope clusters encoded by the HIV-1
Env and Pol. Furthermore, to test the ability of the vector to in-
duce an HIV-specific immune response in vivo in a mouse
model we cloned an H-2d-restricted gp120 CTL epitope (aa
311–320, RGPGRAFVTI)18,19 in the C-terminal end of the
multigen. Here we describe the results obtained with the mice
immunized by different routes and doses of the GTU-MultiHIV
DNA plasmid.
MATERIALS AND METHODS
Plasmid construction and purification
GTU-MultiHIV17 (Fig. 1A, left panel) is the synthetic bac-
terial plasmid that contains the selection marker providing re-
sistence of bacterial cells to kanamycin and a modified form of
pMB1 replicon (pUCori) as backbone elements20 needed for
propagation of the plasmid in Escherichia coli cells. The vec-
tor also contains a cytomegalovirus (CMV) immediate early
promoter combined with a Herpes simplex virus (HSV) thymi-
dine kinase (TK) gene leader sequence, a rabbit -globin gene
second intron sequence, and an HSV TK gene polyadenylation
signal region, which are needed for effective production and
processing of the mRNA antigen coding sequence. The multi-
BLAZEVIC ET AL.668
FIG. 1. (A) Schematic of the GTU-MultiHIV (left panel) and CMV-MultiHIV (right panel) vectors used in immunization of
BALB/c mice. (B) The subcellular localization of the MultiHIV fusion protein encoded by the GTU-MultiHIV in Cos-7 cells.
The cells were transfected with 2 g of GTU-MultiHIV DNA, stained with the anti-Nef antibody, and detected with the FITC-
conjugated antimouse secondary antibody as described in Materials and Methods.
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antigen coding sequence was derived from the HAN2 isolate of
HIV-1 and was inserted downstream of the CMV promoter. It
is composed of fused coding sequences of Rev, Nef, and Tat
(RNT), p17, p24, and 11 17–45 aa long T cell epitopes (human
leukocyte antigen, HLA restricted) rich clusters from Pol and
Env polypeptides (CTL).21 The gene segments encoding p17,
p24, and CTL are synthetic gene codons optimized for expres-
sion in human cells. The fusion of regulatory proteins in the 
order of Rev–Nef–Tat, followed by the p17/24 sequence, 
inactivated the ability of the Tat protein to activate the LTR-
dependent expression of the reporter gene (data not shown). Po-
sitioning of the Nef coding sequence in the middle of the anti-
gen eliminated the ability to localize the Nef protein through
the myristylated N-terminus to the inner surface of the plasma
membrane. An H-2d-restricted HIV-1 gp120 epitope19 coding
sequence was cloned into the 3 end of the MultiHIV antigen
to test the potency of the GTU-MultiHIV in inducing a CD8
CTL response in a mouse model.
In addition to the elements described above, the GTU-Mul-
tiHIV vector also contains 10 clustered high-affinity E2 bind-
ing sites from the BPV-1 genome (10E2BS) positioned just up-
stream of the CMV promoter. The vector also carries an
expression cassette for the BPV-1 E2 protein.22 The E2 ex-
pression is driven from the Rous sarcoma virus 5 LTR (RSV
LTR). The bovine growth hormone polyadenylation region (bgh
pA) was cloned at the end of the E2 transcription cassette from
the pHook3 plasmid (Invitrogen).
A conventional eukaryotic vector16 named CMV-MultiHIV
(Fig. 1A, right panel) was generated by removing the E2 ex-
pression cartridge and its binding sites from the GTU vector
(Fig. 1A, left panel) but retaining identical elements controlling
the expression of the HIV antigens. GTU-MultiHIV and CMV-
MultiHIV were produced in E. coli, and purified by Qiagen
Endofree Giga columns (Hilden, Germany) according to the
manufacturer’s instructions.
In vitro expression studies
Expression properties of the MultiHIV fusion protein were
analyzed in Jurkat, Cos-7, and RD cell lines. The cells were
transfected with 0.5 g or 3 g of the DNA or with control
DNA GTU-LacZ by electroporation as described earlier.22 Two
and five days posttransfection the cells were lysed by treating
with a sample buffer: 50 mM Tris–HCl, pH 6.8, 2% SDS, 0.1%
bromophenol blue, 100 mM dithiothreitol, and 10% (v/v) glyc-
erol. The lysates were run on a 10% sodium dodecyl sul-
fate–polyacrylamide gel (SDS–PAGE) and subsequently trans-
ferred onto a 0.45-m nitrocellulose membrane. After overnight
blocking, the membrane was incubated with monoclonal anti-
p24 antibody 05-001 (FIT Biotech, Tampere, Finland) and
thereafter with HRP-conjugated goat antimouse IgG (LabAs,
Tartu, Estonia) followed by visualization using an ECL chemo-
luminesence detection system (Amersham Pharmacia Biotech,
Uppsala, Sweden). To analyze subcellular localization of the
MultiHIV antigen the transfected cells were fixed in cold 
methanol and stained with anti-Nef (01-001, FIT Biotech) or
anti-p24 antibodies and detected by fluorescein isothio-
cyanate (FITC)-conjugated goat antimouse secondary antibody
(LabAs).
For quantitative analysis of fusion protein expression the
transfected RD cells were lysed in a Tris–HCl buffer (pH 8)
containing 1% Triton X-100 and an EDTA free protease in-
hibitor cocktail (Roche, Penzberg, Germany). The cell lysates
were analyzed by the capture enzyme-linked immunosorbent
assay (ELISA) method based on an anti-Nef antibody immobi-
lized onto Nunc Maxi Sorp plates, and biotinylated anti-p24 an-
tibody 05-001 as detection antibody. The bound anti-p24 anti-
body was detected by streptavidin-horseradish peroxidase
(HRP) conjugate and color developed by TMB substrate
(LabAs).
DNA Immunizations
Six- to nine-week-old female BALB/c (H-2d) mice were im-
munized by DNA administered on shaved abdominal skin us-
ing plasmid DNA-coated gold particles and a Helios Gene Gun
(Bio-Rad, Richmond, CA) using a pressure of 400 psi and a
0.5-mg gold/cartridge. Mice were immunized under general
anesthesia three times (at day 0, day 7, and day 21) with a to-
tal amount of 24 ng, 120 ng, 600 ng, or 3 g DNA/mouse. One-
third of the total DNA dose is given at each immunization. In
another set of experiments mice were immunized three times
intramuscularly (im) in the quadriceps femoris of the hind leg
or intradermaly (id) on the base of the tale with the following
total DNA doses: 6, 30, 150, or 750 g. Mice were sacrificed
and serum and spleens collected 2 weeks after the last immu-
nization. In order to monitor duration of the immune response
groups of mice were sacrificed at weeks 6, 10, 14, and 22 in
addition. Each experimental group consisted of 5-10 animals.
Negative control mice were immunized with DNA carrier only.
Recombinant proteins and peptides
Glutathione S-transferase (GST)-tagged HIV-1 Nef and GST
proteins were affinity purified from lysates from E. coli BL21
(DE3) cells which were transformed with a pGex-Nef-GST or
pGex-GST plasmids using Pharmacia (Piscataway, NJ)
reagents. Coding sequences of Rev, Tat, p17/24, CTL and E2
were cloned into pET24d vector and purified from E. coli lysate
using Ni-NTA Agarose (Qiagen). H-2d-restricted HIV-1 gp120
(Env) 10-mer peptide (aa 311–320; RGPGRAFVTI)19 and 9-
mer HIV-1 Gag peptide (aa 65–73; AMQMLKETI)23 were pur-
chased from Sigma-Genosys (Cambridge, UK) as 95% pure.
Overlapping HIV-1 Rev, Nef, Tat, Gag, and CTL peptides were
purchased from Sigma-Genosys and were at least 85% pure.
The peptides were 15 aa in length, which overlapped by 11 aa.
Anti-double strand (ds) DNA antibodies
dsDNA antibodies were assayed in the serum of immunized
mice, positive control mice (MRL/MpJ-Faslpr, a generous gift
from Dr. Gene Shearer, NIH), and negative control mice (DNA
carrier immunized mice). Each of the sera was diluted 1:10,
1:50, 1:250, and 1:1250 and antibodies were assayed by ELISA
on poly-L-lysine bounded  phage dsDNA as previously de-
scribed.24
HIV-1- and E2-specific antibodies
HIV-1 Rev, Nef, Tat, p17/24, CTL, and E2-specific anti-
bodies were assayed in 1:100 diluted sera by ELISA as previ-
ously described.25 Briefly, the sera were added to protein-coated
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(100 ng/well) 96-well plates (Nunc Maxi Sorp). After extensive
washes the peroxidase-conjugated antimouse IgG was added
(1:500 dilution), plates were washed, and the substrate (2,2-
azino-bis(3-ethylbenzthiazoline-6-sulfonic acid), ABTS, in phos-
phate-citrate buffer] was added for 30 min incubation. The pho-
tometric analysis was carried out using an ELISA plate reader
(Labsystems, Helsinki, Finland). HIV-1 Rev-, Nef-, Tat-, Gag-,
CTL-, and BPV-1 E2-specific monoclonal antibodies (FIT
Biotech) were used as positive controls. Samples were consid-
ered positive when the optical density (OD; at 405 nm wave-
length) value was higher than the cutoff value (mean OD of the
negative control group  3 SD).
Cell preparations
The spleens were dispersed to a single cell suspension and
the splenocytes frozen to liquid nitrogen (LN). For use in the
assays LN frozen cells were washed and suspended in culture
media (CM): RPMI 1640 (BioWhittaker, Verviers, Belgium)
supplemented with 10% fetal bovine serum (FBS), 1% peni-
cillin-streptomycin, and 50 M 2-mercaptoethanol (all from
BioWhittaker). In some experiments, splenocytes were depleted
of CD8 T cells by using magnetic beads (MagCellect, R&D
Systems, Minneapolis, MN) as recommended by the manufac-
turer. The remaining cells contained 4% CD8 T cells, de-
termined by flow cytometric analysis.
ELISPOT-IFN- assay
HIV-1-specific CTL responses were measured by quantifi-
cation of the interferon- (IFN-) production at the single cell
level in an ELISPOT-IFN- assay kit (R&D Systems). In brief,
a monoclonal antibody specific for IFN- was precoated onto
a polyvinylidene difluoride-backed 96-well plate. Liquid nitro-
gen frozen splenocytes unstimulated (CM only), or stimulated
with concanavalin A (con A, 5 g/ml, Pharmacia), 104 of syn-
genic P815 cells26 pulsed with the gp120 or Gag peptides for
2 h (10 g/ml), and mitomycin C (Sigma) treated, or peptides
alone (1 g/ml) were plated at 0.1  106/well and incubated
for 24 h at 37°C and 5% CO2. To assay for each MultiHIV anti-
gen-specific IFN- production 15-mer peptide pools of Rev (29
peptides), Nef (51 peptides), Tat (25 peptides), Gag (91 pep-
tides), and CTL (67 peptides) were used at a final concentra-
tion of 2 g/ml of each peptide. IFN- was detected with a 
biotinylated antibody followed by incubation with strepta-
vidin-alkaline phosphatase conjugate. The reaction was devel-
oped using the BCIP/NBT substrate. Spot-forming cells (SFC)
were counted with an automated ImmunoSpot Series II ana-
lyzer (CTL Europe, Leinfelden-Echterdingen, Germany). The
results are expressed as mean SFC/106 splenocytes of duplicate
wells. The coefficient of variation was 25% for every dupli-
cate. The results are considered positive if 50 SFC/106 sple-
nocytes are above the control (unstimulated cells; CM only) and
twice above the control. The control SFC were 30 SFC/106
cells.
Chromium51 release assay
HIV-1 Env-specific effector cells were generated by in vitro
stimulating liquid nitrogen frozen splenocytes with the H-2d-
restricted gp120 peptide (2 g/ml) and recombinant interleukin
(IL)-2 (25 U/ml, Boehringer Mannheim, Indianapolis, IN) for
5 days. Peptide pulsed (1 g/ml; 2 h at 37°C), MHC class I-
matched, MHC class II-negative P815 syngeneic cells26 were
used as targets. The targets were incubated for 2.5 h at 37°C in
medium containing 150 Ci Na251CrO4 (New England Nuclear,
Boston, MA) and after washing, target cells were mixed with
the effector cells at different ratios in a 5 h chromium release
assay. Control target cells were P815 cells incubated without
the peptide. Results are expressed as mean percent lysis of qua-
druplicate determinations and are calculated by the following
formula: (experimental release  spontaneous media re-
lease)/(maximum detergent release  spontaneous media re-
lease)  100. Spontaneous release of 51Cr from the targets did
not exceed 25% of the maximum release.
Statistics
Differences in mean values were tested by paired and un-
paired two-tailed Student’s t-test (two-tailed for equal variance
assumed); p values  0.05 were considered significant.
RESULTS
In vitro MultiHIV protein expression
In order to study the expression of the MultiHIV fusion pro-
tein encoded by the GTU-MultiHIV vector, the plasmid was
transfected into Cos-7, RD, and Jurkat cell lines. Immunofluo-
rescent staining of the transfected Cos-7 cells by anti-Nef an-
tibody revealed cytoplasmic localization of the fusion antigen
(Fig. 1B). In order to compare the expression capacities of the
GTU- and CMV-MultiHIV vectors, both vectors were trans-
fected in equimolar quantities into the RD cell line. Two and
five days posttransfection the cells were lysed and the expressed
MultiHIV protein was analyzed by Western blot (Fig. 2A) and
capture ELISA (Fig. 2B) as described in Materials and Meth-
ods. The MultiHIV antigen expressed in these cells has a mo-
lecular weight around 120 kDa. As seen in Fig. 2B, only the
GTU-MultiHIV vector produced the fusion protein in an
amount that was detectable by the capture ELISA. The CMV-
MultiHIV vector produced the corresponding protein in con-
siderably lower amounts, which was possible to detect only with
the Western blot developed by the ECL substrate (Fig. 2A).
Anti-HIV and E2 antibodies
HIV-1- and E2-specific antibodies in GTU-MultiHIV im-
munized mice were analyzed by ELISA as described in Mate-
rials and Methods. Figure 3 shows the antibody results of the
mice immunized by gene gun (Fig. 3A) and id (Fig. 3B) with
the escalating doses of the GTU-MultiHIV DNA plasmid. In
these mice a dose-dependent response was seen against Nef and
p17/p24 proteins. The high doses of the DNA induced Nef-spe-
cific responses in 90% of the mice and p17/p24-specific re-
sponses in 70% of the mice. Rev, Tat, and CTL proteins in-
duced antibody responses infrequently and at low magnitude
(data not shown). None of the immunized mice had E2-specific
antibodies (Fig. 3A and 3B). In mice immunized im no HIV-
specific antibodies were detected regardless of the DNA dose
administered.
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Groups of mice were immunized with 1 g DNA by gene
gun once (day 0), twice (day 0 and day 7), or three times (day
0, day 7, and day 21). The effect of the frequency of the im-
munizations on the HIV-1 Nef-specific antibody response is
shown in Fig. 3C. Only mice immunized twice and three times
with the DNA developed Nef-specific humoral responses. How-
ever, the response of mice immunized three times was consid-
erably higher than that of the mice immunized two times (p 
0.05). The production of the antibodies therefore positively cor-
related with the frequency of immunizations.
Cytotoxic T lymphocyte responses
CTL responses were measured as HIV-specific IFN- pro-
ducing CD8 T cells in ELISPOT. We ensured that the IFN-
production by the splenocytes comes from CD8 CTL by us-
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FIG. 2. Comparison of MultiHIV fusion protein expression by the GTU- and CMV-MultiHIV vectors. The plasmids were trans-
fected in equimolar quantities (high and low doses) into an RD cell line (3 g and 0.5 g for GTU-MultiHIV; 2.2 g and 0.37
g for CMV-MultiHIV). As a control the cells were transfected with the GTU-LacZ vector (3 g) encoding -galactosidase.
The cells were lysed 2 and 5 days posttransfection and the MultiHIV antigen was detected by Western blot (A) and capture
ELISA (B) as described in Materials and Methods. For Western blot 5 day time points are shown. Positions of the molecular
weight markers are indicated on the left side.
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ing H-2d-restricted 9- and 10-mer peptides (gp120 and Gag).
Furthermore, by using MHC class II-negative P815 cells as anti-
gen-presenting cells, only class I-restricted responses are de-
tected. All the methods of DNA delivery induced HIV-specific
INF- responses in immunized mice (Fig. 4A). However, the
strength of the response and the DNA dose required were dif-
ferent for each immunization route. All tested mice including
negative control mice responded to con A, indicating good vi-
ability of the cells in the assay, but none had nonspecific SFC
induced by the CM alone (data not shown). In some experi-
ments we used HLA-A2.01-restricted irrelevant peptide from
influenza M1 protein (aa 58–66; GILGFVFTL)27 instead of the
CM to stimulate the cells. The SFC obtained were similar to
the ones induced by the CM alone (30 SFC/106 cells). The
GTU-MultiHIV induced a strong CTL response to the gp120
peptide in 100% of the gene gun-immunized mice already at a
very low DNA dose (120 ng, respectively). Mice immunized
by the im route had only a weak CTL response, while id im-
munized mice had a strong CTL response induced by the high-
est dose of DNA only. None of the negative control mice re-
ceiving the DNA carrier instead of the DNA developed a
positive CTL response to the gp120 peptide (Fig. 4A). Spleno-
cytes of mice immunized with a total of 3 g GTU-MultiHIV
DNA by gene gun were tested by the ELISPOT-IFN- assay
using Rev, Nef, and Tat overlapping peptide pools. IFN- pro-
duction specific for each of the regulatory proteins was detected
(Fig. 4B).
To determine the CD8 T cells requirements for gp120 and
Gag peptide-specific IFN- production, splenocytes were de-
pleted of the CD8 subset before peptide stimulation in the
ELISPOT. The IFN- response to Gag was completely inhib-
ited (228 	 25 SFC/106 intact cells: 33 	 18 SFC/106 CD8-de-
pleted cells), demonstrating that Gag-specific IFN- production
was mediated by CD8 T cells. Magnetic bead depletion of the
CD8 T cells abolished IFN- responses to the gp120 peptide
by 60% (1075 	 SFC/106 intact cells: 425 	 92 SFC/106 CD8-
depleted cells). These results show that when the frequency of
the responding cells is very high the inhibition might not be
complete (low quantities of residual CD8 T cells in the de-
pleted population may account for these responses).
In some instances LN frozen splenocytes of the mice im-
munized with 3 g GTU-MultiHIV by gene gun were tested in
a 51Cr release assay. The cells were cultured in vitro in the pres-
ence of the gp120 peptide as described in Materials and Meth-
ods and tested for lysis of the peptide pulsed P815 target cells.
The results shown in Fig. 4C demonstrate the ability of CD8
T cells from the immunized mice to lyse P815 target cells ex-
pressing HIV antigen, in addition to producing IFN-. More-
over, cells of the mice with stronger responses in the ELISPOT-
IFN- assay also had a higher percentage of the gp120-specific
lysis. These cells therefore had the potential to lyse virus-in-
fected cells.
Duration of the immune responses and effect of the
late DNA boost
Groups of mice immunized three times with the total 3 g
GTU-MultiHIV DNA by gene gun were sacrificed at 2, 6, 10,
14, and 22 weeks following the last immunization (at day 21)
and the cells tested in an ELISPOT-IFN- assay with gp120
and Gag peptides. HIV-1 specific CTL responses during the 22
weeks are shown in Fig. 5A. All immunized mice (100%) had
HIV-specific CTL responses at 2 weeks. The response lasted
up to 22 weeks at remarkable levels to both gp120 and Gag.
However, the response to gp120 at 2 weeks was significantly
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FIG. 3. HIV-1 and E2-specific antibody responses in mice
immunized with GTU-MultiHIV DNA. Mice were immunized
with four escalating doses of the DNA by gene gun (A) and in-
tradermaly (B) as described in Materials and Methods. Anti-
bodies specific for Nef and p17/24 are shown. (C) Mice were
immunized or nonimmunized (—, control, received carrier
DNA) with 1000 ng GTU-MultiHIV DNA by gene gun once
(at day 0), twice (at days 0 and 7), or three times (at days 0, 7,
and 21) and HIV-1 Nef-specific antibody response was tested
in an ELISA assay. Shown is mean OD of the groups. Error
bars represent standard deviation (SD) of the mean.
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higher (p  0.005) than at later time points. In order to raise
the faded CTL response depicted in Fig. 5A, a single booster
immunization with 1 g GTU-MultiHIV DNA by gene gun was
delivered at week 10. Boosting with the 1 g DNA increased
the gp120- and Gag-specific CTL responses assayed at 14
weeks (Fig. 5B).
The effect of DNA boosting as described above on the CD8
CTL responses induced by im and id immunizations was also
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FIG. 4. (A) gp120 peptide (RGPGRAFVTI)-specific CD8 CTL responses were tested in an ELISPOT-IFN- assay. Mice
were immunized or nonimmunized (—, control) with GTU-MultiHIV DNA by different routes (g.g., gene gun; i.d., intrader-
mally; i.m., intramuscularly) and with four escalating DNA doses as described in detail in Materials and Methods. Shown are
mean IFN- spot-forming cells (SFC)/106 cells of 5–10 mice/DNA dose. (B) IFN- production induced by Rev, Nef, and Tat
peptide pools and media control (CM) of GTU-MultiHIV immunized (n 
 10) and control mice (n 
 5). Overlapping 15-mer
peptides were pooled and used to stimulate the cells in the ELISPOT-IFN- assay as described in Materials and Methods. (C)
Lysis of target cells pulsed with the gp120 peptide by the CTL. Mice were immunized with 3 g GTU-MultiHIV by g.g. Sple-
nocytes were stimulated in vitro for 5 days in IL-2-containing media in the presence of the H-2d-restricted gp120 peptide. The
cells were then assayed for Env-specific lysis against P815 target cells pulsed with the gp120 peptide as described in Materials
and Methods. Results are expressed as mean percent lysis of quadruplicate determinations. Nonspecific lysis of the control tar-
gets was subtracted from the specific lysis. Each symbol represents an individual. The gp120 peptide-specific IFN- SFC/106
cells of each mouse are noted in the legend.
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investigated. Mice were immunized with 50 g GTU-Multi-
HIV DNA at days 0, 7, and 21 and an additional booster im-
munization with 50 g DNA was given 10 weeks afterward.
CTL responses were assayed 4 weeks later (week 14) by an
ELISPOT-IFN- assay. The gp120 peptide-specific IFN-
SFC/106 cells were 246 	 92 (mean 	 SD) without the boost
as compared to 182 	 55 SFC with the boost injected to mus-
cle. Similarly, 151 	 36 SFC without the boost and 163 	 38
SFC were detected after the booster DNA delivered id. The
boost did not increase the CTL responses to the Gag peptide
either (data not shown).
Comparison of the immune responses induced by the
GTU-MultiHIV and CMV-MultiHIV plasmids
We further compared HIV-specific antibody responses 
and CTL responses induced by the novel GTU-MultiHIV
DNA plasmid and the conventional CMV-MultiHIV DNA
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FIG. 5. (A) Duration of the CD8 CTL responses to HIV-1
gp120 (RGPGRAFVTI) and Gag (AMQMLKETI) peptides.
Mice were immunized with 3000 ng (3  1000 ng) GTU-Mul-
tiHIV DNA by gene gun. Two, 6, 10, 14, and 22 weeks fol-
lowing the final immunization (at day 21), splenocytes were
isolated and tested in an ELISPOT-IFN- assay. (B) Boosting
effect of the GTU-MultiHIV DNA on the gp120- and Gag-spe-
cific CTL responses. Mice were immunized as described above.
Ten weeks following the final DNA immunization mice were
boosted once with 1000 ng DNA and an ELISPOT-IFN- as-
say was performed 4 weeks later.
FIG. 6. HIV-specific CTL responses and antibody responses
induced by the GTU-MultiHIV and CMV-MultiHIV DNA plas-
mids. Groups of mice were immunized three times (days 0, 7,
and 21) with the following total DNA doses: (A) 24 ng
GTU/17.4 ng CMV (low dose), (B and D) 300 ng GTU/220 ng
CMV (intermediate dose), or (C) 750 g GTU/546 g CMV
(high dose). The low and intermediate doses were delivered by
gene gun and the high dose injected intradermaly. Mean HIV-
1 gp120 peptide-specific and nonspecific (CM, culture medium)
IFN- SFC/106 cells are shown. (D) HIV-1 Nef- and p17/24-
specific antibody responses. Monoclonal antibodies specific for
HIV-1 Nef and p17/24 served as a positive control as described
in Materials and Methods. *Significant responses (p  0.05).
6293_09_p667-677  6/23/06  10:02 AM  Page 674
plasmid. Groups of mice were immunized three times (days
0, 7, and 21) with the following total GTU-MultiHIV DNA
doses: 24 ng (low), 300 ng (intermediate), and 750 g (high),
and CMV-MultiHIV DNA doses: 17.4 ng (low), 220 ng (in-
termediate), and 546 g (high). The difference in the DNA
doses of the two plasmids accounts for the presence of the
E2 expression cassette in the GTU plasmid. The low and in-
termediate doses were delivered by gene gun and the high
dose injected id. The gp120 peptide-specific and nonspecific
(CM; culture medium) IFN- SFC/106 cells are shown in 
Fig. 6A–C, and Nef- and p17/24-specific antibody responses
are shown in Fig. 6D. CTL responses to gp120 were signif-
icantly different (p  0.05) when induced by the low (Fig.
6A) and the intermediate (Fig. 6B) doses of the plasmids.
Comparable responses were induced by the high dose (Fig.
6C). In addition, SFC induced by the mitogen con A were
comparable for each mice tested (1087–1551 SFC/106 cells;
range) indicating good viability of the cells used in the as-
say. Antibody responses were not induced by the low dose
of the plasmids (data not shown) but were stronger in the
group immunized by the intermediate dose of the GTU plas-
mid (Fig. 6D).
In addition to the responses described above, T cell responses
to the overlapping peptide pools covering the entire MultiHIV
antigen were analyzed. The results are shown in Table 1. In
contrast to the GTU-MultiHIV plasmid-induced responses there
was no positive response to any peptide pool induced by the
CMV-MultiHIV at the lowest DNA doses delivered by gene
gun. Furthermore, the intermediate dose (300 ng) of the GTU
plasmid induced responses to each of the peptide pools while
the equivalent dose (220 ng) of the CMV plasmid failed to do
so.
Anti-dsDNA antibodies
Anti-dsDNA antibodies were not detected in any of the im-
munized mice or in the negative control mice (data not shown)
while positive control mouse sera had a strong antibody level
(1,910 OD at 1:50 dilution).
DISCUSSION
This study was designed to test the immunogenicity of a
cloned HIV-1 multiantigen delivered by the novel GTU-plas-
mid as a possible candidate for an HIV vaccine. Due to tran-
scription enhancement as well as to the maintenance element
of the GTU caused by the expression of the nuclear anchoring
protein BPV-1 E2 and the presence of binding sites for E2 in
the plasmid, there is up to a 100 times greater expression level
with GTU as compared to conventional DNA plasmids lacking
these two elements17 (patent application, Novel vectors and uses
thereof, PCT/FI02/00379). E2 is the regulatory protein of BPV-
122 with functions of binding to the chromatin and cellular tran-
scription machinery as well as to the E2 oligomerized binding
sites in the vector that provides transcriptional activation of the
CMV promotor and chromatin attachment function to the plas-
mid. These features of the plasmid should reflect the possible
use of low doses of the GTU to induce immune responses as
compared to conventional DNA plasmids. It is a problem in the
HIV DNA vaccines in general, as they require high quantities
of DNA plasmids for immunizations.28 Indeed our results show
that a very low dose (24 ng) of the GTU-MultiHIV plasmid but
not the conventional CMV-MultiHIV plasmid is able to induce
immune responses in immunized mice. We did not detect any
ds-DNA antibodies or antivector responses, reflected by the
lack of BPV E2-specific antibodies induced by the GTU-Mul-
tiHIV DNA in immunized animals. The reason for the lack of
immune response to E2 is unknown but could be due to the low
level of expression of E2, as compared to the gene of interest,
or due to the fact that E2 protein, after synthesis, is transported
to and sequestered into the nucleus, thereby avoiding presenta-
tion to the immune system. Since no immune response devel-
ops against the GTU vector, it can be used not only for prim-
ing but also for boosting. In addition, biodistribution and safety
studies performed with the GTU-MultiHIV are reported.17,29
All parts of the MultiHIV antigen are immunogenic in vivo,
which demonstrates that the expressed fusion protein is
processed and the immunogenic epitopes properly presented to
the immune system cells.
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TABLE 1. COMPARISON OF THE IMMUNE RESPONSES INDUCED BY GTU-MULTIHIV AND CMV-MULTIHIV IMMUNIZATIONSa
Peptide pools
DNA plasmid (total dose) CM Rev Nef Tat Gag CTL Con A
GTU-MultiHIV (24 ng) 2b 67c 2 12 43 150 2030
CMV-MultiHIV (17.4 ng) 0 0 0 3 2 0 2577
GTU-MultiHIV (300 ng) 0 80 320 51 296 1145 2003
CMV-MultiHIV (220 ng) 4 13 115 31 274 1008 2088
GTU-MultiHIV (750 g) 0 15 105 10 78 455 2102
CMV-MultiHIV (546 g) 0 30 60 20 77 643 2443
aMice (n 
 5) were immunized with GTU-MultiHIV or CMV-MultiHIV plasmids by gene gun (ng doses) or intradermally
(g doses) as described in the legend to Fig. 6.
bShown are mean IFN- spot forming cells (SFC)/106 splenocytes induced by media control (CM), HIV-1-specific peptide
pools (2 g/ml of each peptide in the pool), and con A (5 g/ml) in an ELISPOT-IFN- assay. Standard deviations were 35%
of the mean.
cBoldface denotes significantly different (p  0.05) responses between the groups.
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It is important to determine for each new vaccine the opti-
mal immunization regime in terms of vaccine doses, frequency
of immunizations, and delivery routes. Our results show that
gene gun immunization is superb in inducing B cell and CTL
responses in immunized mice compared to im and id immu-
nizations. Extremely low doses of the GTU-MultiHIV plasmid
DNA delivered by gene gun induce HIV-specific CTL re-
sponses. Intramuscular immunization induces only a low CTL
response without antibody production, which is in agreement
with previously published results.30 Furthermore, the CTL re-
sponse induced by im and id immunizations requires high doses
(micrograms) of the plasmid DNA. Earlier studies have also re-
ported that gene gun immunization is more efficient than nee-
dle injection in eliciting cellular and humoral responses.31,32
The strong and broad immune response induced by gold parti-
cles delivered DNA compared to injected DNA could be due
to the fact that the response is initiated by Langerhans cells in
the skin, which are directly transfected or take up the secreted
antigen from the immunization site (cross-priming), migrate to
local lymph nodes, and stimulate T cells.33 In order to improve
the HIV-specific immune responses induced by needle immu-
nization, which is the widely used route of DNA vaccination
for human subjects, more studies using different molecular ad-
juvants34 and/or different boosting regimens should be per-
formed. Our results show no effect of the homologous DNA
boost on both im and id delivery methods in contrast to gene
gun DNA delivery. It is likely that different heterologous boost-
ing strategies might increase the HIV-specific immune re-
sponses induced by the needle-injected DNA. We are currently
evaluating these strategies. Overall, these results show that gene
gun immunization is more potent in inducing various types of
immune response and requires 1000-fold less DNA to be ad-
ministered than im or id immunizations. Gene gun and deliv-
ery methods based on similar technology should therefore be
considered as alternative methods for delivering DNA vaccines
to human subjects in clinical trials.
The results described here also show that the HIV-specific
immune response induced by DNA vaccination is not only route
and dose dependent, but also depends on the frequency of the
immunizations. HIV-specific antibody response induction re-
quired at least two DNA immunizations while the third immu-
nization induced an optimal response. Our findings are in agree-
ment with the previously published observation that at least two
immunizations are required to obtain detectable humoral im-
mune responses to HIV-1 proteins.16 We have found that al-
most 6 months following DNA delivery HIV-specific CTL re-
sponses could still be detected. It was earlier reported16 that 3
months after the initial DNA delivery there was low IL-2 pro-
duction detected in the stimulated cell culture supernatants. The
weak residual IL-2 production as described above could pro-
vide help for the CTL response35 we detected at 22 weeks post-
immunization. However, one booster immunization with the
GTU-MultiHIV DNA at 10 weeks restored strong HIV-specific
CTL responses.
All components of the MultiHIV antigen are immunogenic
in vivo in a mouse model. Mice have developed considerable
Rev-, Nef-, Tat-, Gag-, and CTL-specific T cell responses as
well as Nef- and Gag-specific antibody responses. The CTL
part of the fusion protein is very immunogenic for T cells as
seen by the strong CD8 CTL responses to H-2d-restricted
gp120 peptide but not for B cells. This is understandable, as
CTL contains 11 clusters of the T cell epitope-rich regions of
HIV-1 Pol and Env. As we could detect T cell responses to each
of the HIV-1 regulatory proteins coded by the GTU-MultiHIV,
our concern that the strong immunodominant epitope, as is the
H-2d-restricted gp120 described here, which induces a high fre-
quency of the responding cells, would preclude responses
against subdominant epitopes is minimized. The reason why
Tat and Rev are poor B cell immunogens in vivo is not known.
However, other investigators have reported low immunogenic-
ity of these proteins in their reports.16,36
As we could induce an immune response to each of the HIV-
1 proteins cloned into the GTU-MultiHIV under the control of
a single promotor, we conclude that there is no interference or
inhibition of the specific responses, which might be the case
when combinations of different plasmids expressing a single
gene are used for immunizations.37 A single DNA vaccine con-
struct as described here, which contains multiple HIV-1 genes,
is easier to administer and more cost effective than developing
and administering a cocktail of single gene DNA vectors. The
results described here support the hypothesis that DNA con-
taining several HIV-1 genes is a potential vaccine candidate
against HIV infection when an immune response to the multi-
ple HIV proteins is desirable in order to minimize virus escape
from the immune system.38
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bstract
A novel animal model for testing the immunogenicity and protective immune response induced by HIV-1 DNA vaccines was developed.
BA/2 mice were immunized with GTU®-MultiHIV DNA encoding multigene for Rev, Nef, Tat, optp17/24 and a stretch of Pol/Env epitopes.
single GTU®-MultiHIV B-clade specific plasmid or Auxo-GTU®-MultiHIVmix (mixture of four plasmids with A, B, C and FGH clade
pecific MultiHIV antigens) were administered via gene gun and cell-mediated and humoral immune responses were analysed. The protective
fficacy of the immune response was evaluated by challenging the mice with syngeneic tumor cells (P815) stably transfected with the MultiHIV
®usion gene. Our results show that the strong MultiHIV-specific immune response generated by the GTU -MultiHIV vaccines in DBA/2 mice
as able to delay the tumor growth substantially, indicating that the CTL response detected in vitro confers protection in vivo. The model
escribed here is a safe and feasible in vivo assay for assessment of the vaccine potency to induce protective cell-mediated immune responses.
2007 Elsevier Ltd. All rights reserved.
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. Introduction
The lack of an effective vaccine against HIV is partly
ue to the fact that the correlates of protection are unknown.
valuation of a vaccine candidate in clinical settings is time
onsuming and costly process, therefore, different animal
odels are used for the evaluation of the immunity and
rotection induced by the vaccine candidates [1]. An ani-
al model closely resembling HIV-1 infection in humans
an be attained in nonhuman primates infected with simian
mmunodeficiency virus (SIV) or HIV/SIV chimeric viruses.
rimate challenge studies have ethical constraints and a
ajor defect as a model for HIV-1 infection, due to theonsiderable differences between HIV-1, SIV and chimeric
HIV infection [2–4]. Several small animal models have
een developed to demonstrate the capability of a vaccine
∗ Corresponding author. Tel.: +358 3 3138 7054; fax: +358 3 3138 7050.
E-mail address: maria.malm@fitbiotech.com (M. Malm).
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oi:10.1016/j.vaccine.2007.01.003o induce protective immunity. Infection resembling HIV-1
nfection in humans has been established in severe combined
mmunodeficiency mice [5] and recently in Trimera mice
6]. However, the usability of these mouse models for vac-
ine studies is limited due to the low availability of these
ice, the safety reasons related to work with the infectious
irus and the limited duration of the HIV-1 infection in mice.
dditional mouse challenge studies utilize different recom-
inant live viruses, including vaccinia virus [7,8]. Recently,
e have tested [9] a DNA vaccine candidate in a protection
odel where immunized mice were challenged with the cells
nfected with a pseudotype virus carrying murine leukaemia
irus (MuLV) envelope and the clade A and B specific HIV
enome [10]. The gene gun immunization with the Auxo-
TU®-MultiHIVmix DNA induced a cross-clade protectionn 83–100% of the pseudotype HIV-1/MuLV challenged mice
9].
Numerous tumor challenge studies are carried out in a
ouse model to evaluate the efficacy of the vaccines [11,12]
3294 M. Malm et al. / Vaccine 25 (2007) 3293–3301
Table 1
Immunizations and challenge experiments in DBA/2 mice
Group Immunizations weeks-5, -4, and -2 Challenge at day 0 Termination day
Study 1
I GTU®-MultiHIV-B 1 × 106 P815-MultiHIV <26a
II – 1 × 106 P815-MultiHIV <26a
III GTU®-MultiHIV-B 1 × 106 P815-wt <26a
IV – 1 × 106 P815-wt <26a
Study 2
I Auxo-GTU®-MultiHIVmix 0.2 × 106 P815-MultiHIV 15 and 22
II – 0.2 × 106 P815-MultiHIV 15 and 22
III Auxo-GTU®-MultiHIVmix 0.4 × 106 P815-MultiHIV 15 and 22
IV – 0.4 × 106 P815-MultiHIV 15 and 22
V Auxo-GTU®-MultiHIVmix 0.8 × 106 P815-MultiHIV 9 and 15
VI – 0.8 × 106 P815-MultiHIV 9 and 15
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a Mice were terminated when the longest diameter of the tumor reached 1
nd cancer immunotherapies [13–15]. After the induction
f immunological memory by vaccination, tumor-specific
ytotoxic T cells (CTL) play a pivotal role in the tumor
learance and protection [16,17]. In concordance, a strong
TL response is thought to be needed for combating HIV-1
nfection in humans [18–20].
Here we describe a novel mouse model developed for
esting the capability of an HIV DNA vaccine to induce pro-
ection against the tumor challenge. The GTU®-MultiHIV
accine described here has been previously shown to induce
trong HIV-specific cell-mediated immune responses in
ALB/c [21] and C57Bl/6 mice [9]. In the present study,
BA/2 mice were immunized with the GTU®-MultiHIV
NA and subsequently challenged with P815 tumor cells
table transfected with the MultiHIV antigen. A protective
ffect of the vaccination was evaluated by comparing the
umor growth in immunized and naı¨ve mice.
. Materials and methods
.1. Animals
Young female DBA/2OlaHsd mice, 6 weeks old at the
ime of the first immunization, were obtained from Harlan
Italy and Netherlands). All procedures were carried out in
ive animals according to the guidelines and permission of
he County administrative board. Treatments were performed
nder ketamine (Ketalar®, Pfizer AB, Espoo, Finland) and
edetomidine (Domitor®, Orion Pharma, Espoo, Finland)
nesthesia.
.2. DNA plasmidsDNA vaccine constructs used here are well described HIV-
DNA vaccines based on the Gene Transfer Unit (GTU®)
echnology developed by FIT Biotech Plc. [9,21–23].
1
S
f– 0
or vertical growth >10 mm) or at day 26.
In the first set of experiments (Study 1, Table 1) the GTU®-
ultiHIV B clade (Han-2) plasmid was used for immunizing
he mice prior to the challenge. The GTU®-MultiHIV plas-
id vector encodes for the HIV-1 multigene, containing fused
ull-length sequences of rev, nef, tat, gag (p17 and p24) and
1 T cell epitope rich clusters from pol and env polypep-
ides. The above DNA plasmid has been shown to induce
strong and broad HIV-specific CTL responses in BALB/c
ice [21].
The second set of experiments (Study 2, Table 1) were
erformed with more advanced DNA vaccine candidate,
uxo-GTU®-MultiHIVmix plasmid, where four different
lasmids (A, B, C and FGH) are combined as a mixture.
hese plasmids contain the MultiHIV consensus sequence
pecific for clade A, B, C or the ancestral sequence for
lades F, G and H, to meet the great variability of the HIV-
subtypes/isolates. The Auxo-GTU®-MultiHIVmix vaccine
as been shown to induce a strong HIV-specific immune
esponse and in addition it is capable to generate cross-
eaction and cross-protection against different clades of
IV-1 [9].
.3. Tumor cell lines and transfections
A mastocytoma cell line P815 of DBA/2 origin carrying
-2d class I MHC molecules, was used for constructing cell
ines for the tumor challenge model. These cells are tumori-
eneic in DBA/2 mice, forming well-defined palpable tumors
elow the skin when injected subcutaneously (sc) [24]. The
815 cell line used for the challenge was stable transfected
ith a p2SR-MultiHIV-Han-2 plasmid (P815-MultiHIV).
s a challenge control the wild type P815 cell line (P815-wt)
as used.
The plasmid p2SR-MultiHIV-Han-2 expresses the HIV-
Han-2 isolate specific MultiHIV antigen, using a strong
R-hybrid promoter comprised of SV40 early promoter
used to HTLV U5 region [25]. In order to be able to select
cine 25
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ransfected cells we have constructed the vector that car-
ies the cassette for expressing puromycin acetyl transferase,
nabling selection of transfected cells in the presence of
he puromycin. In addition, the vector encodes a -subunit
f human chorionic gonadotropin hormone (-hCG), which
s secreted into urine of the tumor bearing animals. The
easurement of urinary -hCG is generally used in tumor
ouse models for augmenting the monitoring of the tumor
rowth, as the amount of the hormone in urine is shown
o positively correlate with tumor load [26]. As the vector
ncoding the MultiHIV antigen does not encode antibiotic-
esistance genes, the above two vectors were ligated together
nto con-catemers. Con-catemers were electroporated into
815 cells and 1 day post-transfection the puromycin was
dded to the cells (0.75g/ml). One week later the pool
f cells was sub-cloned by limiting dilution method onto
6-well plates, containing 0.5g/ml puromycin. The result-
ng clones were cultivated further on 24-well plates and a
ample of cells from each clone was taken and analysed
y Western blot method (WB). For WB analysis the cells
ysate was separated on 10% SDS-PAGE, transferred onto
VDF-membrane and probed with the cocktail of mono-
lonal antibodies against Nef and p24 (01-001 and 05-001,
uattromed Ltd., Tartu, Estonia). Bound antibodies were
etected by HRP-conjugated goat anti-mouse IgG secondary
ntibody and ECL-substrate.
Both, P815-wt and P815-MultiHIV cells were grown in
PMI 1640 (Sigma–Aldrich, St. Louis, MO) supplemen-
ed with 100 U/ml penicillin–streptomycin (Sigma–Aldrich),
-glutamine (BioWhittaker, Verviers, Belgium), 10% fetal
ovine serum (FBS, BioWhittaker) at 37 ◦C with 5%
O2.
.4. In vitro antigen presenting function of the
815-MultiHIV cell line
In order to test that P815-MultiHIV cells express and
resent MultiHIV antigen, they were used in an IFN-
LISPOT assay and Cr51 assay as antigen presenting cells
APC). The P815 cells are routinely used as APC to MHC
lass I-restricted CD8+ T cells [27]. In brief, splenocytes
f BALB/c mice immunized with the GTU-MultiHIV-B by
ene gun as described earlier [9,21] were in vitro stim-
lated for 24 h with mitomycin C treated P815-MultiHIV
ells and P815-wt cells as a control in the ELISPOT IFN-
ssay.
The lysis of the P815-MultiHIV cells by CD8+ CTL of
ice immunized by gene gun with the GTU®-MultiHIV
nd Auxo-GTU®-MultiHIV plasmids was tested in a Cr51
elease assay as described previously [21], using stable trans-
ected P815-MultiHIV and P815-wt as target cells. The target
ells were prepared by incubating the cells in medium con-
aining 150Ci Na251CrO4 (New England Nuclear, Boston,
A, USA) 1.5 h at 37 ◦C with 5% CO2. The assays were
erformed in quadruplicates with 5000 targets/well at effec-
or to target cell ratios (E:T) of 50:1, 25:1, and 12.5:1.
−
u
o(2007) 3293–3301 3295
fter 5 h incubation 100l of supernatant was collected
nd radioactivity counted in a -counter (Wallac Oy, Turku,
inland). Results were expressed according to the for-
ula: % specific lysis = (experimental release − spontaneous
elease)/(maximum release − spontaneous release) × 100.
xperimental release represents the mean count per-minute
eleased by target cells in the presence of effector cells. Max-
mum release represents the radioactivity released after lysis
f target cells with 5% Triton X-100. Spontaneous release
epresents the radioactivity present in medium derived from
arget cells alone.
.5. Tumorigenicity of the P815-MultiHIV and P815-wt
ell lines
The capability of the P815-MultiHIV and P815-wt cells
o induce tumors in DBA/2 mice was tested. We inocu-
ated 1 × 106 cells subcutaneously (sc) in a 50l sterile PBS
BioWhittaker) by 23-gauge needle into the right flank of the
BA/2 mice and the tumor growth was followed by measur-
ng the diameter of the tumor every second day with electronic
alliper. The size (mm2) was calculated as longest diameter
mm) × shortest diameter (mm). The welfare and behaviour
f the mice were also observed. Mice were sacrificed when
he diameter reached 10 mm.
.6. Protection model in DBA/2 mice
In the Study 1 (Table 1) the P815-MultiHIV and P815-
t tumor development was followed in immunized and
on-immunized DBA/2 mice after inoculating 1 × 106 P815
ells. Mice were immunized three times with 1 and 2
eeks intervals (week-5, week-4, week-2) with 1g of
he GTU®-MultiHIV-B by Helios gene gun as described
reviously [9,21]. This immunization schedule was earlier
hown to induce a strong CTL response in immunized mice.
wo weeks after the last immunization (week 0) the mice
ere challenged by sc injection of 1 × 106 P815-MultiHIV
umor cells on the shaved right flank in a 50l sterile
BS by 23-gauge needle. In addition, the following con-
rol groups were used: immunized mice challenged with
× 106 P815-wt cells and non-immunized mice challenged
ith 1 × 106 P815-MultiHIV or 1 × 106 P815-wt cells. The
umor growth was monitored every 2 or 3 days as described
bove. Urine samples were collected for few mice in each
roup at days 6 and 20 for measurement of secreted -hCG
ormone by using Free beta-hCG ELISA assay (IBL, Ham-
urg, Germany). Mice were terminated when the longest
iameter of the tumor reached 15 mm (or vertical growth
10 mm) or at day 26. The spleens were collected and
plenocytes in a single cell suspension were frozen to liq-
id nitrogen. Serum samples were collected and stored at
20 ◦C.
In the Study 2 (Table 1), different cell numbers were
sed for the challenge: 0.2 × 106, 0.4 × 106 and 0.8 × 106
f P815-MultiHIV cells. The immunization regimen was
3 cine 25
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dentical to the one described in Study 1, but the DNA con-
truct used was the Auxo-GTU®-MultiHIVmix. The mice
mmunized but not challenged, were terminated 2 weeks
fter the last immunization, and the splenocytes and serum
ere used for testing the immune response at the time
hen the challenge is given. A group of naı¨ve mice was
ncluded as a control. The challenged mice (n = 8) were
andomly divided into two groups and terminated at two dif-
erent time points, to assay for the immune response during
he tumor development and after formation of the palpa-
le tumors. The termination days are described in details in
able 1.
.7. IFN-γ ELISPOT
Liquid nitrogen frozen splenocytes of the mice were
nalysed using a mouse ELISPOT IFN- assay (R&D
ystems, Minneapolis, MN, USA) to evaluate the HIV-1
pecific immune response. The splenocytes were stimulated
or 24 h at 37 ◦C and 5% CO2 with the following: H-2d-
estricted HIV-1 gp120 peptide (Env = RGPGRAFVTI) and
IV-1 gag peptide (Gag = AMQMLKETI) (Sigma-Genosys,
ambridge, UK) at 1g/ml, 1 × 104 P815-MultiHIV cells
nd 1 × 104 P815-wt cells. P815 cells were Mitomycin
(Sigma–Aldrich) treated for 2 h at 37 ◦C and washed
efore plating. As a positive control concanavalin A (con
, 5g/ml, Pharmacia) was used, and as a negative con-
rol the cell culture media only. After washing the cells,
he spots were detected using an IFN--specific biotinylated
ntibody, and a streptavidin–alkaline phosphatase conju-
ate according to the manufacturer’s instructions. Color
as developed with the chromogenic BCIP/NBT substrate.
utomated ELISPOT plate reader (ImmunoSpotTM Series II
nalyzer, CTL Europe, Aalen, Germany) was used for count-
ng spot forming cells (SFC). The results were considered
ositive if both replica wells were >50 SFC/106 splenocytes
bove the unstimulated cells (control) and twice above the
ontrol.
.8. Antibody ELISA
Antibodies against purified recombinant Gag B and Nef
proteins (FIT Biotech) in termination sera were mea-
ured by enzyme-linked immunosorbent assay (ELISA). Sera
ere diluted 1:400 in PBS + 1% BSA + 0.01% Tween20 and
uplicate samples were incubated on antigen coated plate
or 2 h at room temperature (RT). Horseradish peroxidase
onjugated goat anti-mouse Ig (P0447, DAKO, Glostrup,
enmark) and tetramethylbenzidine (TMB peroxidase EIA
ubstrate Kit, BioRad, Mu¨nchen, Germany) were used for
etection of bound antibodies. The absorbance was measured
t wavelength 450 nm with ELISA plate reader. A positive
ntibody response was determined to be an optical density
OD) above the mean of naı¨ve sera plus 3 standard deviations
S.D.).
a
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c(2007) 3293–3301
. Statistics
Differences in mean values were tested by paired
wo-tailed Student’s t-test (two-tailed for equal variance
ssumed); p values ≤0.05 were considered significant.
. Results
.1. P815-MultiHIV cells act as APC in vitro
The expression of the MultiHIV-B antigen in the trans-
ected P815 cells was confirmed by the Western blot (data
ot shown). Further we tested whether the antigen in addi-
ion of being expressed, is properly presented to the immune
ystem cells. BALB/c mice were immunized with the GTU-
ultiHIV-B or Auxo-GTU-MultiHIVmix as described in
ection 2 and Fig. 1 legend. Splenocytes were tested in an
FN- ELISPOT (Fig. 1A) and Cr51 release assay (Fig. 1B)
ith the P815-MultiHIV cells and P815-wt as a control.
plenocytes isolated from all immunized BALB/c mice
eacted strongly to the P815-MultiHIV transfected cells,
hereas the wild type P815 cells did not induce any secre-
ion of IFN-. Furthermore, we tested whether activated
D8+ T cells of the immunized mice are able to lyse the
ransfected tumor cells. Functional assays, like Cr51 release
ssay show the actual killing of the P815 cells what is
ore relevant for in vivo tumor rejection. As shown in
ig. 1B, P815-MultiHIV cells were efficiently lysed by
he effector cells of the GTU-MultiHIV-B and Auxo-GTU-
ultiHIVmix immunized mice. These results demonstrate
hat the epitopes on P815-MultiHIV transfected cells are
roperly presented to CD8+ CTL. In addition, there was no
ifference in the response regarding the two different DNA
accines used.
.2. Cellular and humoral immunity in DBA/2 mice
The following experiments were performed to test the
mmunogenicity of the Auxo-GTU-MultiHIVmix in DBA/2
ice at the time the tumor challenge cells are injected. Mice
ere immunized three times with 1g DNA at day 0, day
and day 21 by gene gun. Two weeks after the final immu-
ization mice were terminated and the splenocytes assayed
n an IFN- ELISPOT assay. The cells were incubated 24 h
ith the Gag peptide, the Env peptide, 1 × 104 cells P815-
ultiHIV cells, and 1 × 104 P815-wt cells (Fig. 1C). The
bove two peptides are both present in the MultiHIV antigen
equence and are previously described as immunodominant
-2d-restricted epitopes [28,29]. Strong IFN- responses
gainst both peptides were detected in 100% of the immu-
ized mice. P815-MultiHIV cells expressing the MultiHIV
ntigen induced a high specific response, which was not
etected with the wild type P815 cells. HIV-specific anti-
odies were measured in termination sera of the immunized
ice (Fig. 1D). A very high antibody response against B-
lade Gag was detected in all tested mice (5/5 positive). Nef
M. Malm et al. / Vaccine 25 (2007) 3293–3301 3297
Fig. 1. (A) Antigen presenting function of the MultiHIV transfected cells was assayed by measuring IFN- response to P815-MultiHIV cells and P815-wt
cells. BALB/c mice were immunized three times by gene gun either with GTU-MultiHIV-B (3× 1g) or with Auxo-GTU-MultiHIVmix (3× 200g) DNA
and terminated 2 weeks after the final immunization. 1 × 105 splenocytes were stimulated with 1 × 104 P815-MultiHIV cells or with 1 × 104 P815-wt cells
for 24 h and analysed in an IFN- ELISPOT assay as described in Section 2. (B) Lysis of the P815-MultiHIV target cells by the CTL. Splenocytes of the
BALB/c mice immunized with the GTU-MultiHIV-B () or Auxo-GTU-MultiHIVmix () were stimulated in vitro for 5 days in IL-2 containing media and
assayed for MultiHIV-specific lysis as described in Section 2. Results are expressed as mean percent lysis of quadruplicate determinations. The % lysis of wild
type P815 target cells was subtracted from the HIV-specific lysis. Each symbol represents an individual. (C) HIV-specific CD8+ CTL response in DBA/2 mice
immunized with the Auxo-GTU-MultiHIVmix by gene gun. Mice were immunized at day 0, day 7 and day 21, with 1g DNA and 2 weeks after the final
immunization splenocytes were assayed in an IFN- ELISPOT assay as described in Section 2. The cells were incubated 24 h with the Gag peptide, the Env
p otal Ig a
o LISA.
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f the DBA/2 immunized mice described above and of naı¨ve control mice in E
ssay.
-specific antibodies were neglectable, only one of five mice
esponded.
.3. Tumor growth and challenge experiments in DBA/2
ice immunized with the GTU®-MultiHIV-B DNA
lasmid
In Study 1 (Table 1) mice were immunized 3× 1g of
he GTU®-MultiHIV-B and challenged with 1 × 106 P815-
ultiHIV cells or 1 × 106 P815-wt cells as described in
ection 2. Non-immunized mice were challenged the same
ay. Fig. 2A depicts the tumor growth after the challenge
n day 0. In non-immunized groups, there was no differ-
nce in the P815-wt and P815-MultiHIV growth during the
rst 10 days, demonstrating that there is no effect of the
loned MultiHIV antigen or the -hCG on the tumor growth.
oth cell types, P815-MultiHIV and P815-wt were found to
e very aggressive in inducing tumors, as the tumors could
e detected already at 3 days after the inoculation in non-
mmunized groups, and in a several mice the tumors reached
5 mm size already in 9 days. However, at 12 days a clear
egression of the P815-MultiHIV tumors was detected, as
he tumor mass temporarily decreased in each mouse.
i
t
h
dntibodies against Nef and Gag (p17/24) were measured in termination sera
Group mean values are presented. Serum samples were diluted 1:400 for the
In GTU-MultiHIV-B immunized mice a clear delay of
days was observed in tumor growth after the challenge
ith the P815-MultiHIV cells (Fig. 2A), when compared to
he growth of P815-wt tumors. In addition, the growth of
815-MultiHIV tumors was much slower than the growth of
815-wt tumors. After the wild type cell challenge an aggres-
ive tumor growth was seen in all mice, independently of
mmunization. All mice developed tumors eventually; P815-
t challenged mice by day 5 and P815-MultiHIV challenged
ice by day 13. The urinary -hCG was determined for sev-
ral mice in each group at two time points, at days 6 and 20.
t day 6 a non-immunized P815-MultiHIV challenged mice
ecreted detectable levels of the hormone (4.5 ± 0.1 ng/ml),
orrelating to the large tumor size. In immunized P815-
ultiHIV challenged mice no -hCG was detected at this
ime point (below detection limit; 0.25 ng/ml), correlating
ith the delayed tumor growth. At day 20 both immunized
nd non-immunized P815-MultiHIV challenged mice had
qually high tumor loads, however no -hCG was detected,
ndicating the loss of transfected insert in the P815 cells or
he overgrowth of the wild type cells to transfection. -hCG
ormone was not produced by the P815-wt tumors (below
etection limit; 0.25 ng/ml).
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Fig. 2. Study 1: tumor growth and immune responses in DBA/2 mice. (A) Mice were immunized three times (day 0, day 7 and day 21) with 1g of GTU-
MultiHIV-B. Two weeks after the final immunization mice were challenged by injection of 1 × 106 P815-MultiHIV cells () or 1 × 106 P815-wt cells (©) as
shown in Table 1. Non-immunized groups of mice were challenged similarly ( and ). The tumor growth was followed until the longest diameter reached
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Gag B were measured with ELISA at the time of termination, as described
rotected as the tumor growth was clearly delayed, when compared to other
The termination time for each mice varied inside the
roups according to the tumor growth rate, therefore
mmunological assays were performed at the same time
Fig. 2B). These responses therefore reflect the humoral and
ell-mediated immune responses after the follow-up period,
hen most of the mice had large tumor formations and are
nly indicative for responses after the challenge. No humoral
r cell-mediated responses were observed in non-immunized
ice after the wild type challenge. However, as could be
xpected by the biological behaviour of the challenge tumors,
he P815-MultiHIV challenge was shown to induce a specific
FN- response in non-immunized mice to the Env peptide
nd P815-MultiHIV cells, but not to the Gag peptide. Immu-
ized mice, challenged with the P815-MultiHIV or P815-wt
ells responded to the Env peptide, Gag peptide, and P815-
ultiHIV cells by IFN- production (Fig. 2B). In addition
hey produced Nef- and Gag-specific antibodies. The only
ifference observed between the challenged groups was seen
n the Gag peptide-specific responses as the positive response
>50 SFC/106 cells) was detected in five of eight tested mice
n P815-MultiHIV group and in three of seven tested mice in
815-wt group. According to the results shown in Fig. 2A,
nly the immunized, P815-MultiHIV challenged group was
rotected, as the tumor growth was hindered and delayed by
days, compared to the immunized P815-wt challenged or
on-immunized groups.
.4. Tumor growth and challenge experiments in DBA/2
ice immunized with the Auxo-GTU-MultiHIVmix DNA
lasmid
In Study 2 mice were immunized three times with 1g of
he Auxo-GTU-MultiHIVmix DNA by gene gun. At day 0 (2
r
a
a
tuction was measured with an ELISPOT, and antibodies against rNef B and
tion 2. The immunized, P815-MultiHIV challenged mice were considered
ged groups.
eeks after the final immunization) the immunized mice, as
ell as non-immunized control mice were challenged with
he escalating numbers of the P815-MultiHIV cells. In addi-
ion, two termination time points were used as described in
able 1 and Fig. 3 legend in order to detected possible differ-
nce in magnitude or quality of the immune responses during
he tumor growth and after the complete tumor formation.
With each of the tested cell numbers used for challenge,
he immunization was able to delay the growth of the tumor
or at least 4 days compared to the non-immunized mice.
hallenge with 0.2 × 106 and 0.4 × 106 P815-MultiHIV cells
esulted in up to 10 days (average 8 days) delay in the tumor
rowth of immunized group compared to the non-immunized
roup (Fig. 3A and B). One of eight mice challenged with
he 0.2 × 106 cells, and two of eight mice challenged with
he 0.4 × 106 cells stayed completely tumor free until the
nd of the study (day 22). After injection of the 0.8 × 106
815-MultiHIV cells tumor growth was delayed up to 9 days
average 5 days) (Fig. 3C).
The IFN- response was analysed in an IFN- ELISPOT
ssay for each animal after the termination and the group
ean value was calculated for both termination points. The
ag peptide-specific response (Fig. 4A) was detected in
he Auxo-GTU®-MultiHIVmix immunized mice only. The
esponse was clearly higher at the first termination point than
t the second. In addition, the Gag-specific response even at
he first termination point was significantly lower (p < 0.05)
han the response detected at the time of the challenge in
he immunized mice (Fig. 1C). The Env peptide-specific
esponse (Fig. 4B) was detected in each immunized group,
nd as for the Gag response described above it decreased
fter the first termination point. In addition, and unlike to
he Gag response, the inoculated P815-MultiHIV cells alone
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Fig. 3. P815-MultiHIV tumor growth in Study 2. Tumor growth was followed in Auxo-GTU-MultiHIVmix immunized and in non-immunized groups of mice
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. Discussion
In the present study a tumor challenge model traditionally
mplemented in the cancer research [15,30], is for the first
ime used to test protective immune responses induced by an
IV DNA plasmid vaccine. Due to the global spread of the
IV infection a vaccine against HIV is urgently needed [31].
rowing evidence suggests that immune responses needed to
rotect against the HIV cover all main arms of the immune
ystem, especially the cytotoxic T lymphocytes [17,27,32,33]
nd neutralizing antibodies [33,34].
A way of testing the protective role of a vaccine induced
mmune response is to use P815 tumor challenge model in
BA/2 mice [24]. Tumor cell rejection in this model is known
o be the result of action of high avidity CD8+ CTL [17,35]
hile an antibody response is not considered important for the
umor cell clearance. In the present study, DBA/2 mice were
mmunized with GTU®-MultiHIV DNA and subsequently
hallenged with P815 tumor cells stable transfected with
he MultiHIV antigen. The GTU®-MultiHIV based DNA
accines, both B-clade (HAN2) specific and the multiclade
A + B + C + FGH) specific vaccine constructs were able to
nduce strong cell-mediated and humoral immune responses
n DBA/2 mice. The immune response induced with a minute
mount of DNA (3g) was shown to have cytotoxic effect
n vivo, as it was able to delay the P815-MultiHIV tumor
rowth and to induce a complete protection in some animals.
n the protected animals specific CTL responses against the
nv peptide, the Gag peptide and P815-MultiHIV cells were
etected in vitro. The first challenge study was performed
ith the identical MultiHIV sequence (B-clade, HAN2 iso-
ate) present in both, the GTU®-MultiHIV plasmid vaccine
nd the P815-MultiHIV transfected cells used for challenge.
n the second challenge study, the vaccine construct was
hanged to more advanced MultiHIV construct, consisting of
onsensus sequences for A, B, C, and the ancestral sequence
f FGH clades. Importantly, the delay of the P815-MultiHIV
umor growth in immunized mice was observed in both stud-
es as compared to the growth in non-immunized mice or
o the wild type P815 tumor growth. The above observation
emonstrates the efficacy of the DNA plasmid immunization
ith considerable sequence diversity between immunizing
ntigen (B consensus) and challenging antigen (HAN2). To
ur understanding this is an important observation when
onsidering antigenic sequence diversity of the HIV-specific
NA vaccines and multiple viral isolates infecting human
eings world-wide.
P815-MultiHIV cells were shown to function as antigen
resenting cells in vitro (Fig. 1A and B). In consequence,
hese cells are able to present the MultiHIV antigen also in
ivo in challenged mice, resulting to the immunization of
he non-vaccinated animals. In addition, the CTL response(2007) 3293–3301
as been shown to take place approximately 10 days after
ncountering the tumor antigen [35], which is in concordance
o the tumor regression observed 10 days after the challenge
ith P815-MultiHIV cells of naı¨ve mice.
In HIV infection the immune escape of the virus is well
nown [36,37]. A similar mechanism is likely to act during
he P815-MultiHIV challenge in immunized mice. In this
odel, the induction of effector and/or memory cells in vac-
inated mice was able to inhibit an aggressive growth of the
815-MultiHIV cells, leading to delay of the tumor growth.
he drawback of the present model is in the growth and divi-
ion of the transfected P815 cells in immunized mice. We
ssume that the eventual loss of the transfected cells in chal-
enged mice may be a consequence of the immunological
ressure that contrives cells to loose the transfected insert
nd to reverse to wild type cell phenotype. In addition, if the
ransfection efficiency of 100% is not achieved, a few wild
ype P815 cells will be carried along with the transfected cells
t the time of the challenge. However, because of the above
easons there will be slow but almost definite tumor forma-
ion, which makes this model unsuitable for targeting at the
terilizing immunity induction by vaccination. We believe
hat this model is however suitable to demonstrate the induc-
ion and effector function of the HIV-specific CTL generated
y the DNA vaccines.
The above discussed results, together with previously
ublished studies [9,21], demonstrate comparable immuno-
enicity of the single-clade and the multi-clade cocktail
TU®-MultiHIV vaccines in several mouse strains. Further-
ore, CTL induced by the DNA vaccination were shown to
ill HIV-1 antigen presenting cells both in vivo and in vitro
nd to protect the immunized animals from the P815 tumor
hallenge. The safe and novel animal model described here
ould be applicable for the rapid assessment of the in vivo
rotective immune responses induced by the different vac-
ine candidates. Taken together, we show here an attractive
ool for the evaluation of vaccine immunogenicity and pro-
ection and provide further evidence of the potency of the
TU®-MultiHIV vaccines.
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Cross-Clade Protection Induced by Human Immunodeficiency
Virus-1 DNA Immunogens Expressing Consensus 
Sequences of Multiple Genes and Epitopes From 
Subtypes A, B, C, and FGH
MARIA MALM,1,* ERIK ROLLMAN,2,* MART USTAV,3 JORMA HINKULA,2 KAI KROHN,1
BRITTA WAHREN,2 and VESNA BLAZEVIC1
ABSTRACT
The correlate of protection in human immunodeficiency virus (HIV) infection is not known, but pre-
clinical and clinical studies support the involvement of both antibodies and cellular immunity. In
addition, the existence of multiple HIV clades makes HIV vaccine design especially challenging. We
have constructed a vaccine platform with an HIV-1 subtype B DNA immunogen expressing full
length consensus sequences from HIV-1 rev, nef, tat, and gag with additional cellular epitope clus-
ters from the env and pol regions. Furthermore, this platform has been extended to three additional
plasmids expressing the same immunogens but originating from subtypes A or C consensus or FGH
ancestral sequences. Immunogenicity in BALB/c mice, by gene gun or intramuscular delivery, re-
vealed strong IFN- production in response to in vitro re-stimulation with a H-2d restricted gag pep-
tide (AMQMLKETI) or even stronger toward an env epitope (RGPGRAFVTI). Weak humoral im-
munity was detected. Gene gun immunization with a cocktail of all four plasmids induced
pre-challenge cellular immunity in C57Bl6/A2.01 mice and subsequently a robust frequency of pro-
tection (11/12 animals) after experimental challenge with subtype A or B HIV-1/Murine Leukemia
Virus (HIV-1/MuLV). The cross-clade protection observed in this challenge experiment demon-
strates that these multigene/multiepitope HIV DNA immunogens are likely to be potent immuno-
gens also against the HIV-infection of human beings.
1FIT Biotech Plc, Tampere, Finland.
2Swedish Institute for Infectious Diseases Control and Karolinska Institutet, Stockholm, Sweden.
3FIT Biotech Plc, Tartu, Estonia.
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INTRODUCTION
SINCE THE human immunodeficiency virus–1 (HIV-1)was recognized to cause acquired immunodeficiency
syndrome (AIDS) more than 20 years ago, the HIV-1 epi-
demic has expanded throughout all continents. Presently,
the most disastrous spread continues to take place in South-
east Asia, sub-Saharan Africa, and especially Southern
Africa, as well as in Latin America (UNAIDS/WHO. AIDS
epidemic update: December 2004. [online] http://www.un-
aids.org/wad2004/EPI_1204_pdf_en/EpiUpdate04_en.pdf
). Extensive efforts have been made in the last two decades
in trying to develop an effective vaccine against HIV/AIDS
(19).
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Even though more knowledge is constantly gathered re-
garding the mechanism underlying the generation of the
HIV-specific immune response, it is still not clear what the
exact correlates of protection in HIV-1 infection are. Cur-
rent opinion emphasizes the implication of the collective
effect of CD4 and CD8 T cells (20), broadly neutral-
izing antibodies (17), and innate immunity. Especially the
significance of cytotoxic T-lymphocytes (CTL) in protec-
tion is now widely recognized (8,21,25,26). Indications of
the essential role of CD8 T lymphocytes have been
gained by studying individuals who remain apparently un-
infected even after repeated exposure to the virus (12) and
in experimental animal challenge studies (1).
The high viral mutation rate arising from the infidelity
of the reverse transcriptase results in enormous sequence
heterogeneity of HIV-1. This increases the challenges for
vaccine design, as illustrated by the inability to maintain
protection in primate challenge models, with viral muta-
tions leading to CTL escape (2). A strategy to potentially
overcome the development of such mutants that would
lead to immune escape is to generate immunity against a
wide range of HIV-1 subtypes and toward several viral
antigens. DNA immunization can, if delivered efficiently,
induce strong CTL responses, and is shown to be a
promising approach within HIV-1 vaccine development,
used either alone or combined with the different heterol-
ogous prime-boost regimens (22).
Nonhuman primates such as macaques are powerful
models for simian/simian–human immunodeficiency
virus (SIV/SHIV) infection. However, there are several
distinct immune characteristics in the primate models that
differ from HIV-1 infection in humans (22, 32). A sig-
nificant limitation for HIV vaccine development is that
there are no small-animal in which actual productive
HIV-1 infection can be established (3).
In this study we show that DNA immunization with
candidate vaccines comprising multiple genes of clades
A, B, C, F, G, and H create strong cellular responses
in BALB/c mice, especially after gene gun immuniza-
tion. Second, we show the powerful protective effect
of our DNA immunogens upon experimental viral chal-
lenge based on pseudotyped HIV-1/murine leukemia
virus (HIV-1/MuLV)–infected cells (10,16,29). This
model allows challenging the mice with the complete
HIV-1 genome, and immune response to the majority
of the HIV-proteins has been shown (10). The corre-
lates of protection are still under investigation, but al-
ready published data strongly suggest that at least one
of the components necessary is effective T-cell immu-
nity and that antibodies are less needed to mediate
clearance (10).The genetic immunogens studied can
protect against both HIV-1 subtype A and subtype B
experimental challenge inoculates, illustrating cross-
clade protection.
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MATERIALS AND METHODS
The Auxo-GTU®-MultiHIV DNA vaccine vectors.
Four different MultiHIV DNA immunogens have been
designed according to the consensus sequences of A, B,
C, F, G, and H subtypes of HIV-1 and cloned into the
Auxo-GTU vector system (patent applications,
PCT/FI02/00379 filed 03.05.2002 and PCT/FI2004/
000540 filed 15.09.2004), developed by FIT Biotech
(Fig. 1). The antigens are named MultiHIV-A (based on
the subtype A consensus sequence), MultiHIV-B (sub-
type B consensus sequence), MultiHIV-C (subtype C
consensus sequence), and MultiHIV-FGH (based on an-
cestral sequence for subtypes F, G, and H). Multigene se-
quences of the four plasmids were selected to cover
95% of the known HIV-1 isolates published by year
2002 (9,14, HIV Sequence Database. Los Alamos Na-
tional Laboratory. Assessed August 2002. [online]
http://hiv-web.lanl.gov/content/hiv-db/CONSENSUS/
M_GROUP/Consensus.html). The MultiHIV DNAs en-
code 1053-1079 aminoacid (aa) long polypeptides con-
sisting of a fusion of the full-length regulatory proteins
Rev, Nef and Tat as well structural proteins p17 and p24.
In addition, the antigens contain 17–45 aa long regions
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MultiHIV - A
Rev Nef Tat p17/p24
* **
Env/Pol (CTL)
B
Rev Nef Tat p17/p24 Env/Pol (CTL)
C
Rev Nef Tat p17/p24 Env/Pol (CTL)
FGH
Rev Nef Tat p17/p24 Env/Pol (CTL)
FIG. 1. Genetic immunogens. The Auxo-GTU MultiHIV
(MultiHIV) platform consists of a plamid encoding the codon
humanized rev, nef, and tat genes followed by the gag
(p17/p24) codon humanized gene fragment. The 3 end of the
vector is designed to encode 11 clusters from the env and pol
regions that are known to be rich in cytotoxic T lymphocyte
(CTL) epitopes. (A) The Auxo-GTU MultiHIV subtype A vec-
tor where all gene inserts originate from the consensus sub-
type A sequence. (B, C) Corresponding Auxo-GTU MultiHIV
subtype B and C vectors that encode the consensus subtype
B and C gene fragments. (FGH) The Auxo-GTU MultiHIV
subtype FGH vector that is a mosaic vector encoding subtype
F, G, and H fragments. *Symbolizes the position of murine
gag epitope AMQMLKETI. **Indicates the location of the
murine env epitope RGPGRAFVTI located in the very end of
each construct.
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rich in human major histocompatibility complex (MHC)
restricted CTL epitopes from the reverse transcriptase
and envelope proteins (15). The C-terminal end of the
vector is flanked by a murine H-2d restricted HIV-1 CTL
epitope (RGPGRAFVTI). The prefix Auxo signifies for
the bacterial growth selection system, which enables the
production of the plasmids without antibiotics, a modifi-
cation inserted into the original GTU-MultiHIV construct
(Toots et al., manuscript in preparation).
Immunizations. Female BALB/c (H-2d) mice, 6–9
weeks old, were immunized by MultiHIV/MultiClade
DNA. Initially the immune response was evaluated after
three immunizations by gene gun (g.g) at weeks 0, 4, and
12 (Fig. 2A). Equal amounts of clade A, B, C, and FGH
MultiHIV plasmids were mixed together and coated onto
the gold particles to construct the subtype cocktail Mul-
tiHIV DNA immunogen, from here on referred to as Mul-
tiHIVmix. Experimental groups consisted of five animals
per group and all immunizations were done under gen-
eral anesthesia. Each gene gun administration delivered
8, 40, 200, or 1000 ng DNA on shaved abdominal skin
using 0.5 mg gold particles/cartridge with the Helios
Gene Gun (Bio-Rad) at a pressure of 400 psi. Mice were
sacrificed 10 days after the last immunization and indi-
vidual spleens were collected and the cells preserved at
–70°C until used.
In a second set off experiments (Fig. 2B) a short-term
immunization schedule (immunization at weeks 0, 1, and
3) was used to address three different administration
routes; gene gun (g.g.), intramuscular (i.m.) and intra-
dermal (i.d.). Mice were immunized three times with ei-
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ther of the following; 1000 ng of MultiHIVmix DNA/shot
(g.g.), 50 g MultiHIVmix DNA in sterile PBS in quadri-
ceps femoris (i.m.) or 50 g MultiHIVmix DNA under
the tail-base skin (i.d.). In a separate setup, mice were
given 40 ng (g.g.) of MultiHIVmix or the individual con-
structs alone or in different combinations (three of the
constructs combined in equal amounts) to address possi-
ble interference of the individual components of the Mul-
tiHIVmix DNA. G.g. immunized mice were sacrificed 2
weeks (wk 5) after the third immunization. I.m. and I.d.
immunized mice were sacrificed two weeks (wk 5) or 14
weeks (wk 17) after the third immunization. Negative
control mice were immunized i.m. with PBS only. Indi-
vidual spleen and blood samples were collected and the
cells preserved at 70°C until used.
In a fourth experiment C57BL/6 mice transgenic for
HLA-A201 (11,31) were given an experimental chal-
lenge after a short-term immunization schedule (Fig. 2C).
Mice were divided into three groups with 12 animals per
group. One group was g.g. immunized three times with
1000 ng MultiHIVmix DNA, a second group received
three i.m. inoculations with 50 g MultiHIVmix each. The
last group was inoculated with sterile PBS. These mice
were bled 2 weeks after the last immunization and indi-
vidual blood and spleen samples were collected post-
challenge and used fresh in ELISPOT assays.
IFN- ELISPOT. Immune responses in BALB/c mice
were detected using IFN- specific enzyme-linked im-
munospot (ELISPOT) assay (Mouse IFN- ELISPOT
Kit, EL485, R&D Systems, Minneapolis, MN). Liquid
nitrogen–frozen splenocytes were plated on 96-well
680
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FIG. 2. Immunization schedules. (A) The long-interval immunization schedule with the DNA plasmid cocktail (MultiHIVmix)
containing the MultiHIV A, B, C, FGH constructs in BALB/c mice (white mouse symbol). (B) The short-interval immunization
schedule with three inoculations () at weeks 0, 1, and 3. Gene gun (G.g), intradermal (I.d) or intra muscular (I.m) immuniza-
tions were performed in BALB/c mice with experiment termination at week 5 or 17. (C) Short-term immunization in
C57BL/6.A201 mice (black mouse symbol) after blood sampling for pre-challenge immunity (I) and HIV/MuLV challenge
(white/black star). Mice were sacrificed at week 14, 17, and 9 respectively.
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ELISPOT plates at 1  105 cells/well in 10% FCS-RPMI
culture medium (RPMI 1640, BioWhittaker). The H-2d-
restricted HIV-1 gp120 peptide (aa 311-320; RGP-
GRAFVTI) (30) and the HIV-1 gag peptide (aa 65-73;
AMQMLKETI) (23) was added to duplicate wells at a
final concentration of 1 g/mL. Cell viability was con-
trolled using Concanavalin A at 2.5 g/mL. Cells were
stimulated for 24 h at 37°C and 5% CO2. Spots were de-
veloped according to the manufacturer’s instructions. The
spots forming cells (SFC) were counted using an auto-
mated plate reader (ImmunoSpot™ Series II analyzer,
CTL Europe, Leinfelden-Echterdingen, Germany). The
results were considered positive if both replica wells were
positive at values of 50 SFC/106 splenocytes above the
unstimulated cells and twice above the control.
PBMCs were isolated 10 days after the last immu-
nization and pooled groupwise in the challenge experi-
ment with C57BL/6.A201 mice (Fig. 2C). The PBMCs
as well as splenocytes isolated post-challenge were
freshly assayed for IFN- using an ELISpot kit (Mabtech,
Stockholm, Sweden). To assay for envelope-specific cel-
lular immunity in C57BL/6.A201 mice, we used a gp120
15-mer peptide pool overlapping by 8 amino acids (Ther-
moHybaid, Ulm, Germany) and a 15-mer peptide pool
(AnaSpec, San Jose, CA) covering the 11 T cell epitope
rich regions of CTL antigen coded by MultiHIV. HIV
gag-specific responses were measured by stimulating
with a p24 peptide pool containing 15-mer peptides over-
lapping by 10 (ThermoHybaid, Ulm, Germany). Finally,
a 20-mer herpes simplex virus (HSV) peptide
(RRHTQKAPKRIRLPHIREAD) was used as a negative
control. Peptide pools were used at a final concentration
of 2.5 g/mL of each peptide whereas single peptide was
used at 1 g/mL. Spots were quantified in Stockholm,
Sweden by an AID ELISPOT reader (Autoimmune Di-
agnostika GmbH, Germany).
Antibody IgG ELISA. Sera were analyzed against
clade A, B, C and FGH specific antigen recombinant Gag
as previously described (5). In brief, sera were diluted
1:100 in PBS  2% BSA and duplicate samples were in-
cubated o/n at 4°C in an orbital shaker. Peroxidase-
conjugated rabbit anti-mouse IgG (P0161, Dako,
Glostrup, Denmark) was added followed by the substrate 
2,2-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid)
(ABTS). The absorbance of ABTS substrate was mea-
sured at 405 nm. An optical density (OD) above the mean
of naïve sera plus 3 standard deviations was regarded as
positive.
Experimental HIV-1 challenge. Amphotropic murine
leukemia virus (MuLV.A4070) in the cell line Ampho-
CEM-1B (28) was used to prepare pseudovirus with the
subtype B LAI HIV-1 strain or the primary Kenyan sub-
type A 9284 HIV-1 isolate (collected from an HIV-1–in-
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fected patient in 1996 and isolated at the Swedish Institute
for Infectious Disease Control). The Ampho-CEM-1B cell
line was cultured in 10% FCS-RPMI 1640 (Invitrogen/
Gibco, Carlsbad, CA) with 400 ng/mL of Geniticine
(Sigma-Aldrich, St. Louis, MO) until the day before in-
fection. Culture supernatants were screened for HIV-1 p24
antigen (Vironostika, Bio-Mérieux, Boxtel, France) every
3–4 days and supernatants were collected and stored at
70°C when tested positive. Primary C57BL/6.A201
spleen cells were activated by Concanavalin A (5 mg/mL)
for 24 h, washed, and 50  106 cells were transferred to
a T-25 flask in 1 mL 10% FCS-RPMI. Rapidly thawed
HIV-1/MuLV supernatant (2 mL) was added to the cells
and incubated overnight. One day after infection, the
amount of p24 protein per million mouse cells was deter-
mined (7). Remaining cells were diluted to 1–3  106 cells
in 1 mL of 0.5% FCS-RPMI. Challenged animals (Fig.
2C) were given intraperitoneal injections of 1  106 sub-
type B LAI HIV-1/MuLV infected cells expressing ap-
proximately 1 ng p24 protein or 3  106 subtype A 9284
HIV-1/MuLV infected cells. Ten days postchallenge, the
peritoneal cavity of each animal was washed and ascites
cells were co-cultured with human PBMC (activated by
PHA and IL-2) or Jurkat Tat cells. Every 3 days, 50% of
the culture medium was exchanged and analyzed for HIV-
1 p24 antigen content (7,10). If the supernatant was posi-
tive at more than one time point in at least one of the iso-
lation systems (Jurkat Tat or hPBMC), the animal was
regarded as infected from the earliest time point.
Statistical analyses. The software GraphPad Prism was
used for analyses of protection. The log rank survival
analysis was used for comparison of time to infection be-
tween the challenged mouse groups both in the overall test
and in the post hoc pairwise comparisons between the
naïve group and the different vaccinated groups.
RESULTS
Cellular immunity in BALB/c mice. CTL responses
were assayed by measuring IFN- responses to H-2d
CD8 T cell restricted HIV-1 env and gag peptides us-
ing the ELISpot assay. Nonspecific SFC induced by 
media alone was typically 25 SFC/million cells and
positive control (ConA) induced responses (range
2000–8000 SFC/million cells) in all mice, including neg-
ative control mice (data not shown).
With gene gun delivery of MultiHIVmix DNA at weeks
0, 4, and 12 we were able to induce a strong CTL re-
sponse in 19/20 animals (Fig. 3A). A strong CTL-re-
sponse was observed even with a low dose of 3  8 ng
DNA. In comparison, a weaker CTL response was de-
tected if mice were immunized by the intramuscular
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(i.m.) or intradermal (i.d.) route (Fig. 3B). With i.d. in-
jection the response was detected five weeks after the
first immunization and persisted up to 12 weeks later. In
contrast, i.m. immunization induced detectable IFN-
only at week 17.
We further investigated whether a combination of the
four MultiHIV constructs (MultiHIVmix) would lead to
detectable enhancement or inhibition of the HIV-specific
cellular immunity. When mice were immunized with an
individual DNA construct (A, B, C, FGH) or the combi-
nations of the four (Fig. 4A) there was no significant (p 
0.05) difference of the env-specific immune response.
Rather, trends towards stronger envelope specific IFN-
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responses were seen in mice immunized with the com-
binations compared to the each single construct. Upon
gag peptide (AMQMLKETI) restimulation, the strongest
response was detected in cells from subtype B immunized
animals (Fig. 4B). The animals immunized with the sin-
gle construct of A, C, or FGH MultiHIV react weakly
with the gag peptide, which is not too surprising as the
gag peptide sequence is altered in these subtypes
(AMQMLDETI). Among the different combinations of
the four constructs it appears that some of the groups
(ABC, ABFGH and BCFGH) responded
equally well towards gag peptide, as does the MultiHIV
B immunized animals. In contrast, there is a lower gag-
specific IFN- production in the group immunized with
the mixture of the plasmids lacking subtype B and the
group including all four plasmids (ACFGH and
ABCFGH).
Cellular immunity in C57BL/6.A201 mice. For the
HIV-1/MuLV challenge studies, a different mouse strain
(C57BL/6 mice transgenic for HLA-A201) was used. The
choice of mouse strain is based solely on the experience
from historical as well as ongoing parallel experiments
carried out in our laboratory, showing that this is one of
the few mouse strains in which the HIV-1/MuLV chal-
lenge takes place (10). Pre-challenge immunity was eval-
uated with IFN- ELISPOT assay performed on freshly
isolated murine PBMCs at week 5. (Fig. 1C and Fig. 5).
Because the genetics of this mouse strain is different from
the BALB/c mice, additional antigens were used for in
vitro restimulation. After gene gun immunization the
C57BL/6.A201 mice showed robust gag-specific re-
sponse detectable with an overlapping peptide library.
The detectable envelope specific cellular immunity in
these gene gun–immunized animals was very low before
challenge. In comparison, i.m. immunized mice as well
as PBS immunized mice did not respond with HIV-1 spe-
cific cellular responses before challenge that could be de-
tected in PBMCs.
Ten days after the HIV-1/MuLV challenge the IFN-
production was assayed in splenocytes of the mice using
two commercial kits as described in Methods (to be com-
parable with the assays used in previous experiments).
Both analyses showed that an envelope-specific overlap-
ping peptide library as well as the CTL peptide pool
(env/pol) did induce IFN- production (Fig. 5B). Even
though the immune response detected was quite low
(200 SFC/million cells), the majority of the gene gun
immunized animals responded with specific IFN- pro-
duction (in total 9/12 animals). Interestingly, the gag spe-
cific response in the same gene gun immunized animals
was weaker than the envelope responses (compare the
gag/env response ratio in BALB/c animals) and also dras-
tically weaker than the responses seen before the exper-
imental challenge. Cellular post-challenge responses
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FIG. 3. Cellular immunity induced by the MultiHIVMix
DNA. (A) Dose titration (8-1000 ng per immunization) of the
MultiHIVmix DNA cocktail in the long interval immunization
schedule (Fig. 2A) using gene gun. The cellular immunity is
determined as IFN- production against env and gag peptide
epitopes. Each bar represent the group geometric mean IFN-
spot forming cells (SFCs)/million splenocytes from five ani-
mals. (B) The highest dose used in gene gun (1 g) was com-
pared to conventional immunizations by the intramuscular
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DNA. The inoculations were performed over short intervals
(Fig. 2B) and the animals were sacrificed either at week 5 or
at week 17. White mouse indicates that the data is generated in
BALB/c mice.
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FIG. 4. Cellular immunity induced by individual or combined MultiHIV constructs. In order to analyze possible DNA im-
munogen interference, BALB/c mice were immunized with a total amount of 40 ng  3 DNA in the short-interval schedule (Fig.
2B). The total DNA dose was consisted of one construct alone (A, B, C, or FGH) or different mixtures of the four plasmids. (A)
Envelope specific (RGPGRAFVTI) cellular immunity induced after immunization and sacrifice at week 5. (B) Gag specific cel-
lular immunity to the subtype B (Gag; AMQMLETI) peptide in the same animals as in (A). All five animals per group responded
against the env epitope (5/5) but with varying frequency of responders against the gag epitope (3-5/5).
FIG. 5. Pre- and post-challenge cellular immunity, switching from gag to env specificity. (A) Groupwise pooled mPBMCs
responded with gag specific cellular responses detected as IFN- spot forming cells (SFC) per million mPBMCs in gene gun im-
munized mice before experimental challenge. Intramuscularly immunized mice responded comparatively poorly before challenge.
(B) Env specific cellular immunity was detected in splenocytes from gene gun as well as intramuscularly immunized animals af-
ter HIV/MuLV challenge. Weak gag specific immunity was also detectable in the immunized groups after challenge. EnvB.gp120
pool  overlapping HIV-1 envelope 15-mer peptides of subtype B. Env/PolB CTL pool  overlapping 15-mer peptides cover-
ing the 11 CTL clusters, containing both env and pol epitope regions corresponding to the subtype B construct. GagB.p24 pool 
overlapping 15-mer peptides covering the subtype B p24 antigen. SFC  Spot forming cells. R  number of responders (x/5).
Cutoff  mean SFC among four naïve animals  3 standard deviations. Black mouse indicate that the data is generated in the
C57BL/6.A201 mice.
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FIG. 6. The MultiHIVmix DNA cocktail induces protection against experimental subtype A and B HIV-1 challenge. Gene
gun (3  1000 ng DNA) or intramuscular (3  50 ug DNA) immunized mice were challenged with subtype A or B HIV/MuLV
infected cells (Fig. 2C). (A) HIV-1 p24 antigen was measured over time (21 days) in co-cultures of mouse post-challenge ascites
cells and virus permissive hPBMCs (left panel) or Jurkat Tat cells (right panel). The isolation data in (A) can be transformed
into a Kaplan-Meier plot (B) when HIV p24 has been detected more than twice in at least one of the culture systems. *Indicates
“blip,” a situation in which HIV p24 could be detected only at one time-point only, in one of the two systems only, thereby con-
sidering the animal uninfected (see Materials and Methods). The column of letters/numbers in the center of the figure represents
individual animals (ID#) and has been ranked with increasing p24 concentrations. (B) Immunizing with the Auxo-GTU Multi-
HIV DNA cocktail (MultiHIVmix) resulted in complete protection against experimental subtype B HIV-1 challenge (6/6 animals,
). Additionally, prophylactic gene gun immunization also resulted in control of a subtype A challenge (5/6 animals, ). In com-
parison, intramuscular immunization resulted in partial protection of 4/6 animals subsequently challenged with the subtype B
virus () and in 3/6 mice challenged with the subtype A virus (). 1/6 mice challenged with the subtype B virus was not in-
fected (). As expected, none of the untreated animals (0/6) challenged with the subtype A virus were protected at the end of
the culture (). A log rank survival analyses revealed significant (p  0.05) differences in protection when comparing the two
different routes of immunization (11/12 vs 7/12 animals). The vertical line depicts the maximum amount of p24 detectable at one
time point. Black mouse indicate that the data is generated in the C57BL/6.A201 mice.
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where also detected in the intramuscular immunized an-
imals but were absent in the 12 naïve animals.
Antibody responses. Antibodies against recombinant
Gag A-, B-, C-, and FGH -clade proteins were detected
in a few BALB/c mice after immunizing with the Mul-
tiHIVmix. In C57BL/6 mice antibody production was 
analyzed at week 5 after the immunization and after
HIV/MuLV challenge. Before the challenge antibodies
were induced against all four rGag antigens only in a gene
gun–immunized group. After challenging antibodies
were raised in all treated groups, including the nonim-
munized group. Overall the level of antibodies detected
was low (data not shown).
Protection from HIV-1/MuLV challenge. The pro-
tective effect of the vaccination was tested by inoculation
of HIV/MuLV infected syngenic cells into the peritoneum
of the vaccinated mice, followed by HIV isolation on as-
cites fluid withdrawn from the animals after 10 days. The
ascites cells were recovered by co-cultivation with hPBMC
or the Jurkat Tat cell line in vitro and culture supernatant
samples were collected over a 21-day period (Fig. 6A).
The Kaplan-Meier curves in Figure 6B are based on virus
isolation on both hPBMC and Jurkat Tat cells. If HIV p24
could be detected more than once in at least one of the iso-
lation systems during this culture period, then the animal
was regarded as infected. In the group that was immunized
by gene gun administration, all mice (6/6) were protected
from the subtype B challenge. When mice were challenged
with subtype A pseudovirus, only one out of six mice was
shown to be infected on day 17, showing 83% protection.
With intramuscular immunization the protection rates of
mice after subtype B or subtype A challenge were 66%
and 50%, respectively. In the nonimmunized challenge
control group, none of the mice were protected from the
infection when subtype A challenge was introduced, how-
ever one of six mice was spontaneously protected from
subtype B challenge (16% protected).
A log rank survival analyses revealed that there were
differences between the six groups of animals. Post hoc
pairwise comparisons however, showed no significant
differences when comparing gene gun to intramuscular
immunization of groups that later were challenged with
the same virus. The most likely explanation being that
the number of animals per group was too small (n  6).
When the groups that received the same vaccine treat-
ment were analyzed as one group, regardless of subtype
challenge (g.g. 11/12 vs i.m. 7/12 protected) there was a
significant difference in vaccine route (p  0.05).
DISCUSSION
There are two major aspects to consider when evalu-
ating the potency of an HIV-1 vaccine. First of all, the
vaccine should be capable to induce a strong immune re-
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sponse, especially CD8 T lymphocyte mediated reac-
tions. Second, it is preferable to demonstrate that the vac-
cine-induced immunity has in vivo efficacy, already at
the level of preclinical studies. Because it is not possible
to use natural HIV-1 challenge in experimental animals,
substitution methods must be used to evaluate protection.
In this study we have used a mouse model to show that
the HIV-1 GTU-MultiHIVmix vaccine meets both crite-
ria; that of inducing virus-specific CD8 T cellular im-
munity as well as protection against experimental HIV-1
challenge.
In the first part of the study we immunized BALB/c
mice with the MultiHIVmix DNA cocktail using gene gun
as the way of delivery, since this method has earlier been
the most effective when single clade (B and C) Multi-
HIV constructs were used (Blazevic et al., submitted for
publication) and also shown by other research groups
(4,33). Even though low DNA doses were used (8–1000
ng/immunization), all doses resulted in high HIV enve-
lope specific ELISPOT reactivity with 1000-4000 IFN-
 SFC/million cells. There was no clear dose response
observed when the highly immunogenic envelope pep-
tide (RGPGRAFVTI) was used in the IFN- ELISPOT
assay. However, gag-specific immunity, assayed against
the AMQMLKETI epitope was weaker than the envelope
response and dose-dependent. The highest gag-specific
cellular response was observed in the group of animals
that received the 3  1000 nanogram dose, a dose that
was therefore used for gene gun immunizations in the
subsequent challenge experiment.
In the next study we used a shorter immunization
schedule (0, 1, and 3 weeks) to find out if even this sched-
ule, more suitable for a challenge experiment, would give
comparable immune responses. Three different immu-
nization routes (gene gun, i.d., and i.m. deliveries were
evaluated in parallel. The selection of doses for the i.m.
and i.d. immunizations was based on our earlier studies
with the single clade MultiHIV construct. The shorten-
ing of the immunization schedule did not affect the re-
sponses induced by gene gun immunization, which was
superior compared to the other two routes tested. Inter-
estingly the response to both the env and the gag peptide
increased at 17 weeks as compared to the response at 5
weeks, when immunization was by the i.m. This result
may reflect the fact that in the muscle, the plasmid is
most likely taken up by nondividing and stable muscle
cells, whereas by the intradermal route, the plasmid will
be taken up by professional APCs such as dendritic cells
(4,6) that are able to process and present the epitopes
faster and more efficiently to T cells.
The rationale in our vaccine development has been to
use multiclade constructs, to create a broad immune re-
sponse, targeted against multiple epitopes in the differ-
ent HIV-1 subtypes (9,14). Theoretically, however, an
immunodominant epitope in one clade could repress the
685
5919_12_p678-688  12/9/05  1:42 PM  Page 685
response against recessive epitopes in other clades
(27,13). To address this question, we next compared the
immune response obtained when mice were immunized
with the single clade MultiHIV construct or with mix-
tures of three or four plasmids. When the env peptide
RGPGRAFVTI was used as a target antigen, MultiHIV
mixtures gave somewhat higher responses than immu-
nization with each single plasmid, although this differ-
ence was not statistically different. Because the envelope
epitope used for restimulation is equally present in all
constructs and the total amount of DNA delivered to each
animal was identical, it can be speculated that there is a
trend towards envelope specific immune enhancement by
the mixture of four constructs. For the gag peptide, the
sequence in the B clade vaccine (AMQMLKETI) differs
with one amino acid from the other three vaccines
(AMQMLDETI). Therefore, the animals immunized with
the non-B MultiHIV plasmids responded to the gag pep-
tide but to a less degree than the B-clade immunized an-
imals. Furthermore, in the animals immunized with the
cocktail of all four plasmids (MultiHIVmix), the gag-spe-
cific response was weaker. This finding is not surprising
as the MultiHIVmix contains only one fourth of the B-
clade plasmid of the total DNA amount, which might be
less than required to induce the stronger gag-specific re-
sponse seen in other groups. In fact, we are currently clar-
ifying the effects of mixing the four plasmids together,
by comparing the gag-specific immune responses in mice
immunized with the single B plasmid and the Multi-
HIVmix by using identical amount of plasmid B in both
cases.
The weak antibody responses observed were antici-
pated, because DNA plasmid immunization usually re-
quires high doses of DNA for the induction of antibod-
ies. In addition, use of different adjuvants is generally
required (5,24). Our previous data suggest that protection
from experimental HIV-1/MuLV challenge is primarily
based on the action of T cells, recognizing and killing the
engrafted HIV-1 infected cells (10). In addition, we have
shown that in this challenge model the protection is not
mediated by anti-MuLV immunity (29). As gene gun de-
livery of the MultiHIVmix induced strong CD8 T cell
restricted IFN- production in BALB/c mice, as well as
in PBMCs from C57BL/6.A201 mice, we hypothesize
that this vaccine would protect against a subsequent ex-
perimental HIV-1 challenge.
Indeed, we were able to show that 83–100% of the
mice were protected after gene gun immunization and
50–66% when the intramuscular route was used. This dif-
ference in protection proves to be significantly different
using survival analyses (p  0.05). Looking at the im-
mune responses in the immunized C57BL/6.A201 mice
assayed before challenge, the ELISPOT reactivity sug-
gests that animals immunized with gene gun have a high
MALM ET AL.
level of gag specific T cells whereas intramuscularly im-
munized animals do not. We speculate that these gag-
specific CD8 T cells are responsible for the clearance
of the incoming challenge graft. However, the fact that
i.m immunized mice can mount partial protection even
with low pre-challenge HIV-specific T cells reactivity is
somewhat puzzling. The explanation could be in the lim-
ited sensitivity of the mPBMC ELISpot assay for inter-
feron, with another possible reason being that kinetics of
immune response was different. Hence, we have shown
delayed cellular immunogenicity (higher at week 17 than
at week 5 post–initial immunization) in BALB/c mice af-
ter i.m. administration. This was supported by the fact
that there is detectable post-challenge cellular immunity
among the i.m. immunized animals but not among the
naïve controls, demonstrating that vaccine priming had
occurred.
In conclusion, we have demonstrated that a multi-epi-
tope DNA immunogen (GTU-MultiHIV), if delivered by
gene gun immunization, can induce a strong cellular im-
munity in mice, even when only a few nanograms of
DNA was used. Furthermore, a cocktail of four different
MultiHIV plasmids expressing sequences from subtypes
A, B, C, and FGH can be used to induce similar cellular
immunity against one of the epitopes (env) but with a re-
duced response against a second epitope (gag), if com-
pared to immunization with each single DNA. These data
illustrate the complexity of intra- and inter-plasmid im-
munodominance, a problematic issue for many DNA vac-
cines (27,13,34).
The cocktail of MultiHIV protected 19/24 animals
against an experimental HIV-1 challenge. This experi-
ment also demonstrates cross-clade protection, as the sub-
types A and B viruses used for challenge were derived
from different subtypes than the sequences found in the
clade A or B specific MultiHIV constructs. Furthermore,
it demonstrates that consensus approach used in Multi-
HIVmix vaccine is functional and causes protection
against naturally occurring isolates. Gene gun immu-
nization was superior to intramuscular immunization in
terms of both the T cell immunity induced, as well as
higher frequency of protection. Data generated in this
work support the hypothesis that DNA representing sev-
eral HIV-1 subtypes and several genes are immunogenic
and protective.
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Abstract We evaluated the importance of dendritic cells
(DCs) in the induction of the immune response after
immunization of mice with DNA plasmid Auxo-GTU-
MultiHIV. First, GTU-encoded protein was shown to be
expressed by DCs of the draining lymph nodes (LNs) fol-
lowing intradermal (i.d.) immunization. Next, donor mice
were immunized with the MultiHIV DNA plasmid, and
DCs were enriched and further used to immunize naı¨ve
recipient mice. For the first time, the results show that i.d.
immunization with Auxo-GTU-MultiHIV transfects DCs
in vivo, enabling them to present antigens and induce HIV-
specific immune responses in recipient mice.
Dendritic cells (DCs), the most important antigen-pre-
senting cells (APCs) in the body, have been shown to be
the only cell type that can efficiently present both endog-
enous and exogenous antigens (Ag) through major histo-
compatibility complex (MHC) class I and II molecules and
activate naı¨ve CD8? T lymphocytes [2, 19, 21]. Following
dermal DNA delivery, DCs are either transfected directly
or acquire and present Ag from other transfected cells, a
phenomenon known as cross-presentation [21]. After
encountering an immunogen in vivo, DCs mature and
migrate from the periphery to the lymphoid organs, i.e., the
lymph node (LN) and spleen, the primary sites of Ag
presentation [2]. Nevertheless, the role and significance of
skin DCs in naked DNA plasmid immunization remain
poorly evaluated and understood.
GTU-MultiHIV DNA plasmid has been shown to
induce strong HIV-1-specific cellular and humoral immune
responses in several preclinical studies in mice [3, 13, 15],
pigs [18] and macaques [17]. Furthermore, GTU-based
HIV-1 vaccines have been evaluated in several phase I/II
clinical trials [13]. The results of the present study show
the direct involvement of DCs as APCs in DNA
immunization.
Auxo-GTU-MultiHIV-B DNA encodes the B-clade
consensus HIV-1 multigene, containing fused full-length
sequences of rev, nef, tat, gag (p17 and p24) and 11 T-cell-
epitope-rich clusters from pol and env polypeptides [3, 15].
The GTU vector carrying the destabilized form of
enhanced green fluorescent protein (eGFP) derived from
vector pd1EGFP-N1 (7) instead of the MultiHIV antigen
was constructed. The expression and intensity of the GFP
was verified using a FACSCalibur flow cytometer (Becton-
Dickinson, NJ, USA) after in vitro transfection (Cellfectin
Reagent, Invitrogen) of Jurkat cells with GTU-GFP
plasmid.
For the GFP in vivo expression study, mice were
immunized twice, 24 hours apart with 50 ll of GTU-GFP
plasmid (*250 lg/delivery) i.d. in the base of the tail
(Table 1). On the third day, mice were sacrificed, and
lumbar and sacral LNs of the experimental mice and con-
trol mice were collected and pooled. Mice immunized with
the plasmid lacking GFP were used as controls. Cells were
digested from the tissues by incubating twice with 1 mg/ml
collagenase D (Sigma) at 37C, 5% CO2 for 30 minutes,
collected, and mixed with Optiprep (Axis-Shield PoC AS,
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Oslo, Norway), resulting in a 11.5% iodixanol concentra-
tion in suspension. DCs were harvested by density gradient
centrifugation, washed, and labeled with R-PE-conjugated
anti-mouse CD11c antibody or PE anti-mouse IgG1 as a
control (BD Biosciences Pharmingen, San Jose, CA, USA).
Nonspecific binding to CD16 and CD32 (Fcc III/II recep-
tors) expressed on DCs was blocked by preincubation with
Mouse Fc BlockTM (BD Biosciences Pharmingen). DCs
were washed, and 100,000 events were acquired on a
FACSCalibur. CD11c? cells were gated on FSC/FL2
scatter and analyzed using FlowJo (Tree Star, OR, USA).
The percentage of GFP? cells was determined in the gated
population.
For the DC transfer immunization study, 250 lg of
Auxo-GTU-MultiHIV-B plasmid was injected i.d. twice
(day 1 and 2) into BALB/c mice (Table 1). On the third
day, the mice were sacrificed and LNs (lumbar and sacral)
and spleens were collected separately. DCs were enriched
by density gradient centrifugation as described above and
used for immunization. This procedure was done twice at
an interval of one week for two sets of mice to accomplish
DC transfer immunizations at weeks 0 and 1 (Table 1). A
group of BALB/c mice were injected twice with 4 9 105
LN DC/mouse, and another group of mice were injected
twice with 8 9 105 spleen DCs/mouse, i.d. in the base of
the tail. Tail blood samples were collected at weeks 1, 2
and 3, and the mice were terminated three weeks after the
second DC transfer (week 4).
Splenocytes of 1) LN-DC-immunized, 2) spleen-DC-
immunized and 3) naı¨ve control mice were pooled according
to group and analyzed by ELISpot IFN-c assay (Mouse IFN-c
ELISpot Kit, R&D Systems, MN, USA) as described pre-
viously [15]. First, splenocytes were stimulated in vitro for
six days with five peptide pools (Rev, Nef, Tat, Gag and
CTL) consisting of 263 15-mer, 11-amino-acid-overlapping
peptides covering the entire MultiHIV B-clade antigen
consensus sequence. 1 9 105 splenocytes/well were plated
together with the relevant peptide pool (the one used for the
stimulation), an irrelevant peptide pool, concanavalin A
(Con A, positive control, Pharmacia), and cell culture med-
ium alone (CM, negative control). The result was considered
positive if SFC with the specific peptide exceeded the mean
of the SFC from the irrelevant antigen wells ? 3 9 SD.
Anti-Nef and anti-Gag-specific IgG antibodies were assayed
from tail blood and termination sera at 1:100 dilution by
ELISA as described previously [6]. An optical density (OD)
above the mean of naı¨ve sera ? 3 9 SD was regarded as a
positive response.
A GFP in vivo expression study showed that, in the
gradient-enriched CD11c? DC population, the expression
of GFP was detected in GTU-GFP immunized mice but
not in the control mice (Fig. 1). Twenty-five percent of the
gated CD11c? DCs expressed GFP protein. In the DC
transfer immunization study, DC enriched from the LNs
and spleens (LN DC and spleen DC, respectively) of the
Auxo-GTU-MultiHIV-B immunized mice were used for
immunization of a second group of naı¨ve mice. Cellular
immune responses were analyzed by ELISpot IFN-c assay
as described above. Both LN DC immunization and spleen
DC immunization were able to induce HIV-1-specific
T-cell responses (Fig. 2a). All HIV-specific peptide pools
were recognized, but CTL- and Gag-induced responses
were the strongest. Rev- and Tat-specific T-cell responses
were induced only following LN DC immunization. No
response to any HIV-specific antigens was detected in the
control mice. SFC values obtained through Con A stimu-
lation were similar for all groups analyzed ([5000 SFC/106
Table 1 Immunization schemes
Fig. 1 Flow cytometer analysis of GFP expression in LN CD11c?
DCs. Mice were immunized i.d. with GTU-GFP (control mice with
GTU-MultiHIV), and LNs were collected on day 3. Enriched, anti-
mouse CD11c-PE-stained LN DCs were analyzed by FACSCalibur.
Twenty-five percent of the gated CD11c? cells expressed the eGFP
protein after GTU-GFP injection (red histogram line). Control cells
are shown with a black line
M. Malm et al.
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splenocytes), confirming the good viability of the cells.
Anti-Nef and -Gag antibodies were analyzed from the tail
blood samples and sera after LN DC and spleen DC
transfer immunizations. The kinetics of the antibody
responses is shown in Fig. 2b. Both Gag- and Nef-specific
antibodies were generated; however, the level of these
responses was low. Nef-specific antibodies were elicited in
approximately half of the animals in both the LN-DC- and
spleen-DC-immunized groups at the time of sacrifice (2/5
and 4/7 mice were positive, respectively), while a Gag
response was less frequent (Fig. 2b).
Cell-mediated immunity has a pivotal role in the control
of HIV-1. Understanding the mechanisms leading to strong
cellular immunity by DNA immunization is of great
importance for the rational design of HIV-1 vaccines. Here,
we studied the role of in vivo-transfected DCs in HIV-1
DNA immunization.
We first showed that i.d.-immunized mice express the
GTU-plasmid-encoded gene for GFP in the DCs of the
LNs 1-2 days after injection. Previously, we showed in a
qPCR biodistribution study in rats [20] that the plasmid
GTU-MultiHIV was found in the LNs of the test animals
two days and 14 days after i.d. and i.m. injection, respec-
tively. The present results show that the plasmid is not only
present in LNs but is also translated. After administration
of GTU-GFP to the skin, *25% of LN DCs expressed
GFP. As a consequence of the short half-life of this par-
ticular eGFP protein [13], it does not accumulate in the
cells, and therefore, the eGFP expression detected is pro-
portional to the transcriptionally active vector in the cells.
In the present study, it was hypothesized that the strong
HIV-1-specific immunogenicity induced in the mice by
GTU-MultiHIV [3, 4, 13] is likely to be mediated by DCs
and that these cells could consequently be transferred to
naı¨ve recipient mice to induce HIV-specific responses. In
vitro-transfected DCs are generally used for immunization,
e.g., in cancer treatment [1], but in vivo-transfected DCs
have not yet been shown to elicit a specific immune
response. For the first time, we isolated LN or spleen DCs of
GTU-MultiHIV-primed mice to further immunize naı¨ve
recipient mice. Postulating that approximately 2-4% of LN
cells in mice are myeloid CD11c? DC [9], and since *25
% of CD11c? were GFP positive, as described above, it
could be speculated that *0.5-1% of the cells in LNs
express the plasmid-encoded antigen. For LN DC immu-
nization, *3.3 9 107 LN cells were collected. Of these,
*2.5 9 105 would be CD11c? DC-expressing MultiHIV,
the amount that was further divided to immunize five mice.
This would mean that only *5 9 104 MultiHIV-transfec-
ted DCs were injected per mouse at each immunization
time. Given these numbers, it can be deduced that the very
small numbers of the DCs transferred in our experiment
were enough to induce a detectable immune response in
naı¨ve recipient mice and therefore can be regarded as very
potent APCs. In fact, Josien et al. [10] showed that when
5 9 105 ex vivo antigen-pulsed DCs were injected s.c.,
fewer than 1% of the DCs were recovered from the CD11c?
subset of the draining LNs. Furthermore, the migration
efficiency of antigen-pulsed DCs was reported to determine
the magnitude of T-cell proliferation and effector response,
with priming efficiency dropping dramatically when injec-
ted DCs decreased below 7.5 9 107 [16].
Interestingly, the cellular immune responses generated
after the DC transfer immunization described here are
consistent with the responses detected after MultiHIV
DNA plasmid immunization, i.e., the most prominent IFN-
y responses were induced towards the CTL peptide pool,
while Tat was the least immunogenic. HIV-1-specific
antibody responses after DC transfer immunization were of
low magnitude. The amount of Ag administered might not
have been enough for efficient B-cell stimulation, as enri-
ched in vivo-transfected DCs are not comparable to the ex
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Fig. 2 HIV-1-specific immune responses after immunization with
DCs transfected in vivo with Auxo-GTU-MultiHIV-B plasmid. Mice
were immunized twice i.d. with 4 9 105 LN DCs or with 8 9 105
spleen DCs (wk 1 and 2). a) Splenocytes of LN-DC-immunized,
spleen-DC-immunized or naı¨ve control mice were analyzed by
ELISpot IFN-c. The nonspecific (CM) SFC values were subtracted
from the relevant peptide SFC values. The result was considered
positive (*) when the SFC with the relevant peptide exceeded the
mean of the SFC from the negative antigen wells ? 3 9 SD. b)
Antibodies against Nef and Gag were measured from blood. The
mean OD value of naı¨ve control mouse sera was subtracted from test
sample OD values. The number of responders (above the mean
OD ? 3SD of naı¨ve sera) at termination time is shown in the inserted
table. DC immunization points are indicated by arrows
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vivo-pulsed DC preparations described by others. More-
over, the number of cells injected here was less than what
is used in DC vaccination in general [8]. However, as an
HIV-1-specific antibody response was induced, transferred
DCs must have retained the MultiHIV Ag in its native form
for long enough to permit its transport to the secondary
lymphoid tissue for B-cell presentation, as B-cell activation
in a primary immune response is known to require recog-
nition of an intact Ag [5, 14].
HIV-1-specific immune responses detected after injec-
tion with in vivo MultiHIV-transfected DCs may be
induced either by direct priming or cross-priming. Most
likely, the recipients DCs were also involved in the gen-
eration of immune responses by cross-presentation,
obtaining the MHC-peptide molecules from the donor DC.
De Heusch et al. [8] have demonstrated bidirectional
exchange of MHC molecules in the LN between host
CD11c? DC populations and donor DCs after injection of
allogeneic DCs. Given that the mechanisms behind DC-
mediated Ag presentation are still undefined and not fully
characterized, both mechanisms have to be recognized
under our experimental conditions. However, there is a line
of evidence that injection of apoptotic or necrotic DCs does
not induce T-cell responses in vivo [12]. To the best of our
knowledge, this is the first time that in vivo-transfected
DCs were used as HIV-1 antigen-presenting cells to induce
potent HIV-specific immunity.
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